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-Abstract- 
 CD8+ cytotoxic T lymphocytes (CTL) frequently infiltrate tumors, yet most 
melanoma patients fail to undergo tumor regression. We studied the differentiation of the 
CD8+ tumor-infiltrating lymphocytes (TIL) from 44 metastatic melanoma patients using 
known T-cell differentiation markers.  We also compared CD8+ TIL against the T cells from 
matched melanoma patients’ peripheral blood.  We discovered a novel subset of CD8+ TIL 
co-expressing early-differentiation markers, CD27, CD28, and a late/senescent CTL 
differentiation marker, CD57.  This CD8+CD57+ TIL expressed a cytolytic enzyme, 
granzyme B (GB), yet did not express another cytolytic pore-forming molecule, perforin 
(Perf).  In contrast, the CD8+CD57+ T cells in the periphery were CD27-CD28-, and GBHi and 
PerfHi.  We found this TIL subset was not senescent and could be induced to proliferate and 
differentiate into CD27-CD57+, perforinHi, mature CTL.  This further differentiation was 
arrested by TGF-β1, an immunosuppressive cytokine known to be produced by many 
different kinds of tumors.  Therefore, we have identified a novel subset of incompletely 
differentiated CD8+ TIL that resembled those found in patients with uncontrolled chronic 
viral infections.   
In a related study, we explored prognostic biomarkers in metastatic melanoma 
patients treated in a Phase II Adoptive Cell Therapy (ACT) trial, in which autologous TIL 
were expanded ex vivo with IL-2 and infused into lymphodepleted patients.  We 
unexpectedly found a signficant positive clinical association with the infused CD8+ TIL 
expressing B- and T- lymphocyte attentuator (BTLA), an inhibitory T-cell receptor.  We 
found that CD8+BTLA+ TIL had a superior proliferative response to IL-2, and were more 
capable of autocrine IL-2 production in response to TCR stimulation compared to the 
-xvi- 
 
CD8+BTLA- TIL.  The CD8+BTLA+ TIL were less differentiated and resembled the 
incompletely differentiated CD8+ TIL described above.  In contrast, CD8+BTLA- TIL were 
poorly proliferative, expressed CD45RA and killer-cell immunoglobulin-like receptors 
(KIRs), and exhibited a gene expression signature of T cell deletion.  Surprisingly, ligation of 
BTLA by its cognate receptor, HVEM, enhanced the survival of CD8+BTLA+ TIL by 
activating Akt/PKB.  Our studies provide a comprehensive characterization of CD8+ TIL 
differentiation in melanoma, and revealed BTLA as a novel T-cell differentiation marker 
along with its unexpected role in promoting T cell survival.   
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General Background 
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1.1 Melanoma and Current Approved Treatments 
Melanoma is considered to the most aggressive form of skin cancer.  The incidence 
rate has been increasing for the past 30 years (1).  In 2012, there were 76,250 new cases of 
melanoma and  9,180 deaths in the U.S. (1)    These tumors originate in the pigment-
producing melanocytes, which are the melanin (pigment)-producing cells derived from 
neural crest cells that reside in the basal layer of the epidermis (2).  Although melanoma 
commonly arise in the skin, they may also occur at mucosal sites to which neural crest cells 
migrate (2).  There are two types of risk factors for developing melanoma: intrinsic, which is 
based on a person’s family history and genetic predisposition, and environmental (3, 4).  In 
the case of melanoma, the largest environmental risk factor  is exposure to the ultraviolet 
(UV) radiation from the sun or other sources (3, 4).  Although melanin functions to protect 
the deeper layer of skin from the sun’s ultraviolet radiation, excessive exposure to UV 
radiations (UVA and UVB) can cause damage to melanocytes’ DNA that, when not properly 
repaired, lead to mutations in the genes that control cell proliferation, differentiation, and 
apoptosis (3, 4).  If these mutations occur within oncogenes or tumor suppressor genes, the 
cells will experience uncontrolled proliferation that drive tumor growth (4).  Common 
mutation found in melanocytes progressing to maligant melanoma are point mutations in the 
BRAF and NRAS proto-oncogenes (5-8).  Over-expression of anti-apoptotic gene, such as 
survivin, is also common in melanoma (5-8).       
There are 5 different stages of melanoma.  Stage 0 is melanoma in situ, where the 
tumor is in the epidermis and has not spread beyond to the dermis.  Patients in this category  
have favorable 5-year survival rate of 99.9% after surgical excision of the tumor (9).  Stage I 
melanoma is characterized by < 1.0 mm in thickness.  Survival rates are between 92-97% 
- 3 - 
 
with surgery (9).  Stage II melanomas have bigger primary lesion sizes that range between 
1.0 mm in depth to 4.0 mm in depth.  5-year survival rates after surgery decreases in 
proportion with the size of the tumor (between 53% to 81%) (9).  Stage III melanomas are 
characterized by having spread to regional lymph nodes, with 5 year survival rates between 
40-78% (9).  Finally, Stage IV melanoma involves metastases to distant organs, with 5-year 
survival rate between 15-20% (9). 
Melanomas that have not spread beyond their site of origin are highly curable with 
surgery (2).  Most of these are thin lesions that have not invaded beyond the papillary dermis 
(Breslow thickness ≤1 mm) (2).   Melanomas with a Breslow thicknes of 2 mm or more are 
still curable by surgery in a significant number of patients, however the risk of lymph node or 
systematic metastases increase with increasing thickness of the primary lesion (2).   
Therefore patients also need to undergo sentinel lymph node biopsy followed by complete 
lymph node dissection if the sentinel node(s) are microscopically or grossly positive.   
Patients with  > 4 mm Breslow thickness will need to be considered for adjuvant therapy in 
addition to surgery.  Melanomas that have spread to lymph nodes may be curable with wide-
local excision of the primary tumor and removal of the involved regional lymph nodes.  For 
patients with high-risk of relapse, systemic treatment with high dose and pegylated interferon 
alpha-2b (IFN-alpha-2b) are approved for the adjuvant treatment of patients who have 
already undergone a complete surgical resection (10).  Prospective randomized controlled 
trials with both agents have shown an increase in relapse-free survival (RFS) but not overall-
survival (OS) when compared to observation (11).  However these regimens are associated 
with substantial side effects that require close monitoring of the patients (11).  For patients 
with distant metastases, chemotherapeutic agents such as dacarbazine (DTIC), which was 
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approved by the FDA in 1970, has demonstrated, in a Phase III trial, an overall response rate 
of 10-20% with rare complete responders observed (CRs) (12), though no impact on OS was 
demonstrated in randomized trials (10).  Temozolomide, an oral alkylating agent, appeared to 
be similar to DTIC (given intraveneously) in a randomized phase III trial (13).  Another 
option includes an immuno-modulating cytokine, interleukin-2 (IL-2), which was approved 
by the FDA in 1998 on the basis of durable complete response (CR) rates in a minority of 
patients (0 to 8%) with previously treated metastatic melanoma in eight phase I and Phase II 
studies, though no improvement in OS has been demonstrated in randomized trials (10) .   
More recently, the newer agents, ipilimumab (14) and vermurafenib (15), have demonstrated 
improvement in both progression-free survival (PFS) and OS in international, multicenter, 
randomized trials in patients with advanced or unresectable disease, leading to the FDA’s 
approval of these agents in 2011.  Vemurafenib is a selective inhibitor of the mutant BRAF 
kinase (V600E); its indication is limited to patients with a demonstrated BRAF V600E 
mutation by an FDA-approved test (10).  The mechanism of action of ipilimumab, a 
humanized monoclonal antibody against Cytotoxic T-Lymphocyte-4 (CTLA), an inhibitory 
receptor on T cells (16), will be discussed further in the next section.            
1.2 Cancer Immunotherapies 
The dismal prognosis associated with metastatic melanoma was often due to the 
highly radio and chemo-resistant nature of the tumor cells.  A large study conducted by the 
Eastern Cooperative Oncology Group (ECOG) found that prior chemotherapy was associated 
with poorer prognosis (17).  Even with the introduction of  vemurafenib, which specifically 
targets a mutant protein kinase in a crucial cellular signaling pathway driving tumor cell 
divison, the clinical responses are often short-lived (6-8 month median progression-free 
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survival) due to the rapid development of resistance (18).  However, melanoma is also highly 
immunogenic, since it frequently elicits lymphocytic infiltrates, and that the presence of 
tumor infiltrating lymphocytes (TIL) is one of the positive prognostic factors (19).  The 
ECOG study has also shown that prior immunotherapy was associated with better survival 
(17).  During the last decade, significant progress has been made in the identification and 
characterization of several MHC class I–restricted melanoma tumor-associated antigens 
(TAA) recognized by CD8+ cytotoxic T lymphocytes (CTLs). These antigens belong to four 
main categories (20): melanocyte differentiation antigens (e.g., tyrosinase, Melan-A/MART-
1, gp100, TRP-1, and TRP-2) (21), cancer-testis–specific antigens (e.g., MAGE, BAGE, 
GAGE, PRAME, and NY-ESO-1) (22), over-expressed self-antigens (e.g., survivin, Mcl-1, 
and other anti-apoptotic genes) (23), and antigens derived from mutated or aberrantly 
expressed proteins (e.g., MUM-1, CDK4, beta-catenin, gp100-in4, p15, and N-
acetylglucosaminyl transferase V) (24).  CD4+ helper T cells can also recognize several 
MHC class II–restricted epitopes derived from melanoma antigens (25-29).  Thus, the 
developments of immunotherapies for melanoma have come a long way from theoretical 
possibilities a few decades ago to real proven clinical successes.  In fact, the tables are 
turning with various kinds of immunotherapies emerging to be among the most powerful 
approaches to treat metastatic melanoma. 
One prominent example was the recent FDA’s approval of the humanized 
monocloncal antibody anti-CTLA-4 (ipilimumab) as a single-agent therapy for Stage IV 
disease (30).  CTLA-4 is expressed by activated CD4+ and CD8+ T lymphocytes.  When T 
cells are activated by antigen, CTLA-4 is rapidly mobilized from the intracellular 
compartment to the immune synapse where it competes with co-stimulatory receptor, CD28, 
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for binding to its ligands, B7-1 and B7-2, on the antigen-presenting cells (APCs).  As a 
result, T-cell’s activation is attenuated.  Administration of anti-CTLA-4 blocking mAb 
interrupts this key inhibitory checkpoint during T-cell activation and thus “takes the brakes 
off” of T cells, resulting in enhanced proliferation and effector activity against a large array 
of self-antigens, including tumor antigens (31, 32) (Fig. 1-1).   
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Figure 1-1:  Enhancement of T-cell activation by blocking engagement of inhibitory 
receptors on T cells.  (a) Antigenic presentation triggers T cell activation and occurs when a 
peptide derived from an antigen binds to Major Histocompatibility Complex (MHC) 
molecule on an antigen presenting cell (APC) and interacts with the T cell receptor (TCR) on 
the surface of a T cell.  In order to achieve optimal activation, additional co-stimulatory 
signals are required and involve interaction between costimulatory receptor, CD28, on T 
cells, and B7-1 and B7-2 molecules on APCs.  After T cell activation, a natural negative 
feedback exists to attenuate the degree of T cell activation.  For example, cytotoxic T 
lymphocyte-associated protein (CTLA)-4 is mobilized after activation to the cell surface and 
binds to B7 molecules with greater affinity than CD28, which inhibits signaling through 
CD28.  Inhibitory signals can also be provided by co-inhibitory receptors such as 
programmed cell death 1 (PD-1), which binds to PD-1 ligand 1 or 2 (PDL1/2). Other known 
inhibitory receptors expressed by T cells include V-domain immunoglobulin suppressor of T 
cell activation (VISTA) (33), T-cell immunoglobulin and mucin domain-containing protein-3 
(TIM-3) (34), and B-and-T lymphocyte attenuator (BTLA) (35).  (b) Sustaining T cell 
activation through blockade of negative co-inhibitory receptors.  Blocking antibodies against 
CTLA-4 or PD-1 are currently used to neutralize co-inhibitory receptors and prevent 
dampening of the T cell response. Blockade of these inhibitory immune checkpoints results 
in enhanced and sustained activation of tumor-specific T cells that produce effector cytokines 
including TNF-α, interferon (IFN-γ), and granzyme B.   
Reprinted from: Trends in Immunology, Volume 34, Issue 2, Gao J, Bernatchez C, Sharma 
P, Radvanyi L, and Hwu P. Advances in the development of cancer immunotherapies, p90-
98, 2012, with permission from Elsevier. 
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Figure 1-1:  
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In addition to CTLA-4, another inhibitory receptor currently receiving intense interest 
is programmed death-1 (PD-1), which was reported to be expressed at high levels on 
activated T cells as well endogenous melanoma antigen-specific T cells and TIL (36, 37).  
The ligand for PD-1 are PD-L1 (B7-H1) and PD-L2 (B7-DC).  PD-L1 is expressed by many 
normal non-hematopoietic tissues as well as dendritic cells as a self-tolerance mechanism, 
especially at sites of inflammation.  However, this pathway has alsoo been usurped in cancer, 
with many types of cancer cells, including melanoma, found to express PD-L1.  PD-L2 is 
mainly expressed by dendritic cells and other myeloid cells, such as macrophages (38).  PD-
L1 expression on tumor tumor cells has been postulated to cause immune suppression of 
tumor-infiltrating T cells (36) (Fig. 1-1).  However, it is also possible that PD-L1 and PD-L2 
expression in tumor resident dendritic cells and macrophages may also contribute to this T-
cell suppression. The inhibitory role of PD-L1 on T-cell activation suggests that its 
expression would be a poor prognostic factor in cancer.  Although initial 
immunohistochemistry studies in renal cancer and other cancers suggested that higher PD-L1 
expression in tumor cells correlated with poorer progression-free and overall survival (39-
42), more recent data suggests the contrary (43, 44).  These contrasting data seems to be due 
to the degree of T-cell infiltration in the tumor microenvironment with T-cell associated 
cytokines such as IFN-γ, which is known to induce PD-L1 expression on cancer cells (45) as 
one of the mechanisms of “adaptive resistance” (43).  Thus, paradoxically, higher PD-L1 
expression may be an indicator of increased activated T-cell infiltration into tumor and a 
better prognosis as a result.  
In a phase I trial in 39 patients with refractory metastatic melanoma, colorectal 
cancer, prostate cancer, non-small cell lung cancer (NSCLC), or renal cell carcinoma (RCC), 
anti-PD-1 blocking antibody (MDX-1106) resulted in complete or partial response in three 
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patients and less significant tumor regression in two others (46).  A recent phase I clinical 
trial with a different anti-PD1 antibody (BMS-936558) showed durable objective response 
rates between 18-28% depending on tumor types in patients with advanced NSCLC, RCC, 
and melanoma (47).  Another phase I trial with anti-PD-L1 antibody showed mild to modest 
antitumor activity in patients with advanced NSCLC, melanoma, and RCC (objective 
response rates between 6 to 17% with prolonged stabilization of disease) (48) .  Blocking 
antibodies against other T cell co-inhibitory receptors, such as LAG-3 and TIM-3, are still at 
early stages of development as potential targets for immune checkpoint blockade (34, 49) 
(Fig. 1-1).     
B- and T- lymphocyte attenuator (BTLA) is another inhibitory receptor with two 
immunotyrosine-based inhibitory motifs (ITIMs) that are similar to other well-known 
inhibitory receptors, PD-1 and CTLA-4 (50) (Fig. 1-1; Chapter 3, Fig. 3-15).  Interestingly, 
unlike PD-1 and CTLA-4, the cytoplastmic domain of BTLA has been reported to contain a 
third conserved tyrosine-containing motif, which has been shown to recruit Grb-2 and p85 
subunit of PI3K in vitro (51).  BTLA signaling is generally considered to be suppressive, as 
ligation with its cognate receptor, Herpesvirus entry mediator (HVEM), results in the 
recruitment of SHP1/2 phosphatases and leads to decreases in T-cell’s proliferation and 
cytokine secretion (50, 52).  However, it is controversial whether BTLA expression truly 
marked “exhausted” CD8+ T cells.  Although it was reported that BTLA is up-regulated on 
exhausted, NY-ESO-1 tumor antigen-specific CD8+ T cells (53), a number of studies on 
human CD8+ T cells have shown that BTLA was already expressed at a high level on naïve 
CD8+ T cells and was gradually down-regulated during normal differentiation (52, 54).  A 
recent study has suggested a close relationship between the expressions of multiple inhibitory 
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receptors (e.g., PD-1, TIM3 and LAG3) and the antigen-specificity, anatomic localization, 
and differentiation of CD8+ T cells in humans (Chapter 3, Fig. 3-3).  In our phase II ACT 
trial with melanoma TIL, we found that that patients receiving more CD8+ TIL expressing 
BTLA were significantly correlated to positive clinical responses (55) (Chapter 3, Fig. 3-2).  
However, we did not find clinical correlations with CD8+ TIL’s expressions of other 
inhibitory receptors such as PD-1 (programmed death-1) or TIM-3 (T-cell immunoglobulin 
domain and mucin domain 3 receptor) (55) (Chapter 3, Fig. 3-2).  It is not known whether 
BTLA’s third signaling motif can modulate T cell survival in vitro and in vivo.  If that is true, 
that may provide one of the explanations for our observed positive clinical correlations.   
A number of other immunotherapy approaches have also been developed and 
improved over the last decades with incremental successes.  These include IL-2 therapy (56), 
peptide vaccines together with IL-2 (57), and adoptive T-cell therapy using autologous 
expanded tumor-infiltrating lymphocytes (TIL) (58-60).  In addition, agonistic monoclonal 
antibodies that enhance T cell response by activating co-stimulatory receptors [e.g., OX40 
(CD134), 4-1BB (CD137)] are being tested (61-63).  Moreover, rational combinations of 
these immunotherapies with chemotherapies or targeted therapies against the components of 
the MAPK signaling pathway are now making an entry into the clinic (15, 64, 65).  These are 
based on the newly discovered synergistic mechanism of chemotherapies and targeted 
therapies in facilitating immune responses by activating innate immunity (“immunogenic 
chemotherapy”) (66-68) or enhancing T-cells’ recognition of tumor cells by inducing 
expressions of tumor antigens (65, 69).  
1.3 Adoptive T-cell Therapy (ACT) using TIL for metastatic melanoma 
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To date, one of the most powerful immunotherapies against metastatic melanoma has 
been adoptive T-cell therapy (ACT) using autologous ex vivo-expanded TIL that are re-
infused back into patients.  Adoptive transfer of TIL for the treatment of human metastatic 
melanoma was initially described in 1988 (70) and has since yielded highly encouraging 
results since its initial development with >50% clinical responses;  these clinical responses 
have been shown to be durable for years in recent clinical trials (58-60, 71).  More recently, 
other forms of ACT using genetically-modified T cells are now being developed and tested 
clinically.  Genetic modifications frequently involve modifying the affinity and avidity of the 
TCR for the targeted tumor antigen.  A schematic of TCR, its signaling subunit, CD3, and a 
brief description of the signaling event downstream of TCR are shown (Figure 1-2a).  The 
other ACT approaches include expanding tumor-associated antigens (TAA)-specific T-cells 
from peripheral blood mononuclear cells (PBMCs) through pAPC pulsed with tumor antigen 
peptides(72-74), engineering recombinant TCR α and β chains recognizing peptides derived 
from tumor-associated antigens (TAAs) (75, 76), and introducing into T-cells chimeric 
antigen receptors (CAR), which are composed of single-chain immunoglobulin variable 
regions (scFv) recognizing tumor antigens fused to a linker region followed by the signaling 
domains of the TCR ζ chain and costimulatory molecules, such as CD28 and CD137/4-1BB 
(77, 78) (Figure 1-2b).  As a side note, a recent clinical trial from a group at the University 
of Pennsylvania has demonstrated impressive clinical efficacy of CAR-modified T-cells 
against a leukemic B-cell antigen, CD19 (79).  Table 1-I provides a summary of different 
types of ACT that are currently being investigated for the treatment of metastatic melanoma, 
a brief descriptions of the methods, the antigens targeted, and the status of clinical 
development.   
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Figure 1-2: (a) Diagram of the TCR:CD3 complex. The T-cell receptor (TCR) is composed 
of two subunits, α and β subunits. The other four protein subunits (ε, δ, γ, ζ) assemble in 
three different dimers to form the CD3 complex. The square boxes on the CD3 subunits in 
cytoplasm represent the immunoreceptor tyrosine-based activation motifs (ITAMs).  An 
early event in TCR activation is phosphorylation of ITAMs in the cytoplasm of TCR/CD3 
complex by lymphocyte protein-tyrosine kinase (Lck). The CD45, which is a receptor 
tyrosine phosphatase, modulates the phosphorylation and activation of Lck and other Src 
family tyrosine kinases.   ζ-chain associated protein kinase (ZAP-70) is recruited to the 
TCR/CD3 complex where it becomes activated, promoting recruitment and phosphorylation 
of downstream adaptor or scaffold proteins.  More detailed TCR signaling events is at the 
following reference (80).   
Reprinted with permission from: de Felipe, P., Skipping the co-expression problem: the new 
2A ”CHYSEL” technology.  Genet. Vaccines Ther.  2004. 2(1):13.  BioMed Central Open 
Access Article. 
(b) Structure of chimeric antigen receptors (CARs)(81). CARs are composed of a single-
fragment length antibody (scFv) containing the heavy (VH) and light chain (VL) variable 
regions derived from a murine hybridoma expressing a monoclonal antibody (mAb) targeting 
a desired TAA.  CARs typically contain a scFv-based TAA binding domain fused to an inert 
transmembrane domain of the CD8 (“first generation”), or a signaling domain of CD28 
receptor (“second generation”) fused to a TCR ζ chain. “Third generation” CARs contain 
tandem cytoplasmic signaling domains from 2 co-stimulatory receptors (i.e., CD28-OX-40 
and CD28-4-1BB).   
Reprinted with permission from: Chekmasova, A. 2010. 
http://www.discoverymedicine.com/Alena-A-Chekmasova/2010/01/22/adoptive-t-cell-
immunotherapy-strategies-for-the-treatment-of-patients-with-ovarian-cancer. Accessed 
January 27th, 2013. 
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Figure 1-2: 
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Table 1-I: A summary of different types of ACT for the treatment of metastatic 
melanoma and the status of clinical development 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted with permission from: Wu, R. Forgét, MA, Chacon J, Bernatchez C, Haymaker C, Chen 
JQ, Hwu P, and Radvanyi L.  Adoptive T-cell Therapy Using Autologous Tumor-infiltrating 
Lymphocytes.  2012. The Cancer J. 18(2):160-75.  doi: 10.1097/PPO.0b013e31824d4465. 
Strategy for 
ACT Brief Description Targets Clinical Status 
Tumor infiltrating 
lymphocytes (TIL) 
Isolation of T 
lymphocytes from 
primary or secondary 
tumors followed by in 
vitro expansion with IL-
2 
Polyclonal (shared 
melanoma 
differentiation 
antigens, antigens 
derived from 
mutated genes)  
Clinical  (phase II) 
Dudley, et al. (59, 82, 83) 
Rosenberg, et al.  (84, 85) 
Radvanyi, et al. (60, 71) 
 Besser, et al. (58, 86) 
Antigen-expanded 
CD8+ or CD4+ 
T cells 
In vitro reactivation 
and expansion of T 
lymphocytes 
specifically recognizing 
tumor-associated 
antigen (TAA)  
MART-1, 
Tyrosinase, gp100, 
NY-ESO-1, or 
polyclonal 
Clinical (phase I/II) 
Yee, et al. (74) 
Mitchell, et al. (73) 
Mackensen, et al. (72) 
Hunder, et al. (87) 
Verdegaal, et al. (88) 
Butler, et al. (89) 
Engineered T cell 
receptor (TCR) 
expression in 
lymphocytes  
Genetic modification of 
T cells for expression 
of second TCR 
(human or mouse) 
directed against TAA 
MART-1, gp100, 
p53, and NY-ESO-
1 
Clinical (phase I/II) 
Morgan, et al. (75) 
Johnson, et al. (90) 
Robbins, et al. (91) 
Chimeric antigen 
receptor (CAR) 
expression in 
lymphocytes 
Genetic modification of 
T cells for expression 
of a chimeric receptor 
partly constituted of 
TAA-specific antibody 
and CD3/co-
stimulatory molecule 
trans-membrane and 
cytoplasmic domains 
Ganglioside GD2, 
GD3, and HMW-
MAA (MCSP-1) 
Pre-clinical 
Yvon, et al. (78) 
 Lo, et al. (92) 
Burns, et al. (93) 
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Adoptive T-cell therapy (ACT) using autologous ex vivo-expanded TIL, which is the 
primary focus of this thesis, involves the expansion of TIL ex vivo in two stages.  The steps 
in TIL expansion and treatment are summarized in Fig. 1-3.  The first stage involves the 
initial expansion of TIL isolated from the tumor fragments over a 5-week period in culture 
medium with IL-2 (94-96).  Medium exchanges with fresh IL-2 are done regularly to ensure 
continued T-cell division and survival during this time.  This first stage yields a product 
(“pre-REP” TILs) that is used to generate a final TIL infusion product following a “rapid 
expansion protocol” (REP) (94, 97).  These pre-REP TILs can either be used immediately for 
secondary expansion with the REP, or they can cryo-preserved and used later.  The REP 
involves activating the TILs through the CD3 complex using an agonistic anti-CD3 mAb 
(OKT3) in the presence of a 200:1 ratio of irradiated (5,000 cGy) PBMC feeder cells 
obtained from the patient (autologous feeders), or pooled from 3 to 6 healthy donors 
(allogeneic feeders).  Two days after initiation of the REP, IL-2 (6,000 U/mL) is added to 
drive rapid cell division in the activated TIL (94, 98, 99).  The TIL are then expanded for 
another 12 days and diluted, as needed, with 1:1 culture medium containing fresh IL-2 (94, 
98, 99). 
A typical REP results in 1,000-fold to 2,000 fold expansion of TIL during a 14-day 
culture period.  The TIL are harvested, concentrated, and infused intravenously into the 
patient along with high-dose IL-2 to drive further TIL survival and expansion in vivo (94, 98, 
99).  Prior to infusing the TIL back into the patient, the patient is lympho-depleted using a 
cocktail of drugs to deplete all endogenous T and B cells.  IL-2 is systemically administered 
in order to help support the transferred TIL following lymphodepletion and TIL infusion (56, 
100, 101) (Fig. 1-3).  Treatment with IL-2 at this point supports the persistence of the infused 
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TIL in vivo; this is critical for the short-term survival of the TIL which contributes to tumor 
regression (84, 102, 103).   
Lymphodepleting patients prior to infusion with autologous TIL has contributed to 
the improved clinical efficacy of ACT.  Metastatic melanoma patients were initially treated 
with TIL and IL-2 without lymphodepletion, resulting in an objective response rate of 39% 
(59, 83, 104, 105).  However, a series of Phase II clinical trials in humans conducted by 
Dudley et al. at the National Cancer Institute in 2002 used a preparative lymphodepleting 
chemotherapy regimen (cyclophosphamide and fludarabine) in melanoma patients prior to 
TIL and IL-2 infusions, resulting in an unprecedented 50% clinical response rate (59, 83, 
104, 106, 107).    Lymphodepleting patients prior to TIL infusion improves persistence of the 
TIL by eliminating endogenous lymphocytes that can compete with the infused TIL for 
homeostatic cytokines such as interleukin-7 (IL-7) and interleukin-15 (IL-15) (59, 83, 104, 
106, 107). Lymphodepletion also eliminates endogenous CD4+Foxp3+ T regulatory cells 
(Tregs) and myeloid-derived suppressor cells (MDSCs) that can inhibit proliferation and 
effector functions of the infused TIL in vivo (108-111).   Although chemotherapeutic 
lymphodepletion has led to  improved clinical responses in ACT,  a potential problem that 
may occur is the post-treatment recovery of endogenous  T-cells, in particular the re-
emergence of Tregs that could suppress the anti-tumor activity of the infused TIL.  In order 
to overcome this issue, total-body irradiation (TBI), at different dosages (2 Gy and 12 Gy), 
plus cyclophosphamide and fludaribine, have been tested (83, 85).  They reported a 
significant enhancement of objective clinical response rate to 72% with the 12 Gy TBI plus 
chemotherapy preparative regimen, together with 40% complete responders (59, 83, 85, 99, 
112).   The NCI group has recently provided a summary of their 10-year experience with the 
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Phase II ACT trials using different preparative regimens.  In sum, these trials have 
demonstrated a response rate of 51%, and 13% rate of durable and complete regression past 5 
years (85, 113). 
Different centers have now utilized ACT with TIL to treat metastatic melanoma 
patients and have reported promising results.  At the M.D. Anderson Cancer Center 
(Houston, TX), our group is currently conducting a phase II trial of TIL therapy in metastatic 
melanoma patients that have not responded to first-line and second-line therapies (60, 71).  
We have treated over 70 patients to date and have achieved a 48% overall response rate (60, 
71).  These responses have been durable, with a majority of responders having relapse-free 
survival over 12 months.  The Sheba Cancer Center (Jerusalem, Israel) has reported an 
overall response rate of 50% using TIL therapy in their clinical trials (58, 86).  In summary, 
these impressive rates of positive clinical response from various groups around the world 
have shown that ACT with TIL is a powerful approach for the treatment of metastatic 
melanoma.     
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Figure 1-3. Schematic representation of the process of TIL expansion and TIL therapy 
for metastatic melanoma.  Suitable tumors from eligible stage IIIc-IV melanoma patients 
are resected and taken to the lab under sterile conditions where they are cut up into small 3-5 
mm2 fragments and placed in culture plates or small culture flasks with growth medium and 
high-dose (HD) IL-2.  The TILs are initially expanded for 3-5 weeks during this “pre-rapid 
expansion protocol” (pre-REP) phase to at least 50 x 106 cells.  The cells are then subjected 
to a rapid expansion protocol (REP) over two weeks by stimulating the T cells using an 
agonistic anti-CD3 mAb (OKT3) in the presence of PBMC feeder cells and IL-2.  The 
expanded TIL are washed, pooled, and infused into the patient followed by one or two cycles 
of HD IL-2 therapy.  Before TIL transfer, the patient is treated with a preparative regimen 
using cyclophosphamide (Cy) and fludaribine (Flu) that transiently depletes host 
lymphocytes.   Lymphodepletion plays an important role in enhancing the efficacy of the 
ACT using TIL, by providing space for the infused TIL to expand, reducing the competition 
between TILs and endogenous T cells for homeostatic cytokines (e.g., IL-7, IL-15), and 
removing regulatory T cells.   
Reprinted with permission from: Wu, R. Forgét, MA, Chacon J, Bernatchez C, Haymaker C, Chen 
JQ, Hwu P, and Radvanyi L.  Adoptive T-cell Therapy Using Autologous Tumor-infiltrating 
Lymphocytes.  2012. The Cancer J. 18(2):160-75.  doi: 10.1097/PPO.0b013e31824d4465. 
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Figure 1-3: 
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1.4  CD8+ CTL differentiation and anti-tumor immune response 
A significant part of the adaptive immune system is consisted of two types of T 
lymphocytes, CD8+ and CD4+ T cells, which operate by reacting specifically to viral or 
tumor antigens.  CD8+ cytotoxic T lymphocytes (CTL) play a major role in anti-tumor 
responses and carry out the antigen-specific cytolysis of tumor cells through the action of 
granzymes (e.g., granzyme B), which belong to a family of serine proteases that cleave at 
aspartate residues in the substrate, and perforin (114, 115).  Perforin forms pores in the 
plasma membrane of target cells, which allows granzymes to enter the target cell and activate 
caspases (e.g., caspase 3), causing apoptosis in the target tumor cells (114).  The Fas-Fas 
ligand interaction may also be important for the tumor cell killing, although the extent this 
pathway contributes to tumor killing is not known (116).  Although the clinical data from 
NCI was less conclusive about the importance of CD8+ TIL (59, 83, 117), the reports from 
the melanoma ACT trials by Besser, et al. (58), and at M.D. Anderson Cancer Center (60, 
71) have revealed a positive correlation between a higher number of infused CD8+ TIL and 
positive clinical response in a majority of Stage IIIc/IV metastatic melanoma patients.   
  Although CD8+ T cells are emerging to be the dominant cell type in adoptive cell 
therapy, the role of CD4+ T cells cannot simply be ignored.  CD4+ T cells play a central role 
in coordinating many elements of the adaptive immunity (118).  They participate not only in 
priming CD8+ T cells, but they can also induce tumor eradication by a number of direct and 
indirect mechanisms: direct killing of MHC class II+ tumor cells presenting TAA, the 
activation of pAPC cross-presenting TAA, the activation of tumor-cytolytic macrophages 
and eosinophil, and the provision of survival signal (lymphokines) for the transferred CD8+ 
CTL (119).   CD4+ T cells in some healthy donors have been reported to express cytolytic 
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molecules typically associated with CD8+ cytotoxic T lymphocyte (CTL), such as granzyme 
B and perforin, in chronic viral infections (120).  Recent data suggest a possible pathway of 
differentiation of a subset of CD4+ T-cells into highly tumor-cytolytic cells expressing the 
transcription factor Eomesodermin (Eomes) that drives granzyme and perforin expression 
(121).  We have observed in our phase II clinical trial that a small percentage of patients 
(about 8-10%) who had a CD4+ T-cell dominated TIL product for adoptive transfer 
nevertheless underwent dramatic clinical responses and even complete remissions in some 
patients (60, 71).  It is a likely that a subset of “cytotoxic” CD4+ T cells may exist in some of 
melanoma patients’ TIL.    However, in the majority of cases, patients receiving CD4+ T-cell 
dominated TIL tended to be nonresponders (60, 71).  It is also possible that in these 
responding patients that recived a CD4+ T-cell dominated TIL product, the few CD8+ T cells 
expanded in vivo and mediated tumor regression.  Detailed tracking of T-cell clones in vivo 
from the infused TIL products will be required to address this possibility.   
Therefore, CD8+ T cells have been the subject of the most intense research in 
melanoma ACT.  CD8+ T cells are heterogeneous with respect to anatomic localization, 
proliferative and engraftment capabilities, and different profiles of cytokine secretion, 
metabolism, and gene expression.  Each of these parameters may have influence on a CD8+ 
T-cell’s ability to mediate cancer regression after ACT.  Many of these properties tend to 
cluster together in discrete populations defined by characteristic patterns of expression of 
cell-surface markers detectable by flow cytometry.  An important discovery in the 
classification of CD8+ T-cell subsets in humans was the full-length form of the protein 
tyrosine phosphatase CD45, CD45RA (122).  It is expressed on the surface of human naive T 
cells (TN) (123), the recently identified memory stem T cells (TSCM) (124), and the 
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terminally-differentiated, CD45RA-re-expressing T cells (TEMRA) (123).  The shorter 
isoform, CD45RO, is expressed by the antigen-experienced central-memory (TCM) (123) and 
effector-memory T cells (TEM) (123) (Fig. 1-4a).  T-cell subsets can be further classified 
functionally for the co-expressions of the lymphoid homing molecules, L-selectin (CD62L) 
and CC-chemokine receptor 7 (CCR7) (123) (Fig. 1-4a).  T-cells that express these 
molecules on their surface can home to secondary lymphoid structures, where they can 
survey pAPC for the presence of foreign antigen.  Cells in this category include naive T cells 
(TN) and two memory T-cell populations, TSCM (124) and TCM (123) (Fig. 1-4a).  Although 
both TN and TSCM express the RA isoform of CD45, TSCM can be distinguished from TN by its 
unique expressions of the IL-2/IL-15β chain receptor (CD122) and Fas (CD95) (124).  TCM, 
on the other hand, express the prototypical human Ag-experienced T-cell marker, CD45RO.  
In addition to their localization in lymphoid organs, all three T-cell subsets possess high 
proliferative and engraftment capacities upon adoptive transfer (125).  In contrast, TEM and 
TEMRA are antigen-experienced T cells that have down-regulated CD62L and CCR7 and 
therefore reside in peripheral rather than lymphoid tissues (123).  These T-cell subsets are 
poised to rapidly execute effector functions upon activation, as shown by their ability to 
release high levels of inflammatory cytokines, such as IFN-γ and TNF-α, and their ability to 
lyse antigen-expressing targets (123).  However, they may also possess a relatively limited 
proliferative and engraftment capacities, which correlate with their shorter telomere length, 
as compared to the CCR7+CD62L+ counterparts (125) (Fig. 1-4a).      
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Figure 1-4:  A current model of CD8+ T cell differentiation in humans.  (a) During an 
immune response, naive T cells (TN) are primed by professional antigen-presenting cells 
(pAPC) in secondary lymphoid organs.  Depending on the strength and quality of stimulatory 
signals, proliferating T cells progress along a differentiation pathway.  Naive T cells (TN) 
express the full-length CD45, CD45RA, and, when primed, develop into TCM or effector T 
cells that can self-renew.  Primed effector T cells express the CD45, RO isoform, and when 
antigen is eliminated, are rescued as memory T cells.  Central-memory T cells (TCM) express 
lymphoid homing receptors, CCR7 (CC-chemokine receptor 7) and CD62L (also known as 
L-selectin), and undergo homeostatic proliferation in lymphoid tissues.  Effector-memory T 
cells (TEM) express low levels of CD62L, do not express CC-chemokine receptor 7 (CCR7) 
or home to lymphoid tissues, and are less proliferative than TCM.  Senescent, terminally-
differentiated effector T cells (TEMRA) reacquire expression of CD45RA and are derived from 
TEM cells. TSCM is a newly discovered memory T cell type that is distinct from the previously 
characterized TCM and TEM cells. TSCM cells are less differentiated and share several markers, 
including CD45RA, with the naive T cells.  TSCM cells self-renew and differentiate in 
response to cytokines (dotted black arrows) or antigen (solid black arrows) and, in adoptive 
transfer experiments in murine models, have the highest reconstitution and antitumor 
capacity (124).  Reprinted with permission from Macmillan Publishers Ltd:  Nature 
Medicine. Sallusto F, Lanzavecchia A. 17(10):1182-3. 2011.  
(b) Costimulatory molecules have been the first markers used to dissect the heterogeneity of 
memory T cells. CD27 and CD28, which are expressed on naive T cells, are also expressed 
on some memory T cells, but are absent in a subset of CD8+ TEMRA cells characterized by 
high effector function.  The CD27-CD45RA+ CD8 T cell population largely overlaps with 
TEMRA.  However, some cells within TEMRA express CD27 and display phenotypic and 
functional features that are intermediate between naive and effector T cells. 
Reprinted with permission from: Annaul Reviews: Annual Reviews in Immunology. 
Sallusto F, Geginat J, and Lanzavecchia A.  22:745-763. 2004.  Reproduced with permission of 
ANNUAL REVIEWS in the format: Republish in a thesis/dissertation via Copyright Clearance 
Center.     
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Figure 1-4:  
(a) 
 
 (b) 
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Costimulatory receptors, CD27 and CD28, have also been used to delineate the 
heterogeneity of memory T cells.  These receptors are expressed on naïve T cells and on 
some memory T cells, but are lost on terminally-differentiated T cells (Fig. 1-4b).  The loss 
of CD28 expression has been associated with the emergence of oligoclonal, senescent, and 
natural-killer (NK)-like CD8+ T cells with shortened telomere length in humans (126) (Fig. 
1-5).  Expression of CD27 may further identify CD8+ CD28-  T cells that are closest to 
terminal differentiation and senescence(127).  It was shown that CD27- CD8+ CD28-  T cells 
have the shortest telomeres, decreased telomerase activity, and reduced capacity to 
proliferate after activation with anti-CD3 and irradiated professional APC (pAPC) compared 
with CD27+ T cells, indicating that CD27- CD8+ CD28- T cells have differentiated to an 
extent where co-stimulatory signals are no longer sufficient to induce telomerase activity 
(128).  The CD27−CD45RA+ CD8+ T cell population largely overlaps with TEMRA.  However, 
some cells within TEMRA express CD27 and display functional features that are in between 
naïve and terminally-differentiated effector T cells(123).  Therefore, Plunkett, et al., (128) 
postulated a linear differentiation pathway of CD8+ T cells from CD28+CD27+ (early-
differentiated) to CD28-CD27+ (intermediate-differentiated) and finally to CD28-CD27- (late-
differentiated) upon repeated stimulation in vitro.  The same pattern of CD28 and CD27 
expressions during the differentiation of CD8+ T cells was also described in vivo, where 
human immunodeficiency virus (HIV)-specific CD8+ T cells, during the early phase of 
infection, differentiated within 2-4 weeks from a CD27+CD28+ to a CD28-CD27+ phenotype 
(129, 130).   This was associated with the acquisition of a carbohydrate epitope HNK-1 
(human natural-killer-1, also known as CD57, synthesized by β-1,3-glucuronyltransferase 1), 
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a proposed marker of replicative senescence of CD8+ T-cells in chronic viral infection (130, 
131).    
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Figure 1-5:  Loss of CD28 expression is a central event in the progression from 
polyclonal naïve T cells to highly oligoclonal, senescent natural killer (NK)-like T cells.  
Results of studies with various in vitro replicative senescence systems have consistently 
demonstrated that the loss of CD28 expression is a central event in the senescence pathway 
of human CD4+ and CD8+ T cells.  Replicative pressure such as activation by common 
persistent Ags and by chronic inflammation leads to down-regulation of CD28 and to 
telomere length shortening that limits T-cell proliferation.  Coincident with these processes 
are the loss and/or gain of function, such as the loss of perforin among CD8+ T cells and the 
acquisition of natural killer cell (NK)-related receptors (NKR), killer cell immunoglobulin 
(Ig)-like receptor (KIR), and an activating NK receptor, NKG2D.  Expression of inhibitory 
forms of KIR and of members of the Ig-like transcripts (ILT) family could also confer 
suppressive activity. Similar to that seen with in vitro replicative senescence systems, normal 
chronological aging results in the accumulation of long-lived, terminally differentiated, 
oligoclonal CD28- NK-like T-cell effectors.    
Reprinted with permission from: Vallejo, A. N. (2005), CD28 extinction in human T cells: 
altered functions and the program of T-cell senescence. Immunological Reviews, 205: 158–169. 
doi: 10.1111/j.0105-2896.2005.00256.x.  Http://onlinelibrary.wiley.com/doi/10.1111/j.0105-
2896.2005.00256.x/abstract  [Ref. (126)].      
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Figure 1-5: 
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It is not clear which subset(s) of CD8+ TIL contribute more to the long term control 
of tumor growth.  The aforementioned differentiation/memory T-cell markers have been used 
to gain an understanding into these questions, but the data has been inconsistent and 
confusing.  In a murine B16 melanoma tumor model, the adoptive transfer of TSCM cells 
exhibited the most effective control of melanoma tumor growth among all different T-cell 
subsets (132) (Fig. 1-4a).  Although such TSCM CD8+ T cells exist in the peripheral blood in 
humans, they have not been found in melanoma TIL populations.  The other T-cell subset, 
TCM, can migrate to lymph nodes, where they may encounter activated pAPC (e.g., dendritic 
cells) presenting TAA either derived from vaccination or from dying tumor cells (133).  
Although an adoptive transfer of melanoma TAA-specific TCM have been shown in murine 
models to be superior T cells for ACT (125),  it must be noted this effect occurs only when a 
vaccination with the specific TAA is given concurrently following cell transfer.  Thus, TCM 
may not be useful for ACT without concurrent vaccination with TAA, since these T cells 
have limited homing to tissue or tumor, and exhibit no anti-tumor cytolytic activity unless re-
stimulated by mature pAPC (133).   Also, only a very few central memory CD8+ T-cells 
(TCM) are found TIL, especially after the extensive expansion with REP used to generate TIL 
infusion products, which were mainly consisted of TEM (early, intermediate, and late) and 
TEMRA CD8+ T cell subsets (60, 71).  Early TEM cells are capable of proliferation, have longer 
telomere length, and have some capacity for self-renewal (133).  However, they have a 
limited capacity as cytolytic effector cells, as they express granzymes, but very low to no 
expressions of perforin and other critical killing proteins, such as granulysin (133).  On the 
other hand, late-differentiated TEM cells and TEMRA, which express much higher amounts of 
granzymes and perforin, have been reported as the most potent cells for inducing effective 
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cytotoxic killing of tumor cells (133)
.
  However, these CD8+ T cells
 
have shorter telomeres 
and less T-cell costimulatory receptors, causing them to be less proliferative following TCR 
stimulation than TEM cells (133).  They are also more sensitive to activation-induced cell 
death (AICD) and cannot traffic to lymph nodes (133).  At the present time, there is no clear 
evidence that they mediate long-term memory response against tumors after ACT.     
NCI’s phase II clinical trials have reported that early-differentiated TEM cells 
expressing CD27 are associated with clinical response to TIL therapy (85, 134).  These 
studies, however, only show a positive correlation when reported as total CD8+CD27+ 
infused, but not as a percentage of the CD8+ T cells infused.   Thus, higher numbers of CD8+ 
T cells infused may account for this correlation.  On the other hand, earlier reports from NCI 
showed that the persistence of TIL in vivo was correlated with positive clinical responses, 
and that the subset of TIL showing persistence in vivo was CD8+CD28+, not CD27+ TIL 
(103, 135, 136).   Our group has also reported that MART-1 (TAA)-specific CD8+CD28+ 
TIL after the REP possessed longer telomere length, proliferated better, survived better, and 
responded better to re-stimulation with pAPC than CD8+CD28- TIL, whereas no difference 
was found between CD27+ and CD27- TIL (96).  Thus there was no clear mechanistic basis 
for the clinical correlation with CD8+CD27+ TIL.  To confuse matters more, in the ongoing 
Phase II ACT clinical trial at MD Anderson Cancer Center where over 70 patients have been 
treated, we have found that the more differentiated CD8+CD27- T cells were significantly 
correlated with positive clinical response to TIL, while the correlation with CD8+ TEM did not 
reach statistical significance (60, 71).   It must be noted that many of these CD8+CD27- T 
cells had retaind at least some CD28 expression. Also many of these cells were positive for 
another activation marker called B- and T- lymphocyte attenuator (BTLA), a marker for less-
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differentiated CD8+ TIL that we have found to be positively correlated to clinical response to 
adoptive cell therapy using melanoma TIL (Chapter 3, also manuscript in preparation).   
A different way in thinking about the relationship between CD8+ T-cell 
differentiation and anti-tumor activity is that a cooperation between early differentiated and  
late differentiated CD8+ memory and effector subsets are needed to maximize the therapeutic 
potential of ACT with TIL for melanoma (Fig. 1-6).  According to this view, late-
differentiated TEM or TEMRA, which highly express granzymes and perforin, yet are poorly 
persisting in vivo, provide immediate control of tumor growth, while early-differentiated TEM 
cells maintain more long-term tumor control by having the capacity to divide and replenish a 
pool of more differentiated T cells after adoptive transfer.  This model is a new conceptual 
framework for ACT with TIL which, if proven correct, suggests that the adoptive transfer of 
different types of TIL products enriched in CD8+ T cells with appropriate early and late 
differentiation phenotypes at different times into patients may be a new approach to ACT.   
This also fits in line with how CD8+ cytotoxic T-cell populations against chronic viral 
infections, such as cytomegalovirus (CMV), are maintained over decades in humans.  Here, 
younger CMV-specific TEM CD8+ T cells are thought to turn over and differentiate into 
terminally-differentiated CD8+CD28-CD57+ populations that have immediate cytotoxic 
potential, can survive for extended periods of time, and turn over more slowly than their 
younger less-differentiated precursors (127, 137).   
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Figure 1-6:  Model for the cooperation of CD8+ T-cells at different stages of 
differentiation in controlling tumors in vivo following ACT with TIL.  The model 
proposes that early, TEM, late TEM, and TEMRA may all play a critical role in adoptive cell 
therapy at different times to control tumor growth.  In order for CD8+ TIL to become 
cytolytic effector cells against tumor cells, this requires differentiation into late TEM and 
TEMRA cells.  In contrast, early TEM cell are long-lived, but have low cytolytic potential.  The 
late TEM and TEMRA subsets, which are more oligoclonal (Fig. 1-5), execute an early wave of 
tumor killing.  These cells are relatively short-lived and can be replaced by the more 
polyclonal early TEM that possess a higher intrinsic proliferative capacity and can 
differentiate later into cytolytic effector cells.  In addition to these infused TIL subsets, 
endogenous T cells re-appearing in the patients after transient lymphodepletion may also play 
a role at these later times by recognizing tumor antigens initially released from early waves 
of tumor killing. 
Reprinted with permission from: Wu, R. Forgét, MA, Chacon J, Bernatchez C, Haymaker C, Chen 
JQ, Hwu P, and Radvanyi L.  Adoptive T-cell Therapy Using Autologous Tumor-infiltrating 
Lymphocytes.  2012. The Cancer J. 18(2):160-75.  doi: 10.1097/PPO.0b013e31824d4465. 
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Figure 1-6: 
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Chapter 2 
 
 
 
Detection and characterization of a novel subset of CD8+CD57+ T 
cells in metastatic melanoma with an incompletely  
differentiated phenotype 
 
 
 
 
Partially reproduced and adapted for this doctoral dissertation with permission 
from the publisher (American Association for Cancer Research):  
 
Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, Murray JL, 
Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.   
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Introduction 
 
CD8+ cytotoxic T lymphocytes (CTL) play a major role in anti-tumor responses by 
lysing tumor cells in an antigen-specific manner through the action of granzymes [e.g., 
granzyme B (GB)], which belong to a family of serine proteases that cleave at aspartate 
residues in the substrate, and perforin (Perf) (114, 115).  Perforin forms pores in the plasma 
membrane of target cells, which allows granzymes to enter the target cell and activate 
caspases (e.g., caspase 3), causing apoptosis in the target tumor cells (114).  Uncovering how 
CD8+ T cells’ differentiation and effector function can be altered in the tumor 
microenvironment is critical to understand why most tumors continue to progress, despite 
being infiltrated with CD8+ T cells.   
Terminally-differentiated effector (TTDE) CD8+CD57+ CTL, which express high 
levels of GB and Perf, have been reported as the most potent type of CTL for combating 
chronic viral infections, as well as inducing effective cytotoxic killing of tumor cells(138-
143).  Most healthy adults contain a population of persisting, long-lived CMV-specific CD8+ 
CD27-CD28- CD57+, and GBHi PerfHi lymphocytes in the peripheral blood that exhibit 
spontaneous anti-viral CTL activity (142-145).  Differentiation of CD27+ CTL precursors 
have been shown to be critical for maintaining a pool of mature CD57+ CTL, which controls 
CMV and EBV infections in humans (131, 141, 145, 146).  However, differentiation towards 
such mature CTL phenotype can be affected in situations where CD8+ T cells undergo 
chronic antigen stimulation, as has been reported for patients having re-activation of HIV and 
EBV infections (144, 147), where an accumulation of incompletely differentiated 
CD8+CD27+CD57+ CTL leads to a loss of control of viral replication (145).   
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In cancer patients, the role of the CD8+CD57+ T cells in the control of tumor growth 
has not been clearly defined (148).  In malignant melanoma, renal cell carcinoma, and gastric 
carcinoma, it was reported that patients who harbored higher percentages of CD8+CD57+ 
lymphocytes in their peripheral blood had shorter overall survival (149-151).  However, in 
those studies, other differentiation markers (e.g., CD27, CD28, CD45RA) that could be 
expressed by the CD8+CD57+ T lymphocytes were not further characterized.  CD8+CD57+ T 
cells in the peripheral blood of advanced gastric carcinoma patients have been shown to have 
lower Perf expression and IFN-γ production as compared to healthy individuals (152).   In 
contrast, CD8+CD57+ cells with a late-differentiated phenotype (CD27-CD28-GBhighPerfhigh) 
accumulate in the peripheral blood of normal aged individuals and are the main IFN-γ-
producing CD8+ T cell subset (153).  CD8+CD57+ T cells have also been positively 
associated with potent anti-tumor and anti-viral (CMV in particular) effector functions and 
longer relapse-free survival in leukemia patients after stem-cell transplant (138, 154).   
Little is known about the frequency and function of the CD8+CD57+ CTL within the 
tumor-infiltrating lymphocytes (TIL) populations in solid tumors, such as melanoma or 
breast cancer.  Recently, a distinct population of CD8+ CTL in human peripheral blood with 
late-differentiation characteristics (CD27-CD28-GBHiPerfHi) was found to express another 
natural-killer (NK) cell marker, CD56 (also known as NCAM, Neural Cell Adhesion 
Molecule) (142, 143, 155).  CD8+CD56+ CTL (CD3+) that did not co-express CD57 
exhibited an even higher spontaneous cytolytic activity than CD57+ CTL against tumor 
targets; they re-express CD45RA as well as high levels of Perf and GB expression (155).  It 
is not known whether CD8+ TIL preferentially differentiate to become CD56+ or CD57+ 
effector CTLs.   
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In this study, we conducted a detailed analysis of the phenotypic differentiation of 
CD8+ TILs in 44 melanoma metastases (lymph-node (LN) and non-LN) and 5 breast cancer 
metastases using multicolor flow cytometry.  A similar study previously reported by others 
focused exclusively on T-cells infiltrates in lymph mode metastases (156).  In our studies 
here, we included a large number of non-lymph node visceral melanoma metastases in order 
to exclude contributions from non-tumor specific, resident lymph node immune cells.  Our 
study was also important because melanoma patients frequently die from visceral, non-lymph 
node metastases.  We did not find a population of CD8+CD56+ CTL in freshly-isolated 
melanoma TIL, but instead observed a significant population of CD8+CD57+ TILs.  
Moreover, we found that the majority of the CD57+ TIL in melanoma and breast cancer 
pleural effusions also co-expressed CD27 and CD28, markers of effector-memory T cells 
(TEM) (123, 147, 157)  with intermediate levels of GB expression and low-to-absent Perf 
expression, similar to that of the CD8+CD27+CD57+ T-cell population that was recently 
described in HIV-infected patients who were progressors (145).  These CD8+CD27+CD57+ 
T-cells could be induced to differentiate into late-differentiated CD27-CD57+, PerfHi CTL 
after short-term TCR stimulation and recovered high cytolytic activity.  In addition, we 
showed that the differentiation of this unique subset in TIL could be inhibited by TGF-β1, a 
cytokine with potent immunosuppressive activity and is known to be produced by many 
types of tumor cells, including melanoma (158-161).  These results suggest that the 
differentiation pathway of CD8+ TIL to a late-differentiated, mature CD8+CD57+ CTL 
lineage is blocked, which may be caused by the presence of immunosuppressive factors 
within the tumor microenvironment. 
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Materials and Methods 
 
Reagents.  Flow cytometry antibodies were purchased from BD Biosciences (San Jose, CA), 
eBioscience (La Jolla, CA), or Beckman-Coulter (Brea, CA). Human recombinant IL-2 
(ProLeukin™) was a generous gift from Novartis (East Hanover, NJ).  KLRG1-Alexa 488 
mAb was a gift from Dr. H. Pircher (Freiburg, Germany).   
Patient TIL and PBMC samples.  TIL and blood samples for laboratory studies were 
obtained from patients with Stage IIIc to Stage IV melanoma who were undergoing surgery 
at The University of Texas MD Anderson Cancer Center according to an Institutional Review 
Board–approved protocol and patient consent.  The resected melanoma metastases were cut 
up into 3-5 mm2 fragments after trimming away fat and connective tissue and disaggregated 
in cold RPMI 1640 using gentle mechanical pulverization using a Seward Stomacher device 
(Fisher, Pittsburgh, PA).  This process rapidly produces a single cell suspension without 
enzymatic digestion.  The cell suspension was filtered through a 75 µm pore-size screen (BD 
Biosciences, San Jose CA) and washed culture medium.  A portion of the cells used for 
immediate staining and analysis by flow cytometry were washed in culture medium and the 
cell suspension layered over a discontinuous 70% followed by a 100% Ficoll Isopaque 
gradient, and centrifuged separate the tumor cells (70% interface) from the enriched TIL 
(100% interface).  Typically 0.5 x 106 to 5 x106 lymphocytes were isolated initially from 
tumor fragments, depending on the size of tumors.  In cases where cultured TIL were studied, 
the TIL from tumor samples were expanded in TIL culture medium (TIL-CM) consisting of 
RPMI 1640 with Glutamax (Invitrogen), 10% human AB serum (Sigma, St. Louis, MI), 50 
mM 2-mercaptoethanol (Invitrogen), 1 mM pyruvate, 1X Penicillin/Streptomycin 
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(Invitrogen) using high-dose (HD) 3,000 IU/mL recombinant IL-2, as described previously 
(96).        
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient 
separation with Ficoll-Isopaque from normal donors from buffy coats obtained from the Gulf 
Coast Regional Blood Center (Houston, TX) or peripheral blood from Stage IV melanoma 
patients collected in heparizined tubes (BD Biosciences).  The PBMC were cryopreserved in 
10% DMSO, 90% human AB serum until analysis. 
Pleural effusions were also collected from metastatic breast cancer patients under an 
IRB-approved protocol.  Lymphocytes in pleural effusions were isolated by centrifugation 
over 70% and 100% Ficoll-Isopaque double layers to separate tumor cells from lymphocytes.  
The lymphocytes were collected at the 100% Ficoll-Isopaque layer and washed in TIL-CM 
before flow cytometry staining.   
Surface and intracellular staining by flow cytometry.  Freshly-isolated TIL and TIL 
cultured and expanded with IL-2, as well as thawed normal donor or patient PBMC, were 
washed twice in D-PBS and stained using Live/Dead® Fixable Aqua Dead Cell Stain Kit 
(Life Technologies, CA) according to manufacturer’s instruction (Fig. 2-1A).  Cells were 
then washed twice in FACS wash buffer (D-PBS + 1% BSA) and stained for 30 min at 4°C 
with antibodies conjugated with fluorochromes against different T-cell cell surface and 
intracellular markers. In the cases of HLA-A2.1+ patients, the TIL suspensions were 
additionally stained with MART-1 peptide (ELAGIGILTV) HLA-A2.1 tetramer, gp100 
peptide (IMDQVPFSV) HLA-A2.1 tetramer, or control HLA-A2.1 tetramer containing   
HIV-gag peptide (SLYNTVATL) (Beckman Coulter, Brea, CA) (Fig. 2-2).  The cells were 
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finally fixed in D-PBS, 1% p-formaldehyde and 0.25% ethanol. Intracellular staining for GB 
and Perf was done by according to manufacturer’s protocol (BD Biosciences).  Flow 
cytometric analysis was performed using a FACSCanto II flow cytometer (Becton-
Dickinson, San Jose, CA).  The positive and negative regions of the staining of the indicated 
surface markers were determined by comparing against the unstained samples (Fig. 2-1B). 
Data was analyzed using FACSDiva (BD Biosciences) or FlowJo software (Tree Star Inc, 
Ashland, OR).  Proliferation was assessed by intracellular staining for Ki67 using an anti-
Ki67-APC antibody (BD Biosciences).  
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Figure 2-1: Methods for distinguishing between live and dead cells in TIL freshly isolated 
from melanoma metastases and defining the positive and negative regions of the indicated 
surface markers.  (A) TIL were isolated from tumor fragments as described in Supplementary 
Methods.  Typically 0.5 x 106 to 5 x 106 lymphocytes were isolated, depending on the size of 
the tumor fragments. Freshly-isolated TIL were stained with Live/Dead® Aqua cell exclusion 
dye (Invitrogen) followed by staining for the indicated surface markers. At least 100,000 
light scatter events were acquired by the flow cytometer. Live cells were gated on in the 
Aqua-negative region. (B) The expressions of the indicated surface markers were determined 
by comparing the stained (A) versus unstained (B) TIL sample from the same patient.   
 
Reprinted with permission from:  Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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Figure 2-1: 
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Figure 2-2.  Method for determination of tumor antigen-specific CD8+ population in TIL.  In 
order to determine the actual vs. background staining of CD8+ melanoma TIL for the HLA-
A2 tetramers loaded with MART-1 or gp100 peptides (Beckman Coulter, see Material and 
Methods), a comparison was made between TIL samples from a HLA-A2+patient against a 
HLA-A2- patient. A minimum of 100,000 gated light scatter events were acquired for each 
sample. (A) Flow cytometry plot of a HLA-A2+ TIL patient having low frequencies of tumor 
antigen-specific CD8+ TIL for MART-1 (0.5%) or gp100 (0.2%).  (B) Flow cytometry plot 
of a HLA-A2- patient whose CD8+ TIL did not react with HLA-A2 tetramers.   
Reprinted with permission from:  Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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Figure 2-2: 
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Sorting and 3H-thymidine incorporation assay.  IL-2-cultured TILs were stained with anti-
CD8-Pacific Blue, anti-CD27-APC-Cy7 and anti-CD57-FITC in PBS containing 1% BSA 
and 5% goat serum.  The CD8+CD27+CD57- and CD8+CD27+CD57+ subsets were sorted 
using an InFlux® cell sorter (BD Biosciences).  5 x 104 viable cells per well were plated into 
96-well Costar 3361 High-bind plates (Sigma-Aldrich, St. Louis, MO) precoated overnight 
with anti-CD3 (OKT3; Ortho Biotech, Raritan, NJ) or anti-CD3 and anti-CD28 (eBioscience, 
La Jolla, CA) agonistic antibodies.  After 3 days, the cells were pulsed with 1 µCi of [3H]-
thymidine (methyl-T-thymidine, PerkinElmer Inc., Boston, MA) for 18 h.  The incorporated 
[3H] thymidine was determined as counts per minute by using a beta liquid scintillation 
counter (Beckman Coulter, Brea, CA).   
Human Th1/Th2 multiplex cytokine analysis.  The tissue culture supernatants from a 
triplicate wells of sorted, TIL subsets from unstimulated and stimulated conditions were 
collected and plated on the multiplex ELISA plate configured to detect a panel of human 
Th1/Th2 cytokines (IFN-γ, IL-2, IL-4, IL-5, IL-10, IL-12 p70, and IL-13), according to the 
manufacturer’s instructions (Meso Scale Discovery, Gaithersburg, MD). The signals were 
captured and analyzed by the SECTOR Imager 2400 (Meso Scale Discovery, Gaithersburg, 
MD).  The concentration of each cytokine was calculated from its each respective standard 
curves.  For analysis using a multiplex cytokine bead assay, the tissue culture supernatants 
from a triplicate wells of sorted, TIL subsets from unstimulated and stimulated conditions 
were collected, diluted to 1:3 ratio, and added to magnetic beads coated with immobilized 
antibodies against selected human cytokines (IFN-γ, IL-5, IL-13 and TNF-α) in a Milliplex® 
MAP human multiplex cytokine kit, according to the manufacturer’s instructions (EMD 
Millipore, Billerica, CA).  The signals from the Strepavidin-Phycoerythrin (PE) coated beads 
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were acquired and analyzed by the Luminex® 100 IS System (Luminex® Corporation, 
Austin, TX).  The concentration of each cytokine was calculated from its each respective 
standard curves.    
TCR Vβ spectratyping.  RNA was isolated from sorted CD8+ TIL subsets with RNA-STAT 
60 reagent (Isotex Diagnostics, Friendswood, TX) according to manufacturer’s instructions.  
After reverse-transcription of 1 µg of RNA to cDNA with SuperScript®III reverse 
transcriptase (Invitrogen, Carlsbad, CA), TCR Vβ mRNA expression profiling and size 
spectratyping of the 23 antigen-binding Vβ CDR3 regions was performed as previously 
reported (162).  Primer sequences for each of the 23 Vβ families are available upon request.  
CDR3 spectratypes were assessed using the OpenGene® System (Bayer, Berkeley, CA).    
In vitro differentiation assay.  CD8+ TIL were sorted into subsets as described previously 
and stimulated with anti-CD3 or anti-CD3 and anti-CD28 antibodies precoated on Nunc® 
plates (Thermo Fisher Scientific, NY).  IL-2 (200 IU/ml) was added to each culture to 
maintain cell viability.  Human TGF-β1 (R&D Systems, Minneapolis, MN) was used at 1 
ng/ml for the TGF-β1-treated group.  After 7 days, the cells were stained for CD8, CD27, 
CD28, CD56, and CD57.  Intracellular staining for GB and Perf was done as described 
above. 
Redirected cytotoxic T-cell assay.  Analysis of CTL activity on the sorted CD8+ subsets was 
done according to a novel flow cytometric method measuring the cleavage of caspase-3 in 
anti-CD3 coated target cells as described previously (163).   Briefly, 5 x 106 murine 
mastocytoma target cells (P815) were labeled with a fixable, far-red fluorescent tracer, 
CellTrace® Far Red DDAO-Succinimidyl Ester (DDAO-SE; Invitrogen, Carlsbad, CA) 
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according to manufacturer’s instructions, washed, resuspended at a density of 2.5 x 106/mL, 
and pulsed with 200 µg/mL of anti-CD3 mAb in a low-serum containing media (RPMI 1640 
with 2% FBS) at RT for 30 min.  Unpulsed target cells served as controls. Labeled, pulsed 
P815 target cells were added to the sorted TIL subsets at E:T ratios of 1:1 and 3:1, or 1:10 
and 1:20 in a round-bottom 96-well plate and spun down for 5 min at low centrifuge speed 
(300 RPM) in order to maintain optimal contact between target cells and effector T cells.  
The cells were co-incubated for 3 h before harvesting. The 3 hour time point was chosen to 
prevent the apoptotic target cells from becoming necrotic and losing the cleaved caspase-3 
signal. The cells were stained intracellularly with an anti-cleaved caspase-3-PE mAb (BD 
Biosciences).  Target cells were distinguished from effector T cells by the far-red tracer 
DDAO-SE (which fluoresce in the APC channel), and the extent of the caspase-3 cleavage in 
the target cell population was analyzed by the FACSanto II flow cytometer (BD 
Biosciences).  
Statistical analysis.   The two-tailed, paired Wilcoxon rank-sum test was used to analyze the 
statistical significance in differences between two groups, and two-tailed nonparametric 
Kruskal-Wallis test followed by Dunn’s multiple comparison test were used for more than 
two sample groups.  p ≤ 0.05 was deemed to be statistically significant.   GraphPad Prism 
version 5.0 (GraphPad Software, La Jolla, CA) was used for graphing and statistical 
analysis.    
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Results 
Patient tumor samples and experimental approach 
In this study, tumors were surgically excised from Stage III/IIIc and Stage IV (M1a-
M1c) melanoma patients as part of an ongoing adoptive T-cell therapy clinical trial at MD 
Anderson Cancer Center (Houston, TX).  A supplemental table, showing the characteristics 
of the melanoma patients, including patient age, sex, tumor location, disease stage, and 
anatomical sites, is available online as part of the following publication: Wu R, et al. 2012. 
Clin. Can. Res. 18(9): 2464-77.   The tumors were processed immediately after surgery for 
multicolor flow cytometry staining and expansion of TIL.   
Presence of a CD8+CD57+ subset highly positive for CD27 and CD28 and absence of 
CD8+CD56+ T cells in TIL freshly isolated from melanoma tumors  
As CD8+ T cells transition from TEM into fully-differentiated (TTDE) CTL, they 
generally acquire GB and Perf expression, down-regulate CD27 and CD28, and express 
CD57, or in some cases, CD56.  This TTDE phenotype (CD27-CD28-CD56+ or CD27-CD28-
CD57+) is associated with immediate cytolytic activity, with no requirement for antigenic re-
stimulation to induce CTL function (140, 143, 155, 157).  To determine the extent of the 
TTDE phenotype in tumors, we first gated on the live CD8+ lymphocytes, as determined by the 
Aqua Live/Dead® exclusion dye (Invitrogen), on TIL freshly isolated from tumors (Fig. 2-1).  
We then analyzed them for CD4, CD8, CD27, CD28, CCR7 and CD45RA expressions using 
multicolor flow cytometry. A majority of the bulk as well as tumor antigen-specific CD8+ 
TIL from melanoma tumors displayed a TEM phenotype (CD27+, CD28+, CCR7-, CD45RA-)  
(123, 157) (Fig. 2-3 and 2-4) 
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Figure 2-3:  Melanoma metastases contained bulk and tumor antigen-specific CD8+ T cells 
with a CD27+CD28+CD45RA- effector-memory phenotype.  Single cell suspensions, isolated 
from surgically-removed LN and non-LN melanoma metastases were stained with a panel of 
fluorochrome-conjugated antibodies against human CD4, CD8, CD27, CD28, CD57, CCR7, 
and CD45RA. Results were shown by gating on the live cells as described previously.  (A) 
FACS dot plots of one representative bulk TIL preparation from Tumor #2276 is shown. 
CD8+ T-cells or CD8- cells were identified in dot plots of side scatter (SSC) versus CD8 after 
dead cell removal; each gated subset was then analyzed for the indicated markers shown.  (B) 
Isolated cell suspensions from involved LN and non-LN  melanoma metastases of HLA-
A2.1+ patients were stained with antibodies for the same markers as in panel A, in addition to 
an HLA-A2.1 tetramer containing either Melan-A/MART-1 peptide, gp100 peptide, or CMV 
peptide (negative control, not shown).  The CD8+ T-cell subset was gated and analyzed for 
MART-1 or gp100 tetramer+ cells.  The tetramer+ cells were then gated and analyzed for 
CD27 and CD28 expression.  Figure shown in panel B represents the tetramer staining of two 
different tumor antigen specificities (Mart-1 and gp100) from the same patient.  (C) Tetramer 
staining of a different HLA-A2.1+ patient with antigen specificity to gp100 only, which  
showed the majority of antigen-specific TIL being CD27+CD28+.  The HIV gag peptide 
tetramer in each case stained <0.05% of the CD8+ cells (not shown).  
Reprinted with permission from:  Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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Figure 2-3: 
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Figure 2-4: Summary of CD27 and CD28 expression in the CD8+ TIL subsets (n=39) and in 
the CD8+MART-1 tetramer+ TIL subset (n=11) of metastatic melanomas showing a lack of 
CD27-CD28- fully differentiated T cells and the preponderance of CD27+CD28+ TEM.  
Isolated TIL were stained in a panel of fluorochrome-conjugated antibodies against (A) CD4, 
CD8, CD27, CD28, CD57, CCR7, CD45RA, and (B) MART-1 tetramer in HLA-A2+ 
patients.  Results were shown by gating on the live cells as described previously. They were 
analyzed for CD27+, CD28+, CD27+CD28+, CD27-CD28-, and CCR7+ cells as indicated.  
Each dot represents a single patient sample with the bars indicating the averages for all 
samples. Results for gated CD8+ (A) and CD8+MART-1 tetramer+ (B) subsets are shown.  
 
Reprinted with permission from: Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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The specificity of the MART-1 and gp100 tetramer staining was verified against a 
negative control, HIV gag tetramer (data not shown) as well as comparing against HLA-A2- 
patients (Fig. 2-2).  We then stained the TIL for CD8, CD27, CD28, CD56, and CD57 and 
analyzed the relationship between end-stage CTL markers (CD57 and CD56) vs. TEM 
markers (CD27 and CD28).  We found that a significant population of CD57 single positive 
cells was seen without CD56 expression (see Fig. 2-5A for a representative example).       
Fig. 2-5B shows this predominance of CD8+CD57+ cells (mean percentage ± SEM = 16.2 ± 
3.5) over CD8+CD56+ cells (mean percentage ± SEM: 1.0 ± 0.6) (paired Wilcoxon rank-sum 
test; p < 0.005) in the CD8+ subset in freshly-isolated TIL for ten separate patient samples.  
Upon further analysis of the staining profiles from the freshly-isolated TIL samples, we 
found that many CD8+CD57+ T cells co-expressed CD27 and CD28, which could be 
considered as a hybrid of late-stage CTL and early TEM markers (Fig. 2-5C).  We also found 
that PD-1, a marker for antigen-experienced CD8+ T cells, exhausted CD8+ T cells, or CD8+ 
TEM in normal donor PBMC (164-166), was more enriched in the CD27+CD57+ than the 
CD27+CD57- subset (Fig. 2-6; Kruskal-Wallis test, p < 0.05), in the tumors from ten different 
metastatic melanoma patients, which suggests that the CD27+CD57+ “hybrid” phenotype 
may represent a more differentiated effector phenotype than that of the CD27+CD57- TIL 
subset.   
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Figure 2-5:  Lack of CD56-expressing end-stage CTL and the appearance of a novel subset 
of CD8+CD57+ melanoma TIL co-expressing CD27 and CD28.  (A)  Fresh TIL isolates were 
stained with a panel of fluorochrome-conjugated antibodies for CD4, CD8, CD27, CD28, 
CD56, and CD57. Results were shown by gating on the live cells as described previously.  A 
minimum of 100,000 gated light scatter events per sample were acquired on the flow 
cytometer. CD56 and CD57 expression in the CD8+ subset in a representative patient TIL 
sample is shown.  (B) A summary of the CD8+CD56+ and CD8+CD57+ populations in 10 
freshly-isolated TIL from melanoma tumors. Significant difference was calculated by a two-
tailed, paired Wilcoxon rank-sum test.  (C) The gated CD8+CD57+ and CD8+CD57- sub-
populations were further analyzed separately for CD27 versus CD28 expression.  Examples 
of TIL from two melanoma patient tumor samples are shown.   
Reprinted with permission from: Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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Figure 2-6:  PD-1 expression is enriched in the CD8+CD27+CD57+ TIL subset freshly 
isolated from melanoma metastases (n=10).  (A) Fresh TIL isolates from 10 melanoma 
patients were stained in a panel of fluorochrome-conjugated antibodies against CD4, CD8, 
CD27, CD28, CD57, and PD-1. . A minimum of 100,000 gated light scatter events per 
sample were acquired on the flow cytometer.  Results were shown by gating on the live cells 
that were determined using Live/Dead® Fixable Aqua Dead Cell Stain Kit (Life 
Technologies, CA).  PD-1 expression in the each gated CD8+ TIL subset from patients’ TIL 
samples are shown. Significant differences between the groups were calculated by a two-
tailed, nonparametric Kruskal-Wallis test followed by Dunn’s multiple comparison test.                 
ns: not significant.   
Reprinted with permission from: Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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We also stained PBMC from patients and normal donors to determine the extent of 
CD27+CD28+ CD8+CD57+ T cells.  Comparing TIL and PBMC from the same patient, we 
found that the CD8+ T cells in the PBMC had only a few (<5%) of CD57+ T cells co-
expressing CD27 and CD28, while almost 60% of the CD8+CD57+ TIL co-expressed CD27 
and CD28 (Fig. 2-2A).  Similarly, only a few (<5%) of the CD8+CD57+ in PBMC of normal 
donors co-expressed CD27 and CD28 (Fig. 2-7A).  In contrast, melanoma TIL contained, on 
average, >20% of the CD8+CD57+ subset co-expressing CD27 and CD28 in samples 
analyzed from a larger number of patients (Fig. 2-7B).  An examination of the melanoma 
antigen-specific CD8+ subsets (MART-1 and gp100) in fresh TIL isolates by using tetramer 
staining revealed these tetramer+ cells were either CD27+CD57- or CD27+CD57+, with a 
negligible fraction of cells having a CD27-CD57+ or CD57-CD27- phenotype (Fig. 2-7C).   
 
 
 
 
 
 
 
 
 
- 60 - 
 
Figure 2-7:  Relatively few fully differentiated CD8+CD27-CD28-CD57+ TIL were found in 
metastatic melanomas compared to peripheral blood of patients and normal donors.  TIL 
isolated from melanoma metastases and PBMC from Stage III/IV melanoma patients were 
stained in a panel of fluorochrome-conjugated antibodies against CD4, CD8, CD27, CD28, 
CD56, and CD57.  PBMC from 2 normal donors were similarly stained for comparison. 
Results were shown by gating on the live CD8+ lymphocytes, as described previously, and 
analyzed for CD27 and CD28 expressions.  (A) The results from one representative TIL 
isolate from tumor #2163, one representative patient PBMC sample, and two normal donors.  
(B) Analysis of the CD57+ subset co-expressing CD27 and CD28 in the CD8+ T-cell 
population in a larger group of melanoma TIL samples (n=18), melanoma patient PBMC 
(n=12), and normal donor PBMC (n=6) samples.  The percentage of gated CD8+CD57+ 
subset co-expressing CD27, CD28, or both, was plotted for each sample type.  Each dot 
represents a single sample with bars indicating the averages for each sample group. Results 
of a Student’s t-test between the TIL and patient PBMC are shown for each subset (p< 0.05 
indicates statistical significance).  (C)  Melanoma metastases from HLA-A2.1+ patients were 
stained with antibodies for the same markers as in panel A together with tetramer containing 
either a human HLA-A2.1 MART-1 epitope or the human gp100 epitope. The CD8+ T-cell 
subset was gated and analyzed for MART-1 or gp100 tetramer+ cells.  The tetramer+ cells 
were then gated and analyzed for CD27 and CD57 expression.  Shown are two examples of 
the analysis done using TIL from two different patient metastases (#2058 and #2276).   
 
Reprinted with permission from: Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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Figure 2-7: 
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CD8+CD57+CD27+ melanoma TIL are GB+, but Perf-/low  
We next determined the intracellular GB and Perf expression, markers used to identify end-
stage (TTDE) CTL, in CD8+CD27+CD57+ TIL in melanoma.  We also obtained pleural 
effusions from newly diagnosed metastatic breast cancer patients to determine whether 
CD8+CD57+ co-expressing CD27 and CD28 were also found in other forms of cancer, and 
what their GB and Perf expression might be.  First, in melanoma TIL, we found that the 
majority of gated CD8+CD27+CD57+ and CD8+CD27+CD57- cells expressed GB, but most of 
the cells in both subsets had low or negative Perf expression (Fig. 2-8A).  Using the same 
gating approach, we analyzed fresh melanoma TIL samples from 7 Stage IV melanoma 
patients, PBMC samples from 17 Stage IV melanoma patients, and PBMC from 6 normal 
donors.  Shown in Fig. 2-8B was an example of the analysis that compared CD8+CD57+ T 
lymphocytes’ GB and Perf contents in a patient’s TIL against the same patient’s PBMC and 
that of a normal donor.  In Fig. 3C, 48.0 ± 8.6 % (mean ± SEM) of CD8+CD27+CD57+ TIL 
from 7 patients were found to express GB, whereas only 20.5 ± 6.0 % expressed Perf.  In 
contrast, averages of 94 ± 1.7 % and 80.9 ± 4.2 %, of the CD8+CD57+ lymphocytes in the 
peripheral blood of 17 melanoma patients were positive for GB and Perf, respectively.  The 
difference was statistically significant for both GB and Perf (p<0.001, respectively; Kruskal-
Wallis test).  When we analyzed lymphocytes isolated from breast cancer pleural effusions, 
we also found that many CD8+CD57+ cells co-expressed CD27 and CD28, and that these 
cells were predominantly GB+ with very little or no Perf expression (Fig. 2-9).   
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Figure 2-8:  CD8+CD57+ subset in the melanoma microenvironment has a unique           
GB+Perf-/low phenotype compared to the same subset in patient and normal donor PBMC.  
(A)  TIL isolates were stained for CD8, CD27, CD28, CD57, GB, and Perf expression, as 
described in Material and Methods. Results were shown by gating on the live cells as 
described previously.  The gated CD8+CD57+ and CD8+CD57- sub-populations were further 
analyzed separately for GB and Perf expression.  One representative melanoma TIL sample 
is shown.  (B) Results comparing GB and Perf expression in the CD8+CD57+ TIL and 
CD8+CD57+ T cells in PBMC from the same patient (#2163) and in a representative normal 
donor. (C) Summary of GB and Perf expression in CD8+CD57+ TIL subsets from a number 
of melanoma metastases (n=7) compared to PBMC of patients (n=17) and PBMC from a 
group of normal donors (n=16).  The percentages of CD8+CD57+ T-cells expressing GB or 
Perf are shown.  Each dot represents a single sample with the bars indicating the averages 
and standard error on the means (SEM) for each TIL’s CD8+ subset.  Significant differences 
between the groups were calculated by the two-tailed, nonparametric Kruskal-Wallis test 
followed by Dunn’s multiple comparison test. ns: not significant.   
Reprinted with permission from: Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
 
 
 
 
 
 
 
 
- 64 - 
 
Figure 2-8: 
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Figure 2-9:  Accumulation of incompletely differentiated CD8+CD27+CD28+ effector-
memory (TEM) lymphocytes co-expressing CD57 with high GB and low Perf expression in 
pleural effusions of metastatic breast cancer patients.  Isolated lymphocytes were stained for 
CD4, CD8, CD27, CD28, CD57, GB, and Perf expression. The gated CD8+CD57+ subset 
was further analyzed separately for surface CD27 or CD28 expression, or intracellular GB or 
Perf expression. Shown in each FACS plot are the percentages out of the gated subsets as 
indicated in the figure.  Results of two of five pleural effusion samples with similar results 
are shown.   
Reprinted with permission: from Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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Figure 2-9: 
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CD8+CD27+CD57+ TIL persist in culture with IL-2, can be induced to enter cell cycle, and 
are potent IFN-γ producers after TCR stimulation. 
Several studies have demonstrated that CD8+CD57+ cells do not divide appreciably, 
or at all, in response to TCR stimulation, indicating that they are senescent cells (131, 167).  
We therefore asked whether the CD8+CD27+CD57+ cells found in melanoma TIL were 
capable of further proliferation and cytokine production in the presence of IL-2.  Culturing of 
isolated melanoma TIL in culture medium with high-dose (HD) IL-2 (3,000 IU/ml) is a 
standard method to expand TIL for adoptive cell therapy (96, 168).  Routinely, we find that a 
two-week culture period of isolated TIL with IL-2 expands the CD8+ T cells between 200- to 
300- fold (data not shown).  We stained 2-week IL-2-expanded TIL for CD8, CD27, CD57, 
and Perf.  The percentage of the CD27+CD57+ subset increased from 4% to 20% of the gated 
CD8+ subset (Fig. 2-10A).  A small percentage of cells (~10%) in both CD27+CD57+ and 
CD27+CD57- subsets expressed another marker for senescence and terminal differentiation, 
KLRG-1 (data not shown) (169-171).  To further examine the proliferative capacity of these 
cells, we stained the cultured TIL with Ki67 at the end of the 2-week culture period and 
found that both CD8+CD27+CD57+ and CD8+CD27+CD57- subsets contained a significant 
frequency of Ki67+ cells (Fig. 2-10B).   
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Figure 2-10:  CD8+CD27+CD57+ subset in TIL can persist, proliferate, and expand ex vivo in 
high-dose IL-2 culture. TIL were isolated from the indicated patients’ melanoma metastases 
and cultured in high-dose (HD) IL-2 (3,000 U/mL) as described in the Material and Methods. 
(A) Surface phenotype of the TIL after two weeks of HD IL-2 culture.  By gating on the 
CD8+ TIL, a population CD27+CD57+ subset increased in frequency as compared to the 
freshly-isolated TIL.  Also, HD IL-2 did not appreciably induce down-modulation of CD27 
on either the CD27+CD57- or CD27+CD57+ subset.  The percentages of the each indicated 
subsets were out of the total gated CD8+ population.  (B) Histograms of the intracellular Ki67 
staining of the indicated CD8+ subsets in TIL.  Bulk TIL were stained with antibody against 
an intracellular proliferation marker, Ki67, as described in the Material and Methods.  Both 
of the CD27+CD57+ and CD27+CD57 – subsets expressed high levels of Ki67 after high-dose 
IL-2 culture.  The percentages indicated in B were determined by (the number of Ki67+ cells 
as compared to the isotype control in each gated subsets)/(the total number of cells in each 
subset) X 100.   
Reprinted with permission from: Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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We then asked whether the CD8+CD27+CD57+ TIL could enter cell cycle and 
produce cytokines after TCR stimulation.  Two-week IL-2-cultured TIL were isolated, 
washed and then re-cultured with low-dose (LD) IL-2 (200 IU/ml) alone (to prevent 
apoptosis due to cytokine withdrawal), or re-stimulated with LD IL-2 plus plate-bound anti-
CD3 or anti-CD3 plus anti-CD28 mAb for 7 days followed by Ki67 staining (all 
CD8+CD27+CD57+ T cells were CD28+; see earlier results in Fig. 2-5 and 2-7).  The gated 
CD8+CD27+CD57+ cells re-cultured with LD IL-2 alone were negative for Ki67 staining.  
However, a significant proportion of these cells were Ki67+ following stimulation with anti-
CD3 or anti-CD3 and anti-CD28 (Fig. 2-11A). 
          The results above indicate that the CD8+CD27+CD57+ T-cells in isolated melanoma 
TIL have proliferative capacity, but it could also be that CD8+CD27+CD57- T cells 
proliferated and induced CD57 expression when cultured with IL-2.  Thus, to more directly 
examine the proliferative capacity of CD8+CD27+CD57+ TIL, we sorted these cells and 
examined their response to TCR stimulation and IL-2.  The CD8+CD27+CD57+ and 
CD8+CD27+CD57- TIL subsets from four different melanoma patients were each stimulated 
with anti-CD3 plus anti-CD28 mAbs, and labeled with [3H]-thymidine after 3 days.  Both 
sorted subsets showed a marked induction of [3H]-thymidine incorporation after TCR 
stimulation, although the sorted CD8+CD27+CD57- subset demonstrated a higher 
proliferative capacity than the sorted CD8+CD27+CD57+ subset in response to CD3 and 
CD28 stimulation, in a majority of patients (Fig. 2-11B).  Analysis of the supernatants from a 
parallel set of cultures of activated cells found that both the sorted CD8+CD27+CD57+ and 
CD8+CD27+CD57- TIL produced Th1/Th2 cytokines (IFN-γ, IL-5 and IL-13) upon TCR 
stimulation, with the CD27+CD57+ subset producing significantly more IFN-γ compared to 
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the CD27+CD57- subset in TIL in 3 out of the 4 patients studied (Fig. 2-11C). Thus, the 
CD8+CD27+CD57+ T lymphocytes found in melanoma TIL were capable of continued cell 
division and were potent IFN-γ producers.  
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Figure 2-11:  The CD8+CD27+CD57+ subset in melanoma TIL was not anergic and could be 
induced to proliferate and produce a high level of IFN-γ and other Th2 cytokines (IL-5, IL-
13) after TCR stimulation with CD28 co-stimulation.  (A) Bulk TIL were rested overnight 
with low-dose IL-2 and stimulated the next day with a combination of plate-bound anti-CD3 
or anti-CD3 with anti-CD28 antibodies for 7 days.  Proliferation was determined by the 
percentage of Ki67+ cells as compared to the isotype control out of the total gated 
CD8+CD27+CD57+ subset.  (B) CD8+CD27+CD57+ and CD8+CD27+CD57- TIL subsets from 
four different patients were purified by sorting and an equal number of both sorted subsets in 
triplicate were stimulated with anti-CD3 and anti-CD28 antibodies.  [3H]-thymidine was 
added for 18 h on day 4 of the stimulation before harvesting and counting.  The negative 
control was sorted TIL treated with low-dose (LD) of IL-2 (200 U/mL) only, which induced 
very low level of proliferation. Results shown were means ± standard error on the means.  
Note for patient #2184, no error bar was shown for the assay performed on sorted 
CD8+CD27+CD57+ TIL due to insufficient number of cells for triplicate wells after sorting. 
Relevant patient information for TIL #2544 and #2545 are available online.  (C) The tissue 
culture supernatants from 5 x 104 cells in each subset in triplicate wells after stimulation were 
collected on day 4 of the stimulation and cytokine levels were determined using MSD® 
human Th1/Th2 cytokine multiplex assay as described in Material and Methods. Results 
shown were means ± standard errors on the means on experiments done on two different 
patients (#2182 and #2206).   
Reprinted with permission from:  Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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CD8+CD27+CD57+ TIL are more oligoclonal than CD8+CD27+CD57- TIL 
CD8+CD57+ T cells in some pathologic situations have been shown to have a more 
restricted Vβ TCR diversity (154, 172).  However, since most of these T cells in the 
periphery do not co-express CD27 or CD28, we asked what the relative Vβ TCR diversity 
was in tumor-associated CD8+CD27+CD57+ TIL versus the dominant subset of 
CD8+CD27+CD57- TIL.  We performed Vβ TCR spectratyping after sorting these T-cell 
subsets obtained from two samples of melanoma TIL and a breast cancer pleural effusion 
sample. The sorted CD8+CD27+CD57+ TIL from representative melanoma and breast cancer 
pleural effusion samples (minimum of 1 x 106 sorted cells each analyzed) had a significantly 
less Vβ TCR diversity and oligoclonality in some Vβ families than the CD8+CD27+CD57- 
TIL (Fig. 2-12B and C).  In addition, the Vβ peaks did not overlap between these two sorted 
subsets. Thus, the CD8+CD27+CD57+ TIL of melanoma and breast cancer seem to be an 
oligoclonal and a subset that is distinct from the CD8+CD27+CD57- subset, the other major 
population in TIL 
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Figure 2-12:  (A) a schematic representation of a TCR Vβ chain spectratype analysis, 
illustrating typical spectratype profiles of polyclonal, oligoclonal, and monoclonal T cell 
populations.  (B) Vβ TCR spectratype analysis on the sorted T-cell subsets from a 
representative sample of melanoma TIL, or (C) a breast cancer pleural effusion sample.  
mRNAs were isolated from at least 1 x 106 cells from each sorted CD8+ TIL subsets as 
indicated in the figure.  After reverse transcription of the RNA to cDNA, TCR Vβ mRNA 
expression profiling and size spectratyping of the 23 antigen-binding Vβ CDR3 regions were 
performed as CDR3 spectratypes were assessed on the Bayer OpenGene® System.  Sorted 
CD8+CD27+CD57+ TIL subset from melanoma or breast cancer pleural effusions displays 
reduced Vβ repertoire and less TCR diversity within most Vβ receptor families as compared 
to the CD8+CD27+CD57- TIL subset.  Oligoclonal expansion in some TCR Vβ families is 
also observed in the CD8+CD27+CD57+ subset.   
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Figure 2-12 con’t. 
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TCR stimulation drives CD8+CD27+CD57+ TIL to differentiate into CD8+CD27-
CD57+Perfhigh cells that are inhibited by TGF-β 
We asked whether CD8+CD27+CD57+ TIL were capable of further differentiation 
towards CD8+CD27-CD57+ CTL expressing increased Perf.  We first took bulk TIL in vitro 
and activated them in LD IL-2 medium with anti-CD3 plus anti-CD28 and tracked the fate of 
the cells after 7 days by staining and analyzing for changes in CD27, CD57 and Perf 
expression in the CD8+ subset.  This process induced further cell division associated with a 
decrease in the frequency of the CD27+CD57+ and CD27+CD57- CD8+ cells and an increase 
in the percentage of the CD27-CD57+ and CD27-CD57- populations (Fig. 2-13A).  Both the 
percentage and level (MFI) of Perf expression was also increased in each cell subset (Fig. 2-
13B).   
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Figure 2-13: CD8+CD57+ T cells in TIL can further differentiate into CD27-CD57+, PerfHi 
effector cells ex vivo.  Freshly isolated TIL from melanoma metastases were cultured in 
3,000 U/mL of IL-2.  After two weeks of expansion, bulk TILs were maintained in low dose  
IL-2 (200 U/mL) or  re-stimulated with CD3 plus CD28 for 7 days as described in the 
Material and Methods.  (A) Surface expression of CD27 and CD57 on gated CD8+ TIL was 
determined by FACS staining.  Low-dose (LD) IL-2 culture did not appreciably down-
modulate CD27, whereas CD3 + CD28 stimulation down-modulated CD27 on either the 
CD27+CD57+ subset (6% CD27- compared to 2% with IL-2 alone), or the CD27+CD57- 
subset (33% CD27- compared to 7% with IL-2 alone). (B) Histograms of the intracellular 
Perf staining versus isotype control (shown in gray).  Bulk CD8+ TIL from both stimulation 
conditions were stained for Perf expression.  Both IL-2 culture alone and CD3 plus CD28 
stimulation increased Perf expression on both CD27+CD57- and CD27+CD57+ subsets.  Perf 
expression, however, was increased to a greater extent by CD3 plus CD28 re-stimulation. 
The newly emerging CD27-CD57+ and CD27-CD57- subsets from CD3 + CD28 stimulation 
also acquired high level of Perf expression/cell (MFI).  (C) Corrected MFI for Perf was 
calculated by subtracting the MFI of the isotype control from that of the perforin staining.  
The values are shown by gating on the indicated subsets.  Results from two different TIL 
isolates are shown.    
Reprinted with permission from: Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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Figure 2-13: 
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To better delineate how TCR stimulation specifically affects the predominant 
CD8+CD27+CD57+ and CD8+CD27+CD57- subsets in TIL, we sorted these subsets from 
melanoma TIL and re-cultured the sorted cells with LD IL-2 or IL-2 and anti-CD3 plus anti-
CD28.  The post-sort purity of the two populations was verified (Fig. 2-14).  The sorted cells 
were also verified to have CD3 and CD28 expression.  The 7-day TCR stimulation induced a 
large decrease in the percentage of the sorted CD8+CD27+CD57+ cells from 72% to 37% 
(Fig. 2-15A) or 66% to 6% (Fig. 2-15B), with a concomitant increase in the percentage of 
CD8+CD27-CD57+ cells from 6% to 49% (Fig. 2-15A, bottom panel), or CD8+CD27-CD57- 
cells from 4% to 54% in other patient (Fig. 2-15B, bottom panel).  On the other hand, the 
sorted CD8+CD27+CD57- cells differentiated into a CD8+CD27-CD57- population with TCR 
stimulation (increase from 6% to 34% and 13% to 73%, respectively, in two different 
patients), although a minor subpopulation converted into CD8+CD27+CD57+ cells in LD IL-2 
culture alone (Fig. 2-15A and B, top panel).   
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Figure 2-14:  Flow cytometry plots of the purity of the TIL subsets after cell sorting. TIL 
lines from patients were sorted by fluorescence-activated cell sorting using Influx® cell sorter 
(BD Biosciences) as described in Material and Methods.  The purity of each sorted CD8+ TIL 
subsets were determined by acquiring the samples through the flow cytometer immediately 
after sorting. . A minimum of 30,000 gated light scatter events per sample were acquired on 
the flow cytometer. Shown here are sorted TIL subsets from two representative patients 
whose cells were used in experiment described in Fig. 2-15.   
Reprinted with permission from: Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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Figure 2-14:  
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Figure 2-15:  Sorted CD8+CD27+CD57+ T cells in TIL could further differentiate into CD27-
CD57+ CTL upon TCR stimulation, which was inhibited by the addition of TGF-β1.  TIL 
were sorted into CD8+CD27+CD57+ and CD8+CD27+CD57- subsets as before.  Post-sort 
purity of the sorted populations is shown in Fig. 2-14.   (A) The sorted TIL subsets (from 
patient #2384) were stimulated with anti-CD3 and anti-CD28 antibodies for 7 days.  The 
cells were then re-stained for CD8, CD27, and CD57 expression and analyzed by flow 
cytometry.  To some cultures of sorted, re-stimulated cells, 1 ng/mL of TGF-β1 was added on 
day 0 with CD3 and CD28.  Cells were harvested similarly on day 7 of the stimulation and 
stained for CD8, CD27, and CD57.  (B) Similar experiment performed on TIL from a 
different patient (#2541).   
Reprinted with permission from: Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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Figure 2-15:  
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We also tracked changes in GB and Perf expression and found that both proteins 
increased in the sorted CD8+CD27+CD57+ and CD8+CD27+CD57- TIL populations following 
TCR stimulation for 7 days, although the extent of the increase in Perf expression was greater 
in the sorted CD8+CD27+CD57+ subset in three different patients (Fig. 2-16A).  The increase 
in Perf expression in both sorted subsets led to an enhanced cytotoxic activity, in a redirected 
lysis assay using anti-CD3 antibody coated P815 target cells (Fig. 2-16B).  We chose the 
redirected lysis assay to assess the cytotoxic activity between the TIL subsets to avoid 
erroneous interpretation of any differences due to differences in the percentages of tumor 
antigen-specific T lymphocytes in each subset. The sorted and TCR-activated 
CD8+CD27+CD57+ subset also exhibited higher or similar levels of cytotoxic activity against 
P815 target cells as compared to sorted CD8+CD27+CD57- subset in TIL from two different 
melanoma patients (Fig. 2-16B).  Thus, TCR stimulation induces the phenotypic and 
functional maturation of the CD8+ CD27+CD57- and CD27+CD57+ subsets into more 
differentiated CD27-CD57- and CD27-CD57+ T cell populations with high Perf expression 
and cytotoxic activity. 
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Figure 2-16:  CD3 and CD28 stimulation of melanoma TIL subsets induced Perf and GB 
expression and increased cytotoxic killing function of the sorted CD8+ TIL subsets, which 
was abrogated in the presence of TGF-β1.  Intracellular flow cytometry staining for GB and 
Perf was performed as described in the Material and Methods.  (A)  Graphs show the 
percentage of GB+ and Perf+ cells in the sorted CD8+CD27+CD57+ and CD8+CD27+CD57- 
subsets, from three different patients,  before and after CD3 and CD28 stimulation for 7 days.  
TGF-β1 (1 ng/ml) was added to some cultures as indicated and the cells incubated and then 
stained in the same way. *ND: Not determined (due to insufficient cell number). (B)  A 
caspase-3 cleavage assay was used to assess the CTL killing activity. Sorted CD8+ TIL 
subsets, cultured with LD IL-2 alone, or after TCR re-stimulation with anti-CD3 and anti-
CD28, with or without added TGF-β1 (1 ng/ml) for 7 days, were co-incubated for 3 h at the 
indicated Effector: Target (E:T) ratios with P815 (murine mastocytoma) target cells, which 
were previously pulsed with 200 ug/mL of anti-CD3 antibody, in a redirected lysis assay.  
Target cells were distinguished from effector T cells by labeling with a fixable, far-red 
fluorescent tracer, CellTrace® Far Red DDAO-Succinimidyl Ester (DDAO-SE) at the 
beginning of the assay.  Non-pulsed P815 cells were used as negative controls.  Results were 
expressed as percent cleaved caspase-3 positive target cells out of the total target cell 
population.  Results shown were from experiments done on sorted TIL subsets from two 
different patients as indicated.   
Reprinted with permission from:  Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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Figure 2-16:   
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TGF-β1 is an immunosuppressive factor produced by melanoma cells and is found in 
about 50% of metastatic melanomas (159-161).  It has also been shown to inhibit CTL 
differentiation in human peripheral blood CD8+ T cells and inhibit the induction of Perf 
expression (158, 173-175). We reasoned that TGF-β may also affect the further 
differentiation of the CD8+CD27+CD57+ cells found in melanoma TIL.  We first tested the 
effect of adding TGF-β to bulk TIL stimulated with anti-CD3 and anti-CD28, and found that 
the differentiation of CD8+CD27+ T cells subsets were arrested, with attenuated perforin 
expression (Fig. 2-17).  We then sorted CD8+CD27+CD57+ and CD8+CD27+CD57- 
melanoma TIL and treated them with TGF-β during TCR stimulation.  In sorted TIL from 
two different melanoma patients, addition of TGF-β increased the frequency of the CD8+ 
CD27+CD57- memory-effector TIL (Fig. 2-15A and B, top panels) as well as maintained the 
CD27+CD57+ “hybrid” phenotype (Fig. 2-15A and B, bottom panels), which were both 
associated with low GB expression and more attenuated Perf expression (Fig. 2-16A).  TGF-
β prevented the loss of CD28 expression (data not shown).  TGF-β1 also strongly diminished 
the cytotoxic activity of CD8+ CD27+CD57+ and CD27+CD57- TIL subsets after stimulation 
with anti-CD3 and anti-CD28 for 7 days, as seen in two different melanoma patients (Fig. 2-
16B).  Thus, the differentiation of the CD27+CD57+ and CD27+CD57- CD8+ TIL into mature 
CD27- GBHiPerfHi CTL in vitro was blocked by TGF-β1, which resembled the phenotype of 
the PerfLo, CD8+ TIL freshly isolated from melanoma tumors.   
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Figure 2-17:  CD8+CD27+CD57- and CD8+CD27+CD57+ subsets in bulk TIL could further 
differentiate into CD27-CD57- and CD27-CD57+ subsets, respectively, and up-regulate 
perforin expression upon TCR stimulation, which were both inhibited by the addition of 
TGF-β1.  Bulk TIL #2276 were re-stimulated with anti-CD3 and anti-CD28 antibodies for 7 
days.  The cells were then re-stained for CD8, CD27, and CD57 expressions and intracellular 
perforin expression, and were analyzed by flow cytometry.  As a control, bulk TILs were 
cultured in LD IL-2 (200 U/mL) only without TCR stimulation. To some cultures of re-
stimulated cells, 1 ng/mL of TGF-β1 was added on day 0 with CD3 and CD28.  Cells were 
harvested similarly on day 7 of the stimulation and stained for CD8, CD27, CD57, and 
perforin.   
Reprinted with permission from: Wu R, Liu S, Chacon JA, Wu S, Li Y, Sukhumachandra P, 
Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi L.  2012. Clin. Can. Res.  
18(9): 2465-77.  doi:10.1158/1078-0432.CCR-11-2034 
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Figure 2-17 
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Discussion 
 
We found that the majority of CD8+ TIL in metastatic melanomas in a large number of 
patients had a CD27+CD28+GB+Perf -/Lo phenotype, reminiscent of early TEM cells (123, 144, 157).  
Importantly, in this study, most of the tumors analyzed were from non-LN visceral 
metastases.  We only found a very few highly-differentiated CD8+ TIL (CD27-CD28-) with 
high Perf and GB co-expressions.  Many of the high CD27-expressing CD8+ TIL also co-
expressed CD57 (HNK-1), a marker previously proposed to mark highly differentiated end-
stage CTL with high Perf and GB levels and potent cytolytic activity (142, 143, 157, 167).   
We also found a similar subset of CD8+ T-cells having this unusual early TEM phenotype co-
expressing CD57 in pleural effusions of metastatic breast cancer patients.  Some of these 
CD8+CD27+CD28+CD57+ melanoma TIL were specific for tumor antigens, as demonstrated 
by co-staining with MART-1 and gp100 peptide tetramers, suggesting that they were not 
non-tumor antigen specific, bystander CD8+ T cells.  However, many of the other 
CD8+CD27+CD28+CD57+ TIL may also have been tumor-specific, recognizing other 
undefined tumor antigens; this will need to be addressed in future studies. The existence of 
this subset in metastatic cancer patients bears resemblance to a population of 
CD8+CD27+CD28+CD57+ T cells found to accumulate in the peripheral blood of patients 
unable to control HIV, EBV, or CMV infections (141, 145, 146).  The circulating gp100 
tetramer+ CD8+ T cells containing a CD27+CD57+ subset has also been previously described  
in the peripheral blood of early stage melanoma patients receiving gp100 peptide vaccination 
(176).  Although it is important to further explore the relationship between tumor stage(s), 
the state of CD8+ TIL’s differentiation, and the appearance of this CD8+CD27+CD28+CD57+, 
our study was hampered by the lack of access to early-stage melanoma tissue samples. We 
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did not find detectable level of Foxp3 expression in the CD8+CD27+CD57+ TIL subset (data 
not shown), indicating that these were not “regulatory” CD8+ T cells with 
immunosuppressive activities.  Furthermore, Anichini, et al. reported that a subpopulation of 
CD8+Foxp3+ T cells residing in melanoma-invaded lympho nodes were CD57- (177).   
Our findings suggest that the CD8+ TIL’s differentiation into potent PerfHi killer cells 
in the melanoma tumor microenvironment may have been arrested at the early TEM stage 
(CD8+CD27+CD28+CD57-).  Although CD8+ TIL started to express CD57 (a marker for late-
differentiated CTL), they failed to down-modulate CD27 and CD28 and induce Perf.  
Another explanation may be that CD8+CD57+ TIL with properties of TTDE do arise, but these 
cells are too short-lived to be detectable ex vivo.  The reason why these cells begin to express 
CD57 is unclear at present.  CD57 (HNK-1) was originally found to be a marker of human 
NK cells.  Recently, it has been shown to be most highly expressed by the most mature CD8-
CD56loCD16hi human NK cell sub-population (178).  CD57 antigen is a terminally sulfated 
glycan carbohydrate epitope, and little is known about its actual function in T cells, although 
studies on other cell types (e.g., motor neurons) have found that it appears to function as a 
cell adhesion molecule (179).  One study reported that CD57 exhibits binding activity to IL-6 
in vitro (180).   
Previous studies have shown that the highly-differentiated CD8+CD27-CD28-CD57+ 
CTL in the peripheral blood accumulated with aging and was a senescent population 
incapable of further cell division and prone to activation-induced cell death after TCR 
ligation (131, 167).  CD8+CD57+ T cells in humans have also been reported to be 
oligoclonal, resulting from multiple expansions of specific clones as a consequence of aging 
or chronic viral infections by EBV and CMV (141, 143, 153, 172).  In our study, we found 
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that the CD8+CD27+CD57+ TIL in both melanoma and breast cancer pleural effusion were 
also more oligoclonal than the CD8+CD27+CD57- TIL, which suggested that the 
CD8+CD27+CD57+ TIL subset were more differentiated than the CD8+CD27+CD57- TIL 
(loss of TCR diversity and oligoclonality is a natural consequence of T-cell differentiation 
and aging; see Fig. 1-5).  However, whether CD57 marks truly senescent CD8+ T cells in 
humans have come under debate, with newer studies demonstrating that these cells could be 
induced to divide and produce cytokines after TCR stimulation (127, 181).   
Based on these previous findings, we examined whether CD8+CD27+CD57+ 
melanoma TIL were capable of further cell division when compared to CD8+CD27+CD57- T 
cells, the other major TIL subset in melanoma.  Several lines of evidence in the present study 
support that the CD8+CD57+ TIL were not senescent and were also capable of further cell 
division and differentiation in vitro.  First, CD8+CD27+CD57+ subset in the fresh TIL isolates 
persisted and expanded over a number of weeks in culture with IL-2.   However, these IL-2-
cultured CD8+ TIL did not show evidence of further differentiation into CD27-CD57+ or 
CD27-CD57- cells, but did up-regulate Perf expression slightly, which has been described 
after IL-2 signaling (182).  Second, in bulk TIL cultures and sorted populations of 
CD8+CD27+CD57+ TIL, we found that stimulation with agonistic anti-CD3 and CD28 
antibodies also stimulated their cell cycle entry and divisions.  Third, the sorted 
CD8+CD27+CD57+ TIL produced IFN-γ, IL-5, and IL-13 after TCR stimulation, with 
significantly higher IFN-γ production than those of the CD27+CD57- subset.  Interestingly, 
TILs in breast and kidney carcinoma have also been observed to produce IL-13, which has 
been shown to negatively regulate IDO (indoleamine-2,3-dioxygenase) expression in tumors 
(183).  Of note, IDO is the first and rate-limiting enzyme of tryptophan catabolism through 
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kynurenine pathway, thereby depleting tryptophan, which can halt the growth of T cells 
(184).   Lastly, our sorting experiments revealed that TCR stimulation induced sorted 
CD8+CD27+CD57+ T cells to differentiate into CD8+CD27-CD57+GBHiPerfHi T cells, 
reminiscent of TTDE CD57+ CTL in the peripheral blood; this observation was not due to 
CD8+CD27+CD57- TIL contaminants, since sorted CD8+CD27+CD57- T cells did not 
differentiate into CD27-CD57+ T cells, but rather, differentiated directly into CD27-CD57- T 
cells, which further supports that CD8+CD57- and CD8+CD57+ TIL belong to distinct 
lineages.  It is not known whether these CD8+CD27+CD57+ TIL persist as short-lived 
effector cells at the tumor site or re-circulate in the periphery.  Addressing this question 
requires an in vivo study using a murine model, but this CD8+CD57+ T cell subset does not 
exist in mice (185). 
Based on our initial observation that incompletely differentiated PerfLo CD8+ TIL 
accumulate in the tumor microenvironment, we reasoned that the existence of certain 
immunosuppressive factors may affect CD8+ TIL’s further differentiation.   TGF-β1 is 
known to be secreted by many tumors, including melanoma cells and certain types of tumor-
associated macrophages (158-160).  Previous studies have shown that TGF-β1 inhibited the 
differentiation of naïve CD8+ T cells into effector cells (173, 175), attenuated the production 
of inflammatory cytokines such as IFN-γ and TNF-α by effector CD8+ T cells (158), and 
significantly decreased Perf expression in lymphokine-activated killer (LAK) cells and 
murine CD8+ T cells (174, 186).  The inhibitory effect of TGF-β1 on CTL’s effector function 
was apparent in studies showing enhanced tumor eradication in mice with T-cells lacking 
TGF-β signaling (173, 187).  In our study, we found that TGF-β1 prevented the 
differentiation of CD8+CD27+ subsets into more mature CD8+CD27- CTL.  This cytokine 
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also inhibited the expressions of Perf and, to a lesser extent, GB in CD8+ TIL.  In addition to 
TGF-β1, other factors in the tumor microenvironment, such as a lack of adequate cytokine 
signaling (e.g, IL-2, IL-15), or the absence of proper costimulatory signals (e.g., through 4-
1BB), or the presence of co-inhibitory signaling through PD-1, BTLA, or TIM-3 following 
TCR activation (52, 164), could also contribute to this arrest of CTL differentiation.  
Alternatively, the presence of other immunosuppressive cytokines, such as IDO, PGE2, or  
IL-10, may also play a role (161, 188).   
In sum, we have identified a unique stage in which CD8+ CTL differentiation was 
blocked in the tumor microenvironment, in both metastatic melanoma and breast cancer 
pleural effusions.  This was associated with the appearance of an unusual early CD8+ TEM 
subset co-expressing a late CTL differentiation marker, CD57.  These 
CD8+CD27+CD28+CD57+ TIL, though expressing GB, had little or no Perf expression and 
therefore were a unique TEM subset in cancer (Fig. 2-18).  Immunosuppressive factors, such 
as TGF-β, might affect the CTL differentiation and led to the appearance of this unique 
CD57+ subset (Fig. 2-18).  It was possible that these unique CD57+ cells might also represent 
a subpopulation of CD8+CD27+CD57- TIL that have attempted to differentiate into CD57+ 
cells, but were blocked from further differentiation into CD27-PerfHi cells in the tumor 
microenvironment.  On the other hand, the CD8+ CD27+CD57- TEM TIL, which were the 
dominant CD8+ TIL population, might represent a putative CTL precursor subset, which, like 
the hybrid CD27+CD57+ subset, was also functionally suppressed by the immunosuppressive 
factors in the tumor microenvironment.  Finally, tumor antigen-specific CD8+ populations 
could be found in both CD27+CD57- and CD27+CD57+ subsets.  Thus, further studies will be 
needed to examine whether the more differentiated CD8+CD27- TIL exhibit better control of 
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tumor growth in vivo than their CD27+ precursors.  In addition, it will be of interest to 
determine whether CD8+CD27+CD57+ TIL can differentiate into long-lived CD8+CD27-
CD57+ cells in vivo, which are reminiscent of the long-lived CD57+ T cells in the periphery 
of healthy individuals that effectively control CMV and EBV infections (141, 146).   
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Figure 2-18:  Differentiation pathway of the tumor-infiltrating CD8+ T cells in metastatic 
cancer. In situations where CD8+ T cells encounter persistent, chronic antigenic stimulation 
such as metastatic cancer or uncontrolled chronic viral infections, CD8+ effector-memory T 
(TEM) cells fail to coordinately down-regulate of CD27 and up-regulate an end-stage CTL 
marker, CD57 and acquire a more cytolytic phenotype. Thus TEM fail to transition from a 
granzyme B (GB+) perforinLo (PerfLo) cells into PerfHi, highly cytotoxic end-stage CTL. This 
resulted in accumulation of CD8+ T cells at a transitional stage where markers for early TEM 
(CD27, CD28) are co-expressed with CD57, even though the cells remain PerfLo. We also 
found that TGF-β1, an immunosuppressive cytokine frequently found in the 
microenvironment of metastatic cancer, could also contribute to the arrested differentiation 
and accumulation of CD27+CD57- precursor T cells and CD27+CD57+ T cells.  Other yet-to-
be identified immunosuppressive factors may also contribute to this arrested state of CD8+ 
TIL’s differentiation. 
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Figure 2-18:   
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Chapter 3 
 
 
 
Phenotypic and functional characterization of a CD8+ TIL subset 
expressing B- and T- Lymphocyte Attenuator (BTLA) associated 
with melanoma regression during adoptive T-cell therapy 
 
 
 
 
 
 
 
Partially reproduced and adapted for this doctoral dissertation from the 
following manuscript in preparation:  
 
*Wu R, *Haymaker C, *Bernatchez C, Chen JQ, Liu H, Wang E, Marincola F, Davies MA, 
Hwu P, and Radvanyi L. 2013.  BTLA Promotes Survival of Young CD8+ Melanoma TIL 
via Akt.  
 
*These authors contributed equally 
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Introduction 
 
 Adoptive T cell therapy (ACT) has emerged as a promising treatment for metastatic 
cancers such as melanoma. This process involves expanding melanoma patients’ autologous 
tumor- infiltrating lymphocytes (TIL) in vitro for a period of 4-5 weeks, followed by a rapid-
expansion protocol (REP) and re-infusion into lympho-depleted patients along with high-
dose IL-2 (59).  Multiple institutions, including our group at M.D. Anderson Cancer Center, 
have conducted ongoing Phase II studies for patients with Stage IIIc/IV metastatic 
melanoma, with reported clinical response rates between 48 to 51% based on the RECIST 
criteria (55, 59, 189).   
 Our group has previously reported that positive clinical response of this therapy and 
the degree of melanoma tumor shrinkage post-treatment were significantly correlated to the 
amount of CD8+ cytotoxic T cells, not CD4+ T cells, that were infused into patients (55) (Fig. 
3-1).   
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Figure 3-1: Comparison of total cells infused and major T-cell subsets in the infused TIL 
product between responders (CR, complete responders, and PR, partial responders) and non-
responders (PD, patients with progressive disease, and SD, patients with stabilization of 
disease).  Clinical response was assessed using Response evaluation criteria in solid tumors 
(RECIST 1.1) (190).  (A) Responding patients were infused with significantly more TIL 
(median 99 × 109 cells) than nonresponders (median 55 × 109; p= 0.0003).  (B) We further 
analyzed the different subsets of T cells using multicolor flow cytometry for the content of 
CD3+CD8+ and CD3+CD4+ T cells, which revealed that both the percentage and total number 
of CD8+ T cells infused were significantly associated with clinical response (p = 0.001 and 
0.0003, respectively).  (C) Non-responders had significantly higher percentages of CD4+ TIL 
(p= 0.001; Fig. 3C).  (D) We further analyzed the role of total CD8+ TIL as a continuous 
predictor of percentage change in tumor burden (p= 0.0003).  Linear regression shows the 
relationship between total CD8+ infused and percentage change in tumor burden (P = 
0.0003), with the solid line in showing the best fit, the broken line representing the 95% 
prediction limits, and the gray area indicating the 95% confidence limits.   
Reprinted with permission from:  Radvanyi, LG, Bernatchez C, Zhang M, et al. 2012. 
Specific Lymphocyte Subsets Predict Response to Adoptive  Cell Therapy Using Expanded 
Autologous Tumor-infiltrating Lymphocytes in Metastatic Melanoma Patients. Clin. Cancer 
Res. 18(24):6758-6770.  doi:10.1158/1078-0432.CCR-12-1177. 
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Figure 3-1: 
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However it is still controversial which phenotypic markers expressed by CD8+ T cells 
and what state(s) of differentiation are correlated to clinical response.  Others have shown in 
a murine B16 melanoma tumor model that the adoptive transfer of the least differentiated, 
stem-like memory CD8+ T cells (TSCM) exhibited the most effective control of melanoma 
tumor growth (132).  Although TSCM CD8+ T cells have been found in the peripheral blood in 
humans (124), they could not be found among tumor-infiltrating lymphocyte populations 
within melanoma patient tumors, which were consisted of more differentiated TEM and TEMRA 
CD8+ T cell subsets (55).  One study reported that infusion of higher numbers of 
CD8+CD27+ melanoma TIL, which marked early-differentiated cells within the TEM 
populations, correlated with positive clinical response (191).  However, CD27 cannot stably 
and reliably define the CD8+ T cell differentiation state since its expression is prone to be 
affected by IL-2 or interaction with its cognate ligand, CD70 (134).  Thus, it is critical to 
explore additional biomarkers in order to better define the subset and the differentiation state 
of the CD8+ TILs contributing to a positive clinical response to ACT.  Identification of such 
a subset of CD8+ TIL could lead to efforts to selectively expand these T cells prior to 
infusion into patients, which has the potential to further improve the efficacy of ACT (192).   
We found that melanoma patients receiving higher numbers of CD8+ TIL expressing 
B-and-T lymphocyte attenuator (BTLA), an inhibitory receptor with two immunotyrosine-
based inhibitory motifs (ITIMs) that are similar to other well-known inhibitory receptors, 
PD-1 and CTLA-4 (50), were significantly correlated to positive clinical responses to ACT 
(55) (Fig. 3-2).  However, we did not find clinical correlations with CD8+ TIL’s expressions 
of other inhibitory receptors such as PD-1 (programmed death-1) or TIM-3 (T-cell 
immunoglobulin domain and mucin domain 3 receptor) (55) (Fig. 3-2).   
- 106 - 
 
Figure 3-2:  Comparison of PD-1, BTLA, and TIM-3 expressions on CD8+ TIL in 
responders (CR/PR) and nonresponders (PD/SD) in metastatic melanoma patients treated 
with ACT.   (A) Results shown were the percentage of cells in the total CD8+ TIL population 
expressing PD-1, BTLA, and TIM-3 in all treated patients.  (B) The percentages of CD8+PD-
1+, CD8+BTLA+, and CD8+TIM-3+ subsets in the infused TIL was compared between 
responders and nonresponders. Wilconxon rank-sum test was used to assess statistical 
significance differences.  There were highly significant differences in BTLA expression 
between responders and non-responders (p=0.0006), while the differences in PD-1 or Tim-3 
expressions did not reach statistical significance (p=0.070 and p=0.004, respectively) after 
Bonferroni correction for multiple comparisons were applied.   
Reprinted with permission from:  Radvanyi, LG, Bernatchez C, Zhang M, et al. 2012. 
Specific Lymphocyte Subsets Predict Response to Adoptive  Cell Therapy Using Expanded 
Autologous Tumor-infiltrating Lymphocytes in Metastatic Melanoma Patients. Clin. Cancer 
Res. 18(24):6758-6770.  doi:10.1158/1078-0432.CCR-12-1177. 
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Figure 3-2: 
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This finding was surprising since signaling through BTLA has been shown to inhibit 
proliferation and cytokine production in melanoma tumor antigen-specific (MART-1-
reactive) CD8+ T cells (52).  However, BTLA has also been reported to harbor a third 
conserved tyrosine-containing motif within the cytoplasmic domain, which has been shown 
to recruit Grb-2 and p85 subunit of PI3K in vitro (51).  The functional significance of this 
interaction in enhancing T cell survival has not been previously explored in the literature.   
It is also not clear whether BTLA expression truly marked exhausted, dysfunctional 
CD8+ T cells.  Although it was reported that BTLA is up-regulated on exhausted, NY-ESO-1 
tumor antigen-specific CD8+ T cells (53), a number of studies on human CD8+ T cells have 
shown that BTLA was already expressed at a high level on naïve CD8+ T cells and was 
gradually down-regulated during normal differentiation (52, 54).  A recent study has 
suggested a close relationship between the expressions of multiple inhibitory receptors (e.g., 
PD-1, TIM3 and LAG3) and the antigen-specificity, anatomic localization, and 
differentiation of CD8+ T cells in humans (193) (Fig. 3-3B) .  Therefore, we hypothesize that 
BTLA may mark a specific stage of differentiation in CD8+ melanoma TIL. 
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Figure 3-3:  Expression profiles of inhibitory receptors with human CD8+ T cell’s 
differentiation.  Peripheral blood mononuclear cells (PBMC) from melanoma patients were 
stained with antibodies specific for these inhibitory receptors, as well as for CD8, CD45RA 
and CCR7.  (A) CD8+ T cells subsets were further classified into naive (N), central memory 
(CM), effector memory (EM) and effector memory CD45RA+ (EMRA) cells as defined by 
CCR7 and CD45RA expression.  (B) Naive cells were frequently BTLA positive and many 
of them also co-expressed TIM-3.   In contrast, all other inhibitory receptors were up-
regulated along with progressive differentiation.  While TEMRA cells were frequently positive 
for 2B4, KLRG-1 and CD160, they expressed less PD-1 and BTLA than TEM cells.  
Reprinted with permission from:  Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals J-P, 
et al. (2012) Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on 
Differentiation, Antigen-Specificity and Anatomical Localization. PLoS ONE.  7(2): e30852. 
doi:10.1371/journal.pone.0030852.     
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Figure 3-3:   
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In this study, we have characterized the CD8+BTLA+ and CD8+BTLA- subsets in 
melanoma TIL in terms of their effector functions and global gene expression profiles.  We 
discovered that BTLA was a stable marker that defined a subset of less-differentiated, highly 
proliferative effector-memroy (TEM) TIL responsive to IL-2 and TCR signals.  In contrast, 
the absence of BTLA expression on CD8+ TIL defined a distinct subset consisting of late-
differentiated TEM and TEMRA TIL that was poorly responsive to IL-2 or TCR signals. This 
subset expressed receptors belonging to the killer-cell immunoglobulin-like receptor family, 
which were typically expressed by natural killer (NK) cells (194) and highly-differentiated or 
senescent CD8+ T cells (66, 166, 195, 196), and exhibited a molecular signature of T-cell 
deletion (197, 198).  We also found that the ligation of BTLA on CD8+ TIL with its cognate 
receptor, herpes virus entry mediator (HVEM), though exerted inhibitory effect on 
proliferation and cytokine production, nevertheless promoted phosphorylation of Akt and 
improved TIL survival.  Therefore, our findings provide an explanation for the positive 
clinical association with the CD8+BTLA+ TIL subset, and suggest that the CD8+BTLA+ TIL 
may be selectively harnessed to improve the persistence of the TIL in patients undergoing 
Adoptive T cell Therapy (ACT). 
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Materials and Methods 
Expansion of tumor infiltrating lymphocytes from human melanoma tumors. Briefly, TIL 
were separated from tumor cells by centrifugation over 75% and 100% Ficoll double layers 
following enzymatic digestion with collagenase type I (0.375%, Sigma-Aldrich), 
hyaluronidase (75µg/ml, Gibco) and DNase I (250 U/ml). TIL lines were cultured in TIL-CM 
[RPMI 1640, 10% human Ab serum, 1 mM glutamine, 1 mM sodium pyruvate, 50 µM 2-
mercaptoethanol, 1× penicillin-streptomycin (Invitrogen, Carlsbad, CA)] and expanded in 
high-dose IL-2 (6,000 IU/mL, Novartis) as described previously (66).  Autologous primary 
melanoma tumor lines were also established by collecting the cells at the 75% Ficoll layer 
and used as targets in CTL assays. 
Flow Cytometry. Freshly-isolated or IL-2 cultured T cells were washed twice in D-PBS and 
stained using Live/Dead® Fixable Aqua Dead Cell Stain Kit (Life Technologies, CA) 
according to manufacturer’s instruction. Cells were then washed twice in FACS wash buffer 
(D-PBS + 1% BSA) and stained with CD3 FITC (SK7), CD4 PerCP-Cy5.5 (RPT-T4), CD8 
PB (RPT-T8), BTLA PE (J168), TIM3 APC (F38-2E2), PD-1 PerCP-Cy5.5 (EH12.2H7), 
CD27 APC-H7 (M-T271), CD28 PE-Cy7 (CD28.2), CD45RA (HI100), and MART-1 APC 
or gp100 APC (HLA-A02+ cells only) (Beckman Coulter).  For KIR phenotyping, TIL were 
stained with CD3 PerCP-Cy5.5 (SK7), CD8 PB (RPT-T8), BTLA PE (J168), CD158a 
(KIR2DL1) (FITC), CD158b (KIR2DL2/3) (FITC), NKAT2 (KIR2DL3) (FITC), and 
CD158e/NKB1 (KIR3DL1) (FITC).  For tetramer staining, TIL were initially stained with 
3ul tetramer for 15 minutes in 100ul of FACS buffer. Cells were then stained for other 
markers without washing between steps. Cells were stained on ice for 30 minutes in 100 µl of 
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FACS buffer. 5% goat serum was added to the FACS buffer when staining fresh tumor 
isolated T cells to block Fc receptors. 
Cell sorting.  TIL were harvested, washed in FACS buffer, and stained for CD8, BTLA, and 
CD27 for 30 min on ice. Cells were then washed and re-suspended in FACS buffer for cell 
sorting. Sorts were performed using an Aria I (BD Biosciences) or Influx (BD Biosciences) 
cell sorter. Cells were sorted directly into TIL media. Only populations with a ≥ 95% post-
sort purity were used for experiments. 
Proliferation and survival assays.  1 µM of CFSE (Molecular Probes™/Invitrogen, 
Carlsbad, CA) was used for labeling sorted TILs in order to monitor the number of cell 
divisions they undergo in response to different concentrations of IL-2 (200 U/mL and 3,000 
U/mL) after 5 days.  In experiments where there was conflict between CFSE and other 
flurochrome-conjugated antibodies, 1 µM of eFluor® 670 Cell Proliferation Dye 
(eBioscience, San Diego CA), which was detected by the flow cytometer’s APC channel, 
was used to label the TILs according to the manufacturer’s protocol. The sorted TILs were 
washed in D-PBS and re-suspended in PBS containing CFSE.  Labeling was done at RT for 
5-7 minutes followed by washing three times with TIL-CM.  After 5 days of stimulation with 
IL-2, the cells were harvested and stained with anti-CD8 mAb.  Data were acquired using 
using FACScanto II cytometer (BD Biosciences).  The number of cell divisions was 
estimated using a curve-fitting method from the FlowJo software’s Proliferation Tool 
(Treestar v7.6.5).  Apoptosis of the TILs was monitored the Apoptosis Detection Kit (BD 
Biosciences).  The cells were harvested, washed in cold D-PBS, re-suspended in the 100 µL 
1X Binding Buffer (supplied with the kit), and stained with anti-CD8 mAb, Annexin V-PE, 
and 7-AAD for 20 minutes.  The cells were washed with 2 mL of 1X Binding Buffer, re-
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suspended in 0.3 mL of 1X Binding Buffer, and analyzed by flow cytometer within 1 hour.  
For [3H]-thymidine incorporation assay, a total of 5 × 104 sorted cells per well were plated 
into 96-well Costar 3361 High-bind plates (Sigma-Aldrich) pre-coated overnight with anti-
CD3 (OKT3; Ortho Biotech) or anti-CD3 and anti-CD28 (eBioscience) agonistic antibodies.  
After 3 days, the cells were pulsed with 1 µCi of [3H]-thymidine (methyl-T-thymidine; 
PerkinElmer Inc.) for 18 hours. The incorporated [3H] thymidine was reported as counts per 
minute (cpm) by a β liquid scintillation counter (Beckman Coulter). 
Phospho-flow staining.  Sorted cells were stimulated with escalating doses of IL-2 (50 
U/mL, 200 U/mL, and 3,000 U/mL) for 20 minutes. Unstimulated cells served as the control. 
At the end of the stimulation, cells were fixed in a pre-warmed BD™ Cytofix Buffer for 10 
min. Cells were then permeabilized by chilled BD™ Phosphoflow™ Perm Buffer III for 20 
min at 4°C.  Cells were washed twice with BD™ Pharmingen™ Stain Buffer and stained 
with fluorochrome-conjugated anti phospho-Stat5 (Tyr694; BD Biosciences) or anti 
phospho-Akt (Ser473; Cell Signaling Technology, Danvers, MA) antibodies for 20 min at 
4°C and washed twice with Stain Buffer.  Data were acquired using using FACSCanto II 
cytometer (BD Biosciences) and analyzed using FlowJo (Treestar version 7.6.5). 
Intracellular cytokine staining.  The sorted cells were stimulated with 25 ng/mL of PMA 
and 1 µg/mL of ionomycin.  Unstimulated cells serve as the control.  At the same time, BD™ 
GolgiStop™ (monensin) was added to each culture according to the manufacturer’s 
instruction.  At the end of the 4-hour stimulation period, cells were fixed and permeabilized 
using BD Cytofix/CytopermTM kit and subsequently stained with IL-2 PerCP-Cy5.5, IFN-γ 
PE-Cy7, and TNF-α APC mAbs (BD Biosciences).  Data were acquired using using 
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FACScanto II cytometer (BD Biosciences), and analyzed using FlowJo software (Treestar 
version 7.6.5).   
Cytotoxic T cell assays.  Analysis of CTL activity of the sorted CD8+ subsets was done 
according to a flow cytometric method measuring the cleavage of caspase-3 in anti-CD3 
coated target cells or in autologous melanoma tumor cells as described previously (163).  
Briefly, 5 x 106 murine mastocytoma target cells (P815) or autologous melanoma tumor cells 
were labeled with a fixable, far-red fluorescent tracer, CellTrace® Far Red DDAO-
Succinimidyl Ester (DDAO-SE; Invitrogen, Carlsbad, CA) according to manufacturer’s 
instructions, washed, resuspended at a density of 2.5 x 106/mL.  For redirected lysis assay 
with P815 target cells, these were additionally pulsed with 200 µg/mL of anti-CD3 mAb in a 
low-serum containing media (RPMI 1640 with 2% FBS) at RT for 30 min.  Unpulsed target 
cells served as controls.  Labeled target cells were added to the sorted TIL subsets at E:T 
ratios of 1:3, 1:1 and 3:1 in a round-bottom 96-well plate and spun down for 5 min at low 
centrifuge speed (300 RPM) in order to maintain optimal contact between target cells and 
effector T cells. The cells were co-incubated for 3h before harvesting. The 3 hour time point 
was chosen to prevent the apoptotic target cells from becoming necrotic and losing the 
cleaved caspase-3 signal. The cells were stained intracellularly with an anti-cleaved caspase-
3-PE mAb (BD Biosciences). Target cells were distinguished from effector T cells by the far-
red tracer DDAO-SE, and the extent of the caspase-3 cleavage in the target cell population 
was analyzed by the FACSCanto II flow cytometer (BD Biosciences).  For CD107a and IFN-
γ co-release assay, sorted T cells were co-cultured with autologous melanoma tumor cells at 
the same E:T ratios for 4 hours. Fluorochrome-conjugated CD107a-PE mAb (eBioscience) 
and BD™ GolgiStop™ were added at the beginning of the cultures.  At the end culture 
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period, cells were fixed and permeabilized using BD Cytofix/CytopermTM kit and 
subsequently stained with CD8-Pacific Blue and IFN-γ PE-Cy7 mAbs (BD Biosciences). 
Data were acquired using using FACScanto II cytometer (BD Biosciences), and analyzed 
using FlowJo software (Treestar version 7.6.5). 
Cytokine multiplex assays. Pre-REP TIL were harvested and washed twice in TIL-CM to 
remove any excess IL-2 and plated for 24h in 96 well plates pre-coated with or without 30 
ng/ml agonistic anti-CD3 mAb and 1 µg/mL of agonistic anti-CD28 mAb. The tissue culture 
supernatants from triplicate wells of each condition were collected, diluted at a 1:3 ratio, and 
added to magnetic beads coated with immobilized antibodies against selected human 
cytokines (IFN-γ, TNF-α, MIP-1β) Milliplex® MAP human multiplex cytokine kit, according 
to the manufacturer’s instructions (EMD Millipore, Billerica, CA). The signals from the 
Strepavidin-Phycoerythrin (PE) coated beads were acquired and analyzed by the Luminex® 
100 IS System (Luminex® Corporation, Austin, TX). The concentration of each cytokine 
was calculated from its each respective standard curves. 
Microarray.  Total RNA was isolated from 1.0x106 or less of the sorted CD8+ TIL subsets 
using RNeasy Mini Kit (Qiagen, Valencia, CA) with DNAase digestion according to 
manufacturer’s instruction, and eluted in 40 µl of elution buffer.  RNA quality was assessed 
by Agilent Bioanalyzer (Santa Clara, CA) and quantified by Nanodrop 2000 
(ThermoScientific, Wilmington, DE).  300 ng of total RNA were amplified using Ambion 
WT expression kit (Life Technologies, Grand Island, NY) according to the manual. Briefly, 
mRNA was reverse transcription into cDNA and followed by second strand cDNA synthesis, 
which was used as a template for in vitro transcription for cRNA synthesis.  After 
purification, the cRNA were converted into cDNA and removed by RNase H treatment. The 
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single strand cDNA was fragmented by restriction digestion and terminal labeled using 
GeneChip WT Terminal Label kit in the presence of controls. Samples were hybridized to 
Human Gene ST 1.0 Arrays (Affymetrix, Santa Clara, CA) in a GeneChip Hybridization 
Oven 640 for >16 hours, at +45°C, 60 rpm, stained on a GeneChip Fluidics Station 450, and 
scanned by GeneChip Scanner 3000 7G (Affymetrix, Santa Clara, CA).  Raw data passed QC 
assessment were generated with Affymetrix GeneChip Command Console, and the data were 
imported into BRB-ArrayTools v4.2.1 (NCI, Bethesda, MD), normalized with robust multi-
array average (RMA) algorithm, and log2 transformed. The microarray data has been 
deposited into the NCBI GEO database (Accession #GSE43260; 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43260).  
Generation of CD32+HVEM+ L cells.  L cells transfected with CD32 (low-affinity Fc 
receptor) in a retroviral vector were a gift from Yong-Jun Liu and have been described 
previously (199).  In order to generate CD32+HVEM+ L cells, L cells transfected with CD32 
in a retroviral vector were a gift from Yong-Jun Liu.  RNA was isolated from a HVEM-
expressing human melanoma tumor cells (52) using RNeasy Mini Kit (Qiagen) and reverse-
transcribed into cDNA using Superscript First-Strand Synthesis System (Life technologies, 
Grand Island, NY).  Using the cDNA as a template, the human HVEM gene was cloned 
using high-fidelity DNA polymerase (BioRad, Hercules, CA) and the following primers: 
forward primer: 5’- CACCATGGAGCCTCCTGGAGA-3’;  reverse primer: 5’-
TCAGTGGTTTGGGCTCCTCCCCGTGAA-3’ with the following settings for PCR: 98°C 
for 10s, 58°C for 30s, and 72°C for 30s for 30 cycles.  The resulting PCR product was ligated 
into a pcDNA™3.1D/V5-His-TOPO® vector provided by the Directional Topo® Expression 
Kit (Life Technologies, Grand Island, NY) according to the manufacturer’s instructions, and 
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transfected into TOP10® Competent E. coli bacteria (Life technologies, Grand Island, NY). 
 The amplified vectors were isolated from grown E. coli bacteria, and DNA sequencing of 
the vector was performed to verify insertion of the HVEM gene.  The vector product was 
subsequently introduced into CD32+ L cells.  The transfected CD32+ HVEM+ L cells were 
grown in L-cell medium [RPMI 1640 (Life technologies, Grand Island, NY), 10% fetal 
bovine serum (FBS)] and selected with 500 µg/mL of Geneticin® (Life technologies, Grand 
Island, NY).  When L cells have grown to 10x107 cells, they were stained with anti-HVEM-
FITC (Ancell, Bayport, MN) and purified by fluorescent-activated cell sorter.  The cell 
sorting, selection, and culturing were repeated two more times to achieve a >97% purity (Fig. 
3-4).   
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Figure 3-4:  Flow cytometry staining of the CD32+ L cells and CD32+HVEM+ L cells.  
Murine fibroblasts (L cells) that have been transduced with a retroviral containing human 
CD32 (low-affinity Fc receptor) gene has been described previously (199).  (Left panel) 
Flow cytometry staining of the CD32+ L cells, showing >98% purity.  (Right panel) CD32+ 
L cells were transfected with human HVEM gene.  Stable CD32+HVEM+ L cell line was 
obtained by repeated cell sorting using anti-HVEM-FITC mAb, selection with G418 
(Geneticin®), and culturing in L-cell medium until >97% purity was achieved, as described in 
Material and Methods.   
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Costimulation of TIL with HVEM+ L cells or HVEM-Fc fusion protein.  Generation of 
CD32+ (low-affinity Fc receptor), HVEM+ L cells (murine fibroblast) was described in 
Supplemental Methods online.  1x106 of CD32+ or CD32+HVEM+ L cells were harvested and 
pulsed with 30 ng/mL of OKT3 mAb in low-serum media (RPMI 1640, 2% fetal bovine 
serum) for 30 min.  The L cells were seeded in a 24-well tissue culture plate and allowed to 
adhere to the plastic for 3h.  1x106  bulk TIL cells were added to OKT3-pulsed L cells in a 
1:1 ratio.  As an additional specificity control, BTLA on TIL was pre-blocked by incubation 
of 10 µg/mL of soluble anti-BTLA blocking mAb clone 3B1 (200), a gift from Genentech 
(San Francisco, CA), in serum-free TIL media for 30 min at room temperature, and were then 
co-incubated with CD32+HVEM+ L cells.  At the end of the 5-day co-culture, the survival of 
TIL was tracked by staining for CD8, 7-AAD, and Annexin-V-FITC as described previously, 
and analyzed by FACSCanto™ II flow cytometer (BD Biosciences).  Additionally, sorted 
CD8+ BTLA+ and BTLA- TILs were washed free of IL-2 and stimulated with 30 ng/mL of 
plate-bound OKT3 and 10 µg/ml control human Ig, OKT3 and 10 µg/ml HVEM-Fc with or 
without 10 µg/ml of soluble anti-BTLA blocking mAb (3B1) or 10 nM of a pan class I PI3K 
inhibitor, GSK2126458 (kindly provided by GlaxoSmithKline), or HVEM-Fc alone for 3 or 
6 hours. TIL cultured in the absence of IL-2 were included as a negative pAkt control. The 
TILs were harvested, fixed, and stained for phospho-Akt using a Phospho-flow protocol 
described previously. In some cases, sorted TIL were labeled with CFSE and cultured for 
three days with OKT3 and HVEM-Fc or OKT3 and the control Ig as above. CFSE dilution 
was measured using a FACsCanto II (BD) and analyzed using FlowJo software version 7.6.5. 
Supernatants were also collected and analyzed for inflammatory cytokine production as 
described above. 
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Statistics. For quantitative comparisons between 2 paired groups, Wilcoxon signed-rank test 
(2-sample, 2-tailed comparisons) was performed with Graph Pad Prism v5.0 (La Jolla, CA) 
with column statistics reported as mean ± S.E.; p < 0.05 was considered statistically 
significant. p values and FDRs for gene sets used in GSEA were calculated with 1,000 
permutations by phenotype, which was the more stringent criteria, in the online tool.  
Enrichment of a particular gene set in an indicated subset of CD8+ TIL was considered 
significant if p < 0.05 and FDR < 0.25, as suggested in the online tool.  We also used a 
comprehensive software package, BRB-ArrayTools v4.2.1 (NCI, Bethesda, MD), to 
determine statistically significant genes (p < 0.05) between CD8+BTLA+ and CD8+BTLA- 
TIL subsets using a paired Student’s t test. 
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Results 
Patient tumor samples and experimental approach.   
Tumor samples were obtained from Stage IIIc to Stage IV melanoma patients 
undergoing surgery at The University of Texas MD Anderson Cancer Center according to an 
Institutional Review Board–approved protocol and patient consent (IRB# LAB06-0755).  
Supplemental Table 1 shows the characteristics of the melanoma patients, including patient 
age, sex, tumor location, disease stage, and anatomical sites.  The tumors were processed 
immediately after surgery for TIL isolation, multicolor flow cytometry staining, and 
expansion with high-dose IL-2 as described in Methods.   
BTLA is expressed on melanoma-specific T cells and co-expressed with PD-1 and TIM3 ex 
vivo.   
First, we wanted to determine BTLA expression levels on TIL freshly isolated ex vivo 
as well as on the known melanoma antigen-specific populations (MART-1 and gp100). 
Shown in Fig. 3-5A was the staining of the TIL with control HLA-A02 tetramer.  We stained 
freshly-isolated CD3+CD8+ TIL from two different HLA-A02 patients with MART-1 and 
gp100 tetramers and assessed for co-expressions with BTLA.  Interestingly, BTLA 
expression was observed to be enriched in the CD8+MART-1+ population (TIL 2385; 86% 
and TIL 2616; 80%) as compared to the corresponding tetramer negative population (TIL 
2385; 71% and TIL 2616; 36%) (Fig. 3-5B).  This trend was also observed in the 
CD8+gp100+ (TIL 2385; 85% and TIL 2616; 88%) populations as compared to the tetramer 
negative population (TIL 2385; 69% and TIL 2616; 44%) (Fig. 3-5B).  The expression of 
BTLA on melanoma antigen-specific cells has been previously demonstrated in the 
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peripheral blood (52, 53).  However, BTLA was strongly co-expressed with another 
inhibitory receptor, PD-1, on both tetramer positive populations in CD8+ TIL.  In fact, the 
overall percentages of freshly isolated, MART-1+ or gp100+ TIL that co-expressed BTLA 
and PD-1 were at least twice of the tetramer-negative population [MART1+ vs. MART-1- 
TIL 2385: 72% vs 35%, TIL 2616: 48% vs 4%; gp100+ vs. gp100-: TIL 2385; 71% vs 32%, 
TIL 2616: 67% vs 15%] (Fig. 3-5B).  Overall, this data provides evidence that BTLA 
expression can be found on freshly-isolated melanoma antigen specific CD8+ TIL, which 
also co-expressed PD-1 ex vivo.  Because a previous report has shown that a majority of 
melanoma antigen-specific CD8+ TIL was found in the PD-1+ population in TIL, and that 
BTLA was known to be co-expressed with PD-1 and TIM-3, on melanoma antigen-specific 
CD8+ T cells in the periphery (53), we wanted to determine their co-expression pattern on  
TIL. To this end, freshly-isolated, bulk CD3+CD8+ TIL were examined for co-expressions of 
BTLA and PD-1 (Fig. 3-5C, top row) or TIM-3 (Fig. 3-5C, bottom row).  Indeed, we found 
that the CD8+BTLA+ population co-expressed PD-1 and TIM-3 in five patient TIL samples 
tested (Fig. 3-5B), though the extent of pattern of co-expression was variable from patient to 
patient. 
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Figure 3-5:  BTLA is expressed on CD3+CD8+ melanoma TIL ex vivo. Melanoma tumor 
samples were first mechanically segregated using glass slides. The isolated TILs were then 
stained with Aqua® dead-cell exclusion dye, anti-CD3, anti-CD8, anti-BTLA, anti-PD-1, 
MART-1 tetramer (HLA-A02 restricted patients), gp100 tetramer (HLA-A02 restricted 
patients), and anti-TIM3. (A) As a control, live CD3+CD8+ TIL (Aqua-) were stained with 
control tetramer.  No appreciable staining was observed.  (B) TIL from two HLA-A02 
patients were stained with the tetramers, gated similarly as in (A), and analyzed for co-
expressions of BTLA and PD-1. MART-1 tetramer+ cells are shown on the left, and gp100 
tetramer+ cells are shown on the right. The top contour plot is gated on the tetramer+ 
population, while the bottom is gated on the tetramer- population as depicted by the arrow. 
(C) BTLA, PD-1, and TIM3 expression from both HLA-A02 and non-HLA-A02 patients 
with TIL line numbers at the top of the contour plot. Gates were drawn based on FMO 
(fluorescence minus one) controls and negative tetramer controls.  The numbers indicate 
percent expression for each marker. 
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Figure 3-5: 
 
CD
8
Ctl tetramer
A
Gated on Aqua-CD3+ TIL
TIL 2385 TIL 2616
2 1
 
36 35
7
14 72
10
CD
8
MART-1
88 12
TIL 2385
B
89 11
CD
8
gp100
14 71
8
37 32
7
BT
LA
PD-1
TIL 2385
4832
2
32 4
2
CD
8
MART-1
12 4
CD
8
gp100
29 15
3
21 67
5
TIL 2616 TIL 2616
Legends:
 
 
 
 
                
                                                                                 
 
 
 
- 127 - 
 
    Figure 3-5 con’t.  
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CD8+BTLA+ TIL are effector cells enriched in CD28, CD57, PD-1 and TIM-3 expressions.   
A number of studies on human CD8+ T cells showed that BTLA was expressed at a 
high level on naïve CD8+ T cells and was gradually down-regulated during normal 
differentiation (52, 54, 201).  Therefore we set out to determine the differentiation state of the 
CD8+BTLA+ and CD8+BTLA- subsets in cultured TIL. TIL from 13 patients that had been 
cultured in IL-2 for 2 weeks were examined for expression of the major differentiation 
markers, CD45RA and CCR7.  Differentiation subsets were broadly defined as follows: 
naïve T cells (TN – CD45RA+CCR7+), central memory T cells (TCM – CD45RA- CCR7+), 
effector memory T cells (TEM – CD45RA-CCR7-), and terminally differentiated effector T 
cells re-expressing CD45RA (TTDE – CD45RA+CCR7-) (123).  These markers provide a 
framework for comparing the differentiation state of the CD8+BTLA+ and CD8+BTLA- 
populations.  Analysis of a representative TIL is shown (Fig. 3-6A, left panel). Indeed, while 
there was no statistically significant difference in the percentages of TEM cells within the 
CD8+BTLA+ and BTLA- subsets (Fig. 3-6A, right panel), the percentages of TEMRA cells 
were significantly more enriched in the CD8+BTLA- subset than the CD8+BTLA+ subset 
(Figure 3-6A, right graph).   
To further define the surface phenotypes of the CD8+BTLA+ subset, TIL were stained 
for CD28, CD27, CD57, CD25, PD-1, TIM3, Granzyme B (GB), and perforin (Fig. 3-6B). 
Within the TEM subset, CD28 and CD27 are markers of early CD8+ effector-memory T (TEM) 
cells.  Based on studies on virus-specific T cells in humans, it was postulated that CD8+ TEM 
cells differentiate in a linear pathway from CD28+CD27+ (early-differentiated) to CD28-
CD27+ (intermediate-differentiated) to CD28-CD27- (late-differentiated) (127).  As CD8+ 
TEM differentiates further, the loss of CD28 and gain of CD57 is an immunological 
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characteristic of humans and primates (127).  In addition, we and others have previously 
reported that the loss of CD28, not CD27, expression marked senescent CD8+ T cells and 
TILs in humans (66, 195).  We found significantly higher expression of CD28 in the BTLA+ 
subset compared to the BTLA- subset (61 ± 6.2% vs. 45 ± 6.8%; p=0.0008; Fig. 3-6B).  
However, the difference in the level of CD27 expression between the two subsets was not 
statistically significant (33 ± 4.6% vs 36 ± 4.6%, respectively, p=0.455) (Fig. 3-6B) 
Therefore the CD8+BTLA+ subset belongs to the early-differentiated TEM population. 
We also examined the difference in CD57 expression, a reported marker for late T 
cell differentiation and senescence (131), in the CD8+BTLA+ and CD8+BTLA- subset.  We 
found that the CD8+BTLA+ subset was enriched in cells expressing CD57 (28 ± 4.1%) as 
compared to their BTLA- counterpart (17 ± 2.4%, p = 0.001) (Fig. 3-6B).  The notion of 
CD57 as a senescent marker has been challenged by recent studies showing that CD8+CD57+ 
T cells could still maintain proliferative capacity (127, 181).  Our group has previously 
reported that a subset of CD8+ TIL co-expressing early TEM markers (CD27 and CD28) and 
CD57 are able to exhibit CTL activity and production of cytokines [Chapter 2 and ref. 
(202)].  Therefore the enrichment of CD57 in the CD8+BTLA+ subset suggests similarity to 
the TEM TIL subset we described previously, which was only found within the TIL 
population and not in the peripheral blood.  We also examined the expression of CD25 (IL-
2Rα), which was reportedly a marker of potent memory T cells in humans (203).  We found 
that the CD8+BTLA+ subset expressed slightly more CD25; the expression level was 29 ± 3.9 
% as compared to 25 ± 3.8% for the CD8+BTLA- subset (p=0.049) (Fig. 3-6B).  
Two reported inhibitory markers, PD-1 and TIM3 were also found to be significantly 
expressed on the CD8+BTLA+ subset as compared to the CD8+BTLA- population. In fact, 
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PD-1 expression was 42 ± 4.1% on the BTLA+ populations versus 29 ± 3.4% on the BTLA- 
cells (p=0.0002) (Fig. 3-6B).  Similarly, TIM3 expression on the BTLA+ subset was 22 ± 
7.1% as compared to 13 ± 4.8% on the BTLA- subset (p= 0.015) (Fig. 3-6B). Finally, we 
examined protein expressions of Granzyme B and perforin as markers associated with 
cytolytic activity.  Of the six independent lines tested, there was no significant difference 
between the BTLA+ and BTLA- subsets for either cytolytic marker (GB: 95 ± 3.4% vs 95 ± 
2.4%, p=0.438; Perforin: 50 ± 9% vs 55 ±10%, p=0.688) (Fig. 3-6B). Overall our phenotypic 
data suggests that CD8+BTLA+ TIL subset has a less-differentiated and a more activated 
phenotype, but may exhibit a similar level of CTL activity as compared to the CD8+BTLA- 
subset. 
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Figure 3-6: CD8+BTLA+ TIL exhibit a less differentiated, more activated phenotype 
than the BTLA- counterparts.  TIL were isolated from melanoma tumors and were cultured 
with high-dose (3,000 IU/mL) IL-2 for 2 weeks.  TILs were stained for expression of CD8, 
BTLA, CD45RA, CCR7, CD28, CD27, CD57, CD25 (IL2Rα), PD-1, TIM-3, and cytolytic 
granule proteins, Granzyme B and Perforin. Dead cells were excluded using Aqua® dead cell 
exclusion dye. (A, left panel) CD45RA and CCR7 expression on the CD8+BTLA+ (left dot 
plot) and CD8+BTLA- (right dot plot) populations on a representative TIL from patient 
#2360 (left panel). (A, right panel) A summary of CD45RA and CCR7 expressions within 
each CD8+BTLA+ or CD8+BTLA- subset (n=13). Differentiation subsets are defined as 
follows: TN: CD45RA-CCR7+; TCM: CD45RA+CCR7+; TEM: CD45RA-CCR7-; TEMRA: 
CD45RA+CCR7-. The results are shown by determining the percentages of TEM or TEMRA 
subsets within each gated CD8+BTLA+ or BTLA- subsets.  TN and TCM are omitted since no 
significant populations were found. (B) A summary of the expressions of surface markers, 
CD28, CD27, CD57, CD25, PD-1, TIM3, and intracellular proteins, granzyme B and 
perforin, by the CD8+BTLA+ and CD8+BTLA- subsets (n ranges from 6 – 42 per marker). 
Statistical significance between the subsets was determined using Wilcoxon signed-rank test. 
The p value for each marker is shown at the top of each graph. *p<0.05, **p<0.01, and 
***p<0.001. 
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Figure 3-6: 
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Stability of BTLA expression on bulk TIL and sorted CD8+BTLA+ and BTLA- TIL subsets.   
While a number of reports have shown high BTLA expression on naïve and less-
differentiated CD8+ T cells (52, 54, 201), one study reported its up-regulation on “exhausted” 
melanoma antigen-specific CD8+ T cells in the periphery (53).  Therefore, we wanted to 
examine the stability of BTLA’s expression during in vitro culture with IL-2 as well as 
during TCR activation. We maintained bulk TILs either with low-dose (LD) IL-2 (200 
IU/ml) or stimulated them with LD IL-2 plus agonistic αCD3 antibody (OKT3) (30 ng/ml) 
for three days. LD IL-2 was used in order to clearly distinguish the effect of TCR 
stimulation. TIL were subsequently stained for CD8, BTLA, CD25, and LIGHT; CD25 and 
LIGHT (homologous to Lymphotoxins, exhibits Inducible expression, and competes with 
HSV Glycoprotein D for Herpesvirus entry mediator, a receptor expressed by T 
lymphocytes, a ligand for the TNF receptor superfamily) were known to be up-regulated on 
activated T cells and hence served to indicate TCR stimulation (204, 205).  On two separate 
TIL lines, we found that TCR stimulation, when compared to LD IL-2, did not significantly 
alter the expression of BTLA on CD8+ TILs (TIL 2430: change from 82% to 89%; TIL 2425: 
change from 100 to 98%), whereas there were significant increases in CD25 (TIL 2430: 
change from 4% to 98%; TIL 2425: change from 86 to 100%) and LIGHT (TIL 2430: change 
from 9% to 79%; TIL 2425: change from 35 to 62%) (Fig. 3-7).     
Next, we sorted CD8+BTLA+ and CD8+BTLA- subsets and assessed the effect of IL-2 
on each subset’s BTLA expression.  The purity sort purity was shown on a representative 
TIL line (95% purity in the BTLA+ subset and 99% purity in the BTLA- subset) (Fig. 3-7C).  
After 3 days of culture with LD IL-2, we found that a significant percentage of the 
CD8+BTLA+ subset became CD8+BTLA- (26% BTLA+ and 72% BTLA-) (Fig. 3-7C).  In 
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contrast, the sorted CD8+BTLA- TIL remain BTLA- (1% BTLA+ and 98% BTLA-) (Fig. 3-
7C).  We were unable to compare the effect of TCR stimulation on sorted TILs due to 
limitations in the number of sorted CD8+BTLA- TILs obtained from multiple TIL lines.  In 
sum, our data demonstrated that CD8+BTLA+ TILs maintained stable expression of BTLA in 
response to TCR stimulation, and that they differentiated into BTLA- TIL when cultured with 
IL-2. CD8+BTLA- TILs, on the other hand, did not up-regulate BTLA in response to TCR 
stimulation or differentiate into BTLA+ TIL with IL-2.  Our results are similar to a previous 
report demonstrating the stability of BTLA expression on peripheral melanoma antigen-
specific CD8+ T cells stimulated with cognate antigen (53). 
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Figure 3-7:  BTLA expression is stable upon TCR stimulation and is not up-regulated 
on the CD8+BTLA- subset.  (A) Bulk TIL (0.5x106 cells) were cultured with 200 IU/ml IL-2 
or IL-2 plus 30 ng/ml αCD3 mAb (OKT3) for 3 days. Cells were then stained for expression 
of CD8, BTLA, CD25 and LIGHT.  Dead cells were excluded using Aqua® live/dead dye. 
The numbers indicate percentages of each marker within the gated CD8+ TIL population. (B) 
A summary table of MFI of the BTLA, PD-1, LIGHT, and CD25 with low-dose (LD) IL-2 
culture or with stimulation using OKT3 mAb, in TIL from two different patients.  (C, left 
panel) the post-sort purity of the CD8+BTLA+ and CD8+BTLA- subsets from a 
representative TIL line after cell sorting as described in Material and Methods. Each sorted 
subset was re-stained for expression of CD8 and BTLA. (C, right panel) shows the 
phenotype of the sorted TIL subsets five days after culturing with 200 IU/ml IL-2 in vitro.  
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Figure 3-7 con’t. 
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Enhanced proliferation of CD8+BTLA+ TIL with IL-2 culture in vitro.   
Less-differentiated CD8+ T cells are known to proliferate more rapidly than highly-
differentiated T cells (124, 132, 191).  Since our data on the surface phenotypes of the 
CD8+BTLA+ subset seemed to suggest it was less differentiated than the BTLA- subset (Fig. 
3-6), we hypothesized that the CD8+BTLA+ TIL exhibited a higher proliferative capability 
than the CD8+BTLA- TIL.  In order to test this hypothesis, we sorted the CD8+BTLA+ and 
CD8+BTLA- TIL, labeled them with CFSE, and tracked the extent of proliferation in each 
subset with cultured with 3,000 IU/ml IL-2.  In fact, CD8+BTLA+ TIL from four different 
patients had higher fractions of proliferating cells and had undergone more cell divisions than 
the CD8+BTLA- subset (TIL 2486: 58% vs. 36%, Division Index: 1.90 vs. 1.43; TIL 2488: 
30% vs 18%, Division Index: 1.44 vs. 1.28; TIL 2605B: 84% vs. 53%, Division Index: 2.67 
vs 1.31; TIL 2612: 73% vs. 8%, Division Index: 0.8 vs 0.18; Fig. 3-8A and Fig. 3-9). 
Furthermore, manual cell counting based on trypan blue exclusion after 6 days in culture 
showed that, CD8+BTLA+ TIL, on average, had higher fold expansion than the CD8+BTLA- 
TIL (TIL 2425: 5.4-fold vs. 1.4-fold; TIL 2396: 2.2-fold vs. 0.9-fold; TIL 2486: 1.7-fold vs. 
0.45-fold; Fig. 3-8A and Fig. 3-9).  However, the lack of proliferation in response to IL-2 
was not due to apoptosis of the CD8+BTLA- subset as staining with Annexin-V did not show 
consistent difference in the survival between the subsets (TIL 2486: 36% vs 37% Annexin-
V+ cells; TIL 2488: 6% vs. 11% Annexin-V+ cells) (Fig. 3-8B).  
Next, when we compared the proliferation of the sorted CD8+BTLA+/- subsets 
stimulated with plate-bound αCD3 Ab (OKT3) or αCD3 + αCD28 (OKT3+aCD28) in a 3[H]-
thymidine incorporation assay in the absence of exogenous IL-2, we consistently noted 
significantly more proliferation in the CD8+BTLA+ subset in four different TIL lines (Fig. 3-
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8C).  Although others have shown that CD8+CD27+ tumor antigen-specific T cells in the 
periphery proliferated more and possessed longer telomere length (191), a previous study 
from our group found that a difference in proliferation existed between the CD8+ CD28+/- 
TIL subsets, not between the CD8+CD27+/- TIL subsets (66).  Therefore, we also compared 
the proliferative capacity of the sorted CD8+ BTLA+/- vs. CD27+/- TIL subsets from two 
patients. We found that there was significantly more differences in the proliferating fractions 
between the sorted CD8+ BTLA+/- subsets than the CD27+/- subsets (TIL 2605B: BTLA+/-: 
84% vs. 53%, CD27+/-: 92% vs. 81%; TIL 2612 BTLA+/-: 73% vs. 8%, CD27+/-: 81% vs. 
100%) (Fig. 3-9).  In sum, our data suggest that the CD8+BTLA+ TIL consistently proliferate 
more than the CD8+BTLA- TIL in response to IL-2 or TCR signaling, and that the difference 
in CD27 expression did not correspond to difference in CD8+ TIL’s proliferation.     
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Figure 3-8:  CD8+BTLA+ TIL have enhanced proliferation in response to IL-2 or TCR 
stimulation compared to the CD8+BTLA- subset.  Sorted CD8+BTLA+/- TIL subsets were 
labeled with CFSE and cultured (1 x 106/ml) with HD IL-2 for 5 days (3,000 IU/mL) (n=4). 
(A) shows the percentages of proliferating cells from two lines (top histograms). The 
absolute number of cells per subsets was determined using trypan blue exclusion and graphed 
as fold expansion (bottom graph). (B) Sorted cells from each were also stained CD8, 
Annexin-V, and 7-AAD.  Two representative TIL lines are shown. The numbers indicate 
percent expression of each marker within the CD8+BTLA+/- subsets. (C) Sorted CD8+BTLA+ 
and CD8+BTLA- cells were stimulated with plate-bound anti-CD3 (OKT3), ant-CD3 and 
anti-CD28 (OKT3+aCD28) or not stimulated (NIL) in the absence of IL-2 for 3 days. Cells 
were pulsed with 1 µCi of [3H]-thymidine for the last 18 hours of culture. Results were 
shown as counts per minute (cpm) from triplicate wells (mean ± S.D.). * indicates 
significance (p<0.05) as determined by Student’s t test. 
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Figure 3-9:  Differences in proliferative capacity in response to IL-2 exists between 
CD8+BTLA+/- TIL subsets, not between CD8+CD27+/- TIL subsets.  Sorted CD8+BTLA+/- 
or CD8+CD27+/- TIL subsets were labeled with CFSE and cultured (1 x 106/ml) with HD IL-2 
for 5 days (3,000 IU/mL) (n=4). (A and B) the percentages of proliferating cells from the 
indicated sorted subsets from two different TIL lines (middle histograms). The absolute 
number of cells per subsets was determined using trypan blue exclusion and graphed as fold 
expansion, with error bars denoting SEM (rightmost graphs). 
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Figure 3-9: 
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The production of and responsiveness to IL-2 drives CD8+BTLA+ TIL’s superior 
proliferation.  
In order to explain the preferential expansion of the CD8+BTLA+ subset in response 
to IL-2, we hypothesized that the CD8+BTLA+ subset might express a higher level of the 
high-affinity IL-2 receptor, CD25 (IL2Rα), than the BTLA- subset as suggested by Fig. 3-5. 
Indeed, we found that a subset of CD25 expression was enriched within the CD8+BTLA+ 
subset in TIL from a representative patient, whereas there was very little CD8+BTLA-CD25+ 
TIL (1%) within the BTLA- subset (Fig. 3-10A, dot plot).  Furthermore, analysis of TIL 
from 28 patients, showed that there was a statistically significant difference in the MFI of 
CD25 expression between the CD8+BTLA+/- subsets (Fig. 3-10A; p = 0.002; bottom panel).   
Next, we hypothesized that the higher expression of CD25 in the CD8+BTLA+ subset 
might confer more responsiveness to IL-2.  In order to this answer this question, we first 
sorted out CD8+ BTLA+/- TIL subsets, treated them with different doses of IL-2 (none, 50 
U/mL, 200 U/mL, and 3,000 U/mL), and determined the activation status of STAT5, which 
is activated downstream of the IL-2 receptor (206).  We found that the CD8+BTLA+ subset 
had higher expression and  MFI of phospho-Stat5 (pStat5) than those of the CD8+BTLA- 
subset at all doses of IL-2 tested (Fig. 3-10B, top panel). Furthermore, when treated with 
200 IU/mL of IL-2 for 20 minutes, CD8+BTLA+ TILs had higher levels of phospho-Stat5 
(∆MFI: 205) and phospho-Akt (∆MFI: 74) than those of the CD8+BTLA- TIL (Fig. 3-10B, 
bottom panel).  We also explored the possibility whether the CD8+BTLA+ TIL could 
produce IL-2 in an autocrine fashion, since this has been reported as a feature of early-
differentiated CD8+ memory T cells in humans (203, 207).  In sorted CD8+ BTLA+/- subsets 
from two different patients, we found that the CD8+BTLA+ TIL produced more IL-2 than the 
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CD8+BTLA- subset when stimulated with PMA and ionomycin (TIL 2547 ∆MFI: 274; TIL 
2538 ∆MFI: 652) (Fig. 3-10C).  Lastly, to further confirm that the autocrine production of 
IL-2 by the CD8+BTLA+ TIL contributed to its superior proliferation, we compared the 
proliferation of the TCR-stimulated CD8+BTLA+ TIL with or without anti-human IL-2 
neutralizing mAb.  We found that IL-2 neutralization significantly reduced the proliferation 
of the CD8+BTLA+ TIL to the same level as the BTLA- counterparts (Figure 3-10D, bottom 
panel).  TCR-stimulated CD8+BTLA- TIL did not proliferate as well as the CD8+BTLA+ TIL 
in the absence of IL-2 (Fig. 3-10D, top panel), and hence neutralization of IL-2 in the 
culture affected its proliferation to a lesser extent than that of the CD8+BTLA+ TIL (Fig. 3-
10D, bottom panel).  Therefore, the superior proliferation of the CD8+BTLA+ TIL subset 
could be partially explained by its higher level of autocrine IL-2 production and better 
responsiveness to IL-2 signaling than those of the CD8+BTLA- TIL.   
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Figure 3-10:  CD8+BTLA+ TIL’s autocrine IL-2 production and higher responsiveness 
to IL-2 contributes to its superior proliferation.  (A, top panel) TIL were stained for 
expression of CD8, BTLA, and CD25 along with the Aqua® live/dead viability dye. The dot 
plot shows representative staining of TIL 2559. The numbers indicated percent expression 
within the CD8+ TIL population. (A, bottom panel) a summary graph of the CD25 MFI 
between the CD8+BTLA+/- subsets (n=23).  p value was calculated using Wilcoxon signed-
rank test. (B) TIL were sorted into CD8+BTLA+ (red) and CD8+BTLA- (blue) subsets. Cells 
were subsequently cultured with increasing concentrations of IL-2 for 20 minutes, fixed, 
permeabilized and stained for pStat5 (Y694) and pAkt (S473). The top panel shows the 
percent pStat5 expression as well as the MFI between the subsets in TIL 2538. The bottom 
histograms show the level of pStat5 and pAkt expression after treatment with 200 IU/ml IL-2 
for 20 minutes. The change in MFI (∆ MFI) between the subsets is shown.  (C) Sorted 
CD8+BTLA+/- subsets were stimulated with PMA and ionomycin for 4 hours and stained for 
IL-2 intracellularly. The numbers indicate the MFI for each subset from 2 TIL lines. (D) The 
sorted subsets were labeled with a cell proliferation dye, eFluor670®, and stimulated with 
increasing doses of anti-CD3 (OKT3) for 3 days with or without 10 µg/ml of an anti-human 
IL-2 neutralizing antibody. (D, top panel) the extent of proliferation of the CD8+BTLA+ 
(circles) vs. CD8+BTLA- (squares) subsets in response to OKT3 alone as percent eFluor 
dilution. (D, top panel) The bottom panel shows proliferation of the subsets with IL-2 
blockade.   
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Figure 3-10: 
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CD8+BTLA+ TIL display a higher degree of polyfunctional cytokines production than the 
CD8+BTLA- subset.   
One measurement of CD8+ T cells’ polyfunctionality is their ability to produce 
multiple cytokines at high levels simultaneously (208).  Thus, we were interested to further 
examine whether CD8+BTLA+ TILs were capable of producing high levels of cytokines 
other than IL-2.  To this end, we collected tissue culture supernatants from 5 x 104 cells of 
each sorted CD8+ BTLA+/- subset, from four different patients, stimulated with agonistic 
αCD3 Ab (OKT3) or αCD3 + αCD28 Abs (OKT3 + CD28) for three days.  We used a 
multiplex cytokine assay to measure the concentrations of IFN-γ, TNF-α, and MIP-1β, which 
are cytokines known to be produced by human CD8+ T cells (208).  In fact, sorted 
CD8+BTLA+ TIL subset from 4 out of the 4 patients tested produced more IFN-γ after CD3 
(OTK3) and CD28 stimulations than the CD8+BTLA- subset (Figure 3-11A and Table 3-I).  
CD8+BTLA+ TIL from 3 out of 4 patients produced more MIP-1β, and the same TIL from 2 
out of 4 patients produced more TNF-α.  Therefore the CD8+BTLA+ TIL subset are in a more 
activated state after TCR stimulation and are more polyfunctional than the CD8+BTLA- TIL 
subset.            
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Figure 3-11: CD8+ BTLA+ TIL are more polyfunctional than their BTLA- counterparts. 
CD8+BTLA+ (red) and CD8+BTLA- (blue) TIL were sorted and stimulated with plate-bound 
anti-CD3 (30ng/ml) (OKT3), anti-CD3 and anti-CD28 (1µg/ml) (OKT3 + CD28) or left 
unstimulated (TIL alone) for 3 days. Supernatants were collected, diluted 1:3 and tested for 
the presence of IFN-γ, TNF-α, and MIP-1β using Multiplex technology. Data is shown as 
mean ± SD from triplicate wells for each condition. (n=4) 
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Figure 3-11: 
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Table 3-I: Concentrations of cytokines before and after stimulation(s) 
IFN-γ (pg/mL) CD8+BTLA+ CD8+BTLA-
Stimulation Conditions Mean Conc. SEM Mean Conc. SEM
TIL 2521 TIL alone 5.5 1 6.1 1.6
OKT3 1493 511.2 191.4 19.1
OKT3 + CD28 29208.5 2394.6 2207.2 149.1
TIL 2527 TIL alone 11.4 0.8 10.6 0.8
OKT3 14.2 5.9 14.8 2.9
OKT3 + CD28 4602.5 156.8 36.2 8.8
TIL 2529 TIL alone 6.1 1.6 4.9 0.6
OKT3 166.8 109.4 13.1 2.9
OKT3 + CD28 3600.4 214.1 396.7 147
TIL 2430 TIL alone 7.3 0 10.5 1.3
OKT3 9.8 1.7 17.7 5.2
OKT3 + CD28 14261.5 642.2 7075.6 265.5
TNF-α (pg/mL)
Stimulation Conditions
TIL 2521 TIL alone 3.5 0.6 0.3 0
OKT3 409.9 5.9 214.9 10
OKT3 + CD28 6248.6 573.6 1754.8 296.1
TIL 2527 TIL alone 0.6 0 1.7 1.1
OKT3 0.4 0.2 10.5 4.1
OKT3 + CD28 122.1 11.3 74.7 18.7
TIL 2529 TIL alone 2.3 0 0.3 0
OKT3 55.3 28.3 20.1 3.1
OKT3 + CD28 1155.7 59.4 810.3 186.7
TIL 2430 TIL alone 0.3 0 0 0
OKT3 0.3 0 0.3 0
OKT3 + CD28 3258.1 174.9 2428.2 107.9
MIP-1β (pg/mL)
Stimulation Conditions
TIL 2521 TIL alone 65.9 5.7 81.4 2.9
OKT3 3812.2 323.3 2364.4 539.7
OKT3 + CD28 31996.9 1032 14351 1031.6
TIL 2527 TIL alone 96.4 8 83.7 4.6
OKT3 113.9 19.6 86.4 15.6
OKT3 + CD28 10558.8 704.7 600.2 135
TIL 2529 TIL alone 12 0 75 8.7
OKT3 1182.2 587.7 263.6 22.9
OKT3 + CD28 10530.9 835.1 3085.6 440.4
TIL 2430 TIL alone 33.5 5.2 33.5 5.2
OKT3 101.6 21.2 42.7 8
OKT3 + CD28 33749.7 694.2 30126.6 679.2
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CD8+BTLA+ and CD8+BTLA- TIL subsets exhibit similar levels of CTL activity.   
We originally hypothesized that CD8+BTLA+ TIL might display a higher level of 
cytolytic activity against either αCD3-loaded targets or autologous melanoma tumor cells, 
which might explain the positive clinical association with this subset.  To test this hypothesis, 
we sorted CD8+ BTLA+/- TIL subsets from 6 different patients and co-cultured them for 3 
hours with αCD3-loaded P815 target cells (murine mastocytoma cell lines) in a redirected 
lysis assay. Target cells were labeled prior to the co-culture with a fluorescent dye, DDAO-
SE, in order to distinguish them from the effector T cells.  Compared to the co-culture system 
with autologous tumor cells, the advantage of this system was that there was an activation of 
polyclonal T cells in each subset, so the CTL activity is not influenced by the frequencies of 
tumor antigen-specific populations in each subset.  Contrary to our expectation, we did not 
find a significance difference in the percentage of the killed (DDAO-SE+Caspase-3+) P815 
target cells co-cultured with either sorted CD8+BTLA+ or BTLA- TIL (Fig. 3-12A).  We also 
co-cultured sorted CD8+ BTLA+/- subsets with autologous tumor cells and tested their 
degranulation (CD107a) and release of IFN-γ as well as direct tumor killing via active-
caspase-3 staining as before. In a representative TIL shown (Fig. 3-12B), we did not find 
significant difference in the percentages of CD107+ populations (BTLA+: 57% vs BTLA-: 
53%) or CD107a+IFN-γ+ double-positive populations between each subset (BTLA+: 39% vs. 
BTLA- : 34%) (Fig. 3-12B). Furthermore, the percentage of tumor targets killed (DDAO-
SE+Caspase-3+) was similar between the two subsets (BTLA+: 32% vs. BTLA-: 29%). 
Notably, we have shown earlier that there were no significant differences in the levels of GB 
and Perf expressions between the two TIL subsets (Fig. 3-12B).  Therefore, parameters of 
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CD8+ T cells functions other than CTL activities between the two subsets may account for 
the observed positive clinical association with CD8+BTLA- TIL.  
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Figure 3-12:  No significant difference in CTL activities between CD8+BTLA+ vs BTLA- 
TIL subsets.  (A) CD8+BTLA+ and CD8+BTLA- TIL were sorted and co-cultured with P815 
target cells pulsed with 300ng/ml OKT3 for 3 hours. Unpulsed targets were used as a 
negative control. Targets (T) were labeled with the far-red dye, DDAO-SE, to distinguish 
from effectors (E). E:T ratios of 1:3, 1:1 and 3:1 were used. After 3 hours, cells were 
permeabilized and stained for the presence of active caspase-3 by flow cytometry. The dot 
plots show representative staining of active caspase-3 on the DDAO-SE labeled targets (3:1 
E:T ratio). The numbers indicate percent expression of caspase-3. The unpulsed control is 
shown on the bottom row. The right graph indicates the level of active caspase-3 staining 
from 6 TIL lines at each E:T ratio. The mean ± SE is shown for each ratio. (B) Sorted 
CD8+BTLA+/- subsets were cultured 1:1 with autologous tumor cells labeled with DDAO-SE. 
After 3 hours, cells were harvested, permeabilized and stained for active caspase-3 as in (A). 
After 6 hours, cells were harvested, permeabilized and stained for surface CD8 and 
intracellular IFN-γ.  CD107a PE antibody was added for the duration of the culture. Cells are 
gated on the CD8+DDAO-SE- population. HLA-mismatched tumor from a different patient 
(2320) was used as a negative control. 
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Figure 3-12: 
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Differential gene expression profiles between CD8+BTLA+ and CD8+BTLA- melanoma 
TIL.           
A major aim of our study was to determine difference in the global gene expression 
profile between of CD8+ BTLA+ and BTLA- TIL.  We used highly purified CD8+BTLA+ and 
BTLA- TIL from five different melanoma patients for gene expression studies using 
Affymetrix® Human Gene 1.0 ST Array containing 33,297 human transcripts. The 
microarray data has been deposited into the NCBI Gene Expression Omnibus (GEO) 
database (Accession # GSE43260).  An example of post-sort analysis of CD8HiBTLA+ and 
BTLA- TILs is shown (Fig. 3-7C, left panel).  To confirm that the sorted cells are T cells 
(NK cells can express low levels of CD8), we did not find significant differences in the 
expression intensities of the TCR subunits, CD3ε and CD3δ, from the microarray data on the 
sorted CD8+BTLA+ and BTLA- TIL subsets (Fig. 3-13).  As an internal control, we 
ascertained that the expression of the BTLA gene was significantly higher in the sorted 
CD8+BTLA+ subset (7.69-fold higher, p = 8.80x10-6; Student’s paired t test) (Table 3-II).  
Using an arbitrary selection criteria to assess for significantly different genes between the 
two subsets (paired t test; fold change ≥ 1.45; p < 0.05), we determined that there were 406 
differentially-expressed genes (DEGs).  Among these, 171 genes were up-regulated in the 
CD8+BTLA+ subset, and 235 genes were up-regulated in the CD8+BTLA- subset.  In 
agreement with the surface phenotypes of the CD8+BTLA+ subset (Fig. 3-6), we found that 
there were significantly increased expressions of effector-memory genes [CD28 (2.38-fold 
higher, p = 0.025), CD127 (IL7R) (2.08-fold higher, p = 0.03)], and late-differentiation 
genes [B3GAT1 (CD57, or β-1,3-glucoronyltransferase 1; 1.79-fold higher, p = 0.0008).  We 
also found CX3CR1 [a chemokine receptor for CX3CL1 (Fractalkine)] to be highly 
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expressed by the CD8+BTLA+ TIL (3.33-fold higher; p = 8.18x105)] (Table 3-II); CX3CR1 
has been reported to be expressed by the senescent CD8+CD57+ T cells in the periphery (167) 
as well highly-differentiated CD8+ and CD4+ T cells (209).  We did not find statistically 
significant difference in the expression of the CD27 gene between the two TIL subsets.  
Interestingly, we also found increased expression of CD86 (2.0-fold higher, p = 0.04) and 
CD80 (1.45-fold higher, p = 0.01), which were costimulatory molecules expressed by 
antigen-presenting cells (APCs) and T cells (206), in the CD8+BTLA+ subset (Table 3-II).  
On the other hand, in the CD8+BTLA- subset, there were significantly increased expressions 
of 13 members of the killer-cell immunoglobulin-like receptor (KIR) gene family, KLRG-1 
(killer-cell lectin-like receptor G1; 2.36-fold higher, p=0.04), and TYROBP gene (DAP12, an 
adaptor protein for the KIR receptors, ref. (210); 4.11-fold higher; p = 0.0002) (Table 3-III).  
KIR receptors are known to be expressed by NK cells (194), highly differentiated CD8+PD-1-
CD45RA+ TEMRA lymphocytes from normal donors’ PBMC (166, 196), and senescent human 
CD8+CD28- T cells (66, 195), while KLRG-1 is known to be expressed by NK cells and 
CD8+ effector and memory T cells in humans with reduced proliferative capacity (170, 171, 
211).  We confirmed the preferential protein expressions of some KIR receptors in the 
CD8+BTLA- subset by flow cytometry (Fig. 3-14B).  We also found that the expressions of 
other genes typically associated with NK cells, such as NCAM1 [(CD56; 3.42-fold higher, p 
= 0.01), LYN (2.41-fold higher, p = 0.025), and SYK (1.8-fold higher, p = 0.02)] (212, 213), 
were also significantly increased in the CD8+BTLA- subset (Table 3-III).  Lastly, we 
observed that the expressions of the genes associated with T cell deletion and anergy (197), 
such as IKZF2 [IKAROS family zinc finger 2; 5.08-fold higher, p = 0.00076; ref. (198, 
214)], EGR2 [Early growth response 2; 1.82-fold higher, p = 0.0185; ref. (198, 215)], and 
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NR4A3 [(Nuclear receptor subfamily, group A, member 3; 1.8-fold higher, p = 0.0014; ref. 
(198, 215, 216)], were also significantly increased in CD8+BTLA- TIL (Table 3-II).  
Similarly, others have shown that the CD8+ TEMRA (PD-1-) lymphocytes from normal donor 
PBMC had increased expressions of the IKZF2, NCAM1, LYN, and TYROBP genes 
compared to the PD-1+ TEM subset (166).            
 
 
 
 
 
 
 
 
 
 
 
 
 
- 159 - 
 
Table 3-II:  Partial list of genes significantly upregulated in CD8+BTLA+ TIL  
Entrez ID Gene Symbol Fold change  (BTLA+/BTLA-) p-value 
151888 BTLA 7.69 8.80E-06 
1524 CX3CR1 3.33 8.18E-05 
940 CD28 2.38 0.0254706 
3575 IL7R 2.08 0.0300249 
942 CD86 2.00 0.0411847 
4345 CD200 1.89 0.0029873 
27087 B3GAT1 1.79 0.0008077 
3122 HLA-DRA 1.69 0.0112811 
3577 CXCR1 1.69 0.0124128 
57007 CXCR7 1.67 0.0003392 
3119 HLA-DQB1 1.67 0.0003418 
3122 HLA-DRA 1.67 0.0156466 
3119 HLA-DQB1 1.67 0.024055 
3111 HLA-DOA 1.64 0.0033466 
3117 HLA-DQA1 1.61 0.004212 
3108 HLA-DMA 1.54 0.0059107 
50615 IL21R 1.52 0.0008461 
3115 HLA-DPB1 1.52 0.0283427 
3108 HLA-DMA 1.49 0.0029988 
3118 HLA-DQA2 1.49 0.0080474 
3127 HLA-DRB5 1.49 0.02435 
3115 HLA-DPB1 1.49 0.038801 
941 CD80 1.45 0.0100546 
3113 HLA-DPA1 1.45 0.0266463 
3684 ITGAM 1.45 0.0423103 
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Table 3-III:  Partial list of genes significantly up-regulated in CD8+BTLA- TIL  
Entrez ID Symbol
Fold change                  
(BTLA-/BTLA+) p -value
3805 KIR2DL4 7.8 0.003174
3804 KIR2DL3 7.78 0.007904
3813 KIR3DS1 6.67 0.009093
3802 KIR2DL1 6.56 0.002523
3805 KIR2DL4 6.38 0.003126
3812 KIR3DL2 6.08 0.004395
100132285 KIR2DS2 6.04 0.005326
3811 KIR3DL1 6.01 0.008326
3806 KIR2DS1 5.81 0.004101
3809 KIR2DS4 5.29 0.006637
3803 KIR2DL2 5.15 0.002984
22807 IKZF2 5.08 0.000761
3811 KIR3DL1 4.83 0.003344
3824 KLRD1 4.44 0.002406
3804 KIR2DL3 4.4 0.003473
100528032 KLRC4-KLRK1 4.35 0.027612
7305 TYROBP 4.11 0.000245
3822 KLRC2 3.91 0.008132
3821 KLRC1 3.62 0.007245
115653 KIR3DL3 3.57 0.00377
2207 FCER1G 3.43 0.000289
3823 KLRC3 3.43 0.012605
4684 NCAM1 3.42 0.011811
115653 KIR3DL3 3.29 0.005053
9173 IL1RL1 3.07 2.09E-05
55359 STYK1 2.78 0.003243
8302 KLRC4 2.66 0.048535
9437 NCR1 2.63 0.004604
10748 KLRAP1 2.61 0.00422
4067 LYN 2.41 0.02504
10219 KLRG1 2.36 0.039295
3595 IL12RB2 2.3 0.002999
3810 KIR2DS5 2.29 0.00413
57292 KIR2DL5A 2.17 0.008793
11126 CD160 2.08 0.017882
3460 IFNGR2 1.97 0.0153
3815 KIT 1.94 0.022978
343413 FCRL6 1.83 0.019832
1959 EGR2 1.82 0.018586
1958 EGR1 1.81 0.044018
8013 NR4A3 1.8 0.001398
6850 SYK 1.8 0.023553
952 CD38 1.71 0.000111
131450 CD200R1 1.56 0.000577
7422 VEGFA 1.55 0.017533
55801 IL26 1.47 0.0488
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Figure 3-13:  No find significant differences in the Log2 normalized expression intensities  
of the TCR subunits, CD3ε and CD3δ, between CD8+BTLA+ vs BTLA- TIL, from the 
Affymetrix® Human Gene 1.0 ST microarray data on the sorted CD8+BTLA+ and BTLA- 
TIL subsets 
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Figure 3-13:  
 
 
 
 
- 163 - 
 
Enrichment of a molecular signature of T cell deletion in the CD8+BTLA- TIL subset.   
We also employed Gene set Enrichment Analysis (GSEA) to analyze our microarray 
data, which is a powerful approach to look for enrichment of global or pre-defined set of 
genes in either TIL subset. The top 50 genes ranked by the degree of enrichment in either the 
CD8+BTLA+ or CD8+BTLA- subsets are shown (Fig. 3-14).  Some of the genes listed in the 
heat map, such as CD28, IL7R, KIR receptors, showed agreement with the lists of DEGs 
described previously (Tables 3-I and 3-II).   A complete list of genes ranked by the 
enrichment scores [-1 (enriched in CD8+BTLA- subset) to +1 (enriched in CD8+BTLA+ 
subset)] are available (data not shown).  We next asked which biologic processes could 
explain the lack of proliferation and responsiveness to TCR and IL-2 signals in the 
CD8+BTLA- TIL subset (Fig. 3-8 and Fig. 3-10).  We set out to determine whether gene-set 
signatures deriving from CD8+ T cells undergoing exhaustion in chronic viral infection or 
cancer (217, 218), deletion (198), or anergy (198), were enriched in our ranked-order list of 
DEGs.  We did not find enrichment of exhaustion signature derived from Baitsch, L., et al. [p 
= 0.31; ref. (217)] or Wherry, E.J., et al.  [(p = 0.50; ref. (218)] in either TIL subsets (Fig. 3-
14C, top panels).  We also did not find enrichment of T cell anergy signature in either TIL 
subsets (p = 0.53; Fig. 3-14C, bottom left panel).  However, we discovered an enrichment 
of a molecular signature corresponding to T cell deletion (p = 0.00) in the CD8+BTLA- TIL 
subset (Fig. 3-14C, bottom right panel).  Our analysis of the microarray data provides 
further support that CD8+BTLA+ TIL is a less-differentiated TEM subset, whereas 
CD8+BTLA- TIL is a highly-differentiated, KIR-expressing subset within TEM exhibiting 
molecular signature of T cell deletion, and hence lack of proliferation and responsiveness to 
IL-2 or TCR signals.  
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Figure 3-14: CD8+BTLA+ TIL have a less differentiated phenotype while CD8+BTLA- 
TIL exhibit a T-cell deletion signature. (A) Enrichment analysis of a global set of genes 
from CD8+BLTA+ or BTLA- subsets. The top 50 genes, ranked by enrichment scores using 
gene-set enrichment analysis (GSEA), that are immunologically relevant in either BTLA+ or 
BTLA- subset are shown. Red indicates over-expression and blue under-expression relative 
to the mean.  Each row represents one gene and each column represents 1 sample of highly 
purified CD8+BTLA+ or BTLA- subset from 1 patient.  (B) Flow cytometry plots of the 
CD3+CD8+ TIL from a representative patient showing the expression of BTLA and killer-cell 
immunoglobulin-like receptors (KIR): CD158a (KIR2DL1), CD158b (KIR2DL2/3), and 
NKAT2 (KIR2DL3).  Percentages of KIR+ population out of the total CD3+CD8+ TILs are 
shown.  (C, D) GSEA of previously published gene-set signatures deriving from CD8+ T 
cells undergoing exhaustion (217, 218), anergy (198), or deletion (198).  Positions of selected 
example genes from statistically significant gene sets (p < 0.05 and FDR < 0.25, as suggested 
in the online tool) are indicated.  Gene sets comprise genes enriched in “exhausted” T cells 
(B) or in anergic T cells or T cells undergoing deletion (D).   
 
 
 
 
 
 
 
 
 
- 165 - 
 
Figure 3-14: 
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BTLA provides a survival signal in TIL correlating with enhanced persistence in vivo.  
Our results so far underscore the fact that BTLA is a marker for less-differentiated 
cells that have an enhanced responsiveness to IL-2.  However, BTLA signaling is considered 
to be suppressive as ligation results in the recruitment of SHP1/2 phosphatases and decreases 
in proliferation and cytokine secretion (50, 52).  Given the strong, positive correlation we 
previously observed between the CD8+BTLA+ subset and responsiveness to ACT (55), we 
set out to determine whether BTLA signaling in TIL was still suppressive. In agreement wth 
a study on MART-1 specific CD8+ T cells in the periphery (52), ligation of CD8+BTLA+ TIL 
in vitro using a plate-bound HVEM-Fc fusion protein along with OKT3 resulted in a marked 
decrease in proliferation (32% in OKT3 alone versus 8% in OKT3 + HVEM-Fc) and 
significant decrease in the production of pro-inflammatory cytokines, IFN-γ and TNF-α, as 
compared to the control human IgG after 3 days (Fig. 3-15A and B).         
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Figure 3-15:  Ligation of BTLA on CD8+BTLA+ TIL with HVEM-Fc fusion protein 
significantly decreases proliferation and productions of IFN-γ and TNF-α.  Sorted 
CD8+BTLA+ TIL from two different patients were plated in a flat-bottom 96-well plates, and 
stimulated with low-dose IL-2 (100 U/mL) and plate-bound 30 ng/ml OKT3 with control Ig 
(OKT3+ Ctl Ig), or with 10 µg/ml HVEM-Fc (plate-bound) (HVEM-Fc + OKT3).  (A) 
Sorted CD8+BTLA+ TIL were labeled with a cell proliferation tracking dye, eFluor670®, and 
stimulated as described for 3 days.  The cells were harvested and the percentages of the cells 
that have diluted eFluor670® in each stimulation condition are shown.  (B) Sorted 
CD8+BTLA+ TIL were stimulated for 3 days, and the supernatants were collected for 
multiplex cytokine analysis as described in Materials and Methods.  Shown are the 
concentrations (pg/mL) of IFN-γ and TNF-α produced by the CD8+BTLA+ TIL under 
different stimulation conditions: 0 ctl Ig (plate-bound control Ig alone), 0 HVEM (plate-
bound 10 µg/mL of HVEM-Fc alone), 30 ctl Ig (plate-bound 30 ng/mL of OKT3 + control 
Ig), or 30 HVEM (plate-bound 30 ng/mL of OKT3 + 10 µg/mL of HVEM-Fc).  Error bars 
with SEM are also shown.   
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Figure 3-15: 
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Given that BTLA has a Grb-2 recruitment domain (51) and may potentially influence 
the survival of T cells (219), we next asked whether the ligation of BTLA on TIL by HVEM 
would impact their survival under low dose (LD) of IL-2 (100 U/mL) in order to diminish IL-
2’s survival-promoting effect.  To answer this question, we first generated CD32-expressing 
and CD32/HVEM-expressing murine fibroblasts (L cells), and we co-cultured the bulk TIL 
with these L-cells loaded with OKT3 mAb.  As shown in a representative TIL (Fig. 3-16A, 
left panel), we noticed a marked decrease in Annexin-V+ 7-AAD- (early apoptotic) cells in 
the CD8+ TIL population when co-cultured for 5 days with HVEM-expressing L-cells under 
LD IL-2 (68% Annexin-V+CD8+ in CD32+  L-cells co-culture vs. 19% Annexin-V+CD8+ in 
CD32+HVEM+  L-cells co-culture).  We consistently noticed the same significant decrease in 
early-apoptotic CD8+ TIL from five different patients (p=0.009; Fig. 3-16A, right panel).   
We next examined whether ligation of BTLA by HVEM could promote survival by 
enhancing Akt activation.  Using a cleaner system where we stimulated sorted CD8+BTLA+ 
TIL from three patients with plate-bound OKT3 mAb and HVEM-Fc fusion protein for 2 
hours, we found that there was significantly more phospho-Akt (S473) in CD8+BTLA+ TIL 
stimulated with OKT3 + HVEM-Fc, when compared to OKT3 + control Ig (p=0.017; Fig. 3-
16B).  This enhanced Akt activation was significantly abrogated when a specific BTLA 
blocking mAb [clone 3B1; ref. (200)] was added (p=0.02; Fig. 3-16B), or with the addition 
of a class I pan PI3K inhibitor (Fig. 3-16B).  Histograms from a representative CD8+BTLA+ 
TIL are shown (Fig. 3-16B, left panels).  In contrast, we did not observe significantly more 
Akt activation in CD8+BTLA- TIL from three patients stimulated with OKT3 + HVEM-Fc, 
when compared to stimulation with OKT3 + control Ig (p = 0.61; Fig. 3-16C).  Histogram 
from a representative CD8+BTLA- TIL is shown (Fig. 3-16C, left panel)              
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Figure 3-16: BTLA ligation provides a pro-survival signal to TIL via Akt/PKB.  (A) 
CD32+  (CD32 L cells) or CD32+HVEM+ L cells (HVEM-L cells) were pulsed with 
200ng/ml OKT3 and cultured with TIL (1x106/ml) along with 100 IU/ml IL-2.  After 5 days, 
TIL were harvested and stained for CD8, Annexin-V and 7AAD. The dot plots show a 
representative TIL line staining gated on CD8+ cells. The right graph shows the percent 
apoptosis among all lines tested (n=5).  Statistical significance was determined using a 
Wilcoxen signed-ranked test.  (B, C) TIL were sorted into CD8+BTLA+ and CD8+BTLA- 
subsets. Sorted TIL were then plated in flat-bottom 96-well plates containing plate-bound 30 
ng/ml OKT3 and 10 µg/ml HVEM-Fc (HVEM-Fc + OKT3), OKT3, HVEM, and 10 µg/ml 
anti-BTLA blocking antibody, 3B1 (HVEM-Fc + OKT3 + αBTLA).  TIL alone without 
stimulation served as a negative control.  As an additional negative control for Akt activation, 
10 nM of a pan class I PI3K inhibitor, GSK2126458, was added to TIL stimulatd with OKT3 
and HVEM (HVEM-Fc + OKT3 + PI3Ki).  TIL were cultured for 2 hours, harvested, and 
were immediately fixed with pre-warmed Phosflow Fix buffer I for 10 min at 37C.  Cells 
were then permeabilized with pre-chilled Phosflow Perm buffer III and stained with pAkt 
(S473) for 30 min on ice. The left histograms show representative staining from TIL 2619. 
The right graphs show the fold change in percent pAkt expression normalized to the TIL 
alone condition (set to 1) (n=3). Statistical significance was determined using a two-tailed, 
paired Student’s t test. 
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Figure 3-16: 
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Discussion 
 
 T cell exhaustion, in which CD8+ T cells progressively lose the ability to to 
proliferate in response to antigen, to lyse target cells efficiently ex vivo, and to produce IL-2, 
TNF-α or IFN-γ (220), has been described in chronic viral infections (220) and melanoma 
(217, 221).  A characteristic feature often used to define exhausted CD8+ T cells has been the 
co-expression of multiple inhibitory receptors such as PD-1, TIM-3, BTLA, LAG3, CD160, 
and 2B4 (53, 217, 221, 222).  BTLA was proposed to mark exhausted tumor-specific CD8+ T 
cells in melanoma because a recent report found that the melanoma antigen (NY-ESO-1)-
specific CD8+ T cells in the periphery expressed higher levels of BTLA, PD-1, and Tim-3 
than those of the CMV-specific T cells from the same patient, and that the subset of CD8+ T 
cells’ co-expressing all three inhibitory receptors were the most deficient in producing IL-2, 
TNF-α, and IFN-γ (53).  However, the concept of BTLA as a marker for exhaustion seemed 
incongruent with our previous clinical observation demonstrating a significant positive 
clinical correlation with metastatic melanoma patients receiving more CD8+BTLA+ TIL in an 
ACT trial (55).  Also, other previous studies on CD8+ T cells in chronic viral infections and 
on melanoma antigen-specific (MART-1) CD8+ T cells isolated from tumor-invaded lymph 
nodes have shown that BTLA was not among a set of phenotypic markers or gene expression 
signatures used to define T cell exhaustion (217, 222).   
In the present study, we have found that CD8+BTLA+ melanoma TIL (bulk and 
antigen-specific) frequently co-expressed PD-1 and TIM-3, and that CD8+BTLA+ TIL 
exhibits a significantly higher proliferative capacity in response to IL-2 compared to the 
BTLA- subset.  An alternative explanation for the differing observations on the CD8+BTLA+ 
T cells between ours and others (53) could be the intrinsic difference between the melanoma 
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antigen-specific T cells in the peripheral blood and TIL in the tumor microenvironment.  
However, our findings are also similar conceptually to a different study, where it was shown 
that melanoma antigen-specific CD8+ TIL were enriched in the PD-1+ population, and that 
these CD8+PD-1+ TIL could recover function after culturing in IL-2 and subsequently 
become insensitive to suppression mediated by PD-L1 (223).  Based on these observations, it 
is possible that T cell exhaustion could be overcome through ex vivo expansion with IL-2, 
much like how T cell anergy was classically shown to be overcome by IL-2-induced 
proliferation (224).  However, adopting such a framework implies that T cell exhaustion is a 
transient, rather than a permanent state of CD8+ T cell’s differentiation as defined by others 
(220).  A new concept is emerging that CD8+ T cells, under normal immune activation, may 
naturally express inhibitory receptors, such as PD-1 and TIM-3, as a self-regulating 
mechanism to prevent hyper-responsiveness without eventual transition to T cell exhaustion 
(127, 225).  Hence the anti-tumor activity of the monoclonal antibodies targeting PD-1 may 
be explained by relieving the suppressive signal via PD-1 and allowing the highly active 
CD8+PD-1+ cells to expand as well as migrate to the tumor (226, 227).  We have shown in 
this study that PD-1 was up-regulated on CD8+ TIL after TCR stimulation, while others have 
shown up-regulation of TIM-3 after TCR signaling in human T cells (228).  Therefore the 
presence of PD-1 and TIM-3 on CD8+ TIL could mark cells which have been previously 
activated through TCR by tumor antigens in the tumor microenvironment.  In support of this 
concept, we have observed that CD8+BTLA+ TIL have significantly higher expressions of 
CD25, a classic marker of T cell activation (204), than that of the BTLA- TIL.     
Furthermore, we reasoned that a likely relationship existed between expression of 
inhibitory receptors and a specific stage of CD8+ TIL’s differentiation.  This concept was 
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suggested in a study by Duraiswamy, et al. (166), who found that CD8+PD-1Hi T cells from 
normal donors did not share the same exhaustion gene signature as the T cells from HIV-
infected patients.  Instead, they exhibited similar phenotype and gene signature as the classic 
TEM (CCR7-CD45RA-) CD8+ T cells.  In addition, other studies have shown a close 
relationship between BTLA and differentiation stages of human CD8+ T cells: in normal and 
CMV-specific CD8+ T cells in the periphery, naïve T cells constitutively expressed BTLA 
and down-regulated BTLA as they differentiated toward TEM or TEMRA phenotypes (54, 201).  
Several lines of evidence in our study provide support that CD8+BTLA+ are less-
differentiated memory T cells compared to CD8+BTLA- TIL.  First, we found that TEM subset 
(CCR7-CD45RA-) was found within the CD8+BTLA+ TIL, while significantly more TEMRA 
subset (CCR7-CD45RA+) was found within CD8+BTLA- TIL.  Although there were three 
melanoma patients whose CD8+BTLA+ TIL express CD45RA, that was not unexpected since 
it has been reported that some cells within a TEMRA subset could still retain TEM marker, 
CD27, and displayed phenotypic and functional features that were intermediate between 
naïve and terminally-differentiated effector T cells (123).  Secondly, we found that 
CD8+BTLA+ subset has significantly more CD28, not CD27, expression at the protein and 
mRNA levels than those of the BTLA- subset.  CD28 has been reported as a key marker 
defining a less-differentiated, proliferative CD8+ memory T cells in humans, whereas the loss 
of CD28 is one of the markers for T cell senescence in humans (195).  Prior study from our 
group has determined that CD28, not CD27, was a key marker in defining a subset of TIL 
with superior proliferation and survival (66).  Third, we found that CD8+BTLA+, compared 
to CD8+BTLA- subset, had other features of early-differentiated memory T cells such as 
higher CD25 expression, a better response to IL-2 signal by activating more Stat5 and Akt, 
- 175 - 
 
higher production of autocrine IL-2 to sustain its own proliferation, and higher levels of 
polyfunctional cytokine (IFN-γ, TNF-α, and MIP-1β) productions.  Our findings are 
consistent with a previous study on memory CD8+ T cells in elderly individuals; it was found 
that memory CD8+CD25+ T cells displayed a polyclonal TCR repertoire and produced as 
well as responded to IL-2 and a variety of antigens, whereas the CD8+CD25- memory T cell 
population had a more restricted TCR diversity, responded to fewer antigens, and did not 
proliferate in response to stimulation with IL-2 (203).  Also, the cytokine profile of 
CD8+BTLA+ vs. BTLA- TIL subsets after stimulation with PMA and ionomycin were 
congruent with findings from another study, where it was reported that IL-2/IFN-gamma 
coproduction, a feature of early-differentiated memory T cells, was absent in human late 
memory (CD27-CD45RA+) CD8+ T cells (207).  Finally, the higher level of Akt activation in 
CD8+BTLA+ TIL in response to IL-2 was likely related to its early-differentiated state, as 
other study has shown a progressive decline in Akt phosphorylation (Ser473) as human CD8+ 
T cells progressively differentiated from CD28+CD27+ to CD28−CD27+ to CD28−CD27− that 
could not be reversed by the addition of IL-2 (128).  
In contrast, we found that CD8+BTLA- TIL poorly proliferate in response to IL-2 and 
TCR signals, and they showed enriched expressions of CD45RA and killer-cell 
immunoglobulin-like receptors (KIRs).  We also found  the enrichment of gene signature for 
T cell deletion, a cell fate defined by CD8+ T cells’ hyporesponsiveness due to TCR 
signaling defect and death by apoptosis triggered by the proapoptotic BH3-only protein, Bim 
(197), in the CD8+BTLA- TIL. Deletion and anergy have considerable similarity at the 
molecular level.  One of the features of anergic T cells is the upregulation of the transcription 
factor Egr-2 and Egr-3 by NFAT activation in the absence of AP-1 activation (197).  Egr-2 
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and Egr-3 then promote the expression of immunosuppressive E3 ubiquitin ligases, such as 
Cbl-b, which degrades TCR signaling molecules (197).  It is known that both Egr-2 and Cbl-
b and other numerous anergy-associated genes were strongly upregulatd during deletion 
(198).  A model depicting diverse CD8+ T cells fates, such as anegy, deletion, exhaustion, 
senescence, or memory are shown in Fig. 3-17.  
 
 
 
 
 
 
 
 
 
 
 
 
 
- 177 - 
 
Figure 3-17:  A model for generating diverse CD8+ T cell fates.  (Top portion) Naïve 
CD8+ T cells (brown cell) that encounter antigen on steady state, tolerogenic DCs (beige 
cell) proliferate without acquiring effector functions (dark blue cells) in a process dependent 
on PD-1 and the molecules, Egr-2, Egr-3, and Cbl-b. Such tolerised T cells typically 
upregulate PD-1 and downregulate IL-7R as indicated, and either undergo deletion (black 
cell) or anergy (i.e., defects in TCR signalling as denoted by the red cross). Antigen (Ag) 
levels control this process, with high Ag levels promoting anergy, and low Ag levels causing 
deletion.  (Lower portion) Immunogenic DCs (red cell), which have encountered pathogen-
derived products, activate naïve CD8+ T cells to form effector cells (cytotoxic granules and 
production of effector cytokines are indicated).  This differentiation process is regulated by 
molecules such as Id2, Spi-6, Notch, T-bet and eomesodermin (Eomes). These effector cells 
can adopt multiple cell fates, such as memory precursor cell fates (characterised by IL-7RHi, 
KLRG-1Lo, T-betLo, Blimp-1Int, Spi-2aHi and Bcl-2Hi expression; bottom left) or short-lived 
effector cell fates (with IL-7RLo, KLRG1Hi, T-betHi and Blimp-1Hi expression; middle).  Such 
short-lived cells can either become senescent effectors and die by bim-dependent apoptosis, 
or persist into early memory as short-lived effector memory cells that are CCR7Lo, CD62LLo 
and KLRG1Hi.  By contrast, memory precursor cells are long-lived and can be CCR7Lo, 
CD62LLo, Blimp-1Int effector memory cells, or CCR7Hi, CD62LHi, Blimp-1Lo central memory 
cells (driven by Bcl-6).  Evidence exists that KLRG1Lo effector cells can also give rise to 
KLRG1Hi short-lived effector memory cells (denoted by broken arrow and question marks; 
NS Joshi, TW Hand and SMK, unpublished observations). In some chronic viral infections, 
PD-1, LAG-3 and IL-10 causes cells to acquire an exhausted phenotype (light blue cell) 
characterised by high PD-1 and LAG-3 expression and low IL-7R levels. Although the 
exhausted cell is depicted as sharing a common effector cell precursor with other cell fates, it 
is currently unclear at what point this fate occurs during effector cell’s differentiation. 
Reprinted with permission from:  Ian A Parish, Susan M Kaech, Diversity in CD8+ T cell 
differentiation, Current Opinion in Immunology, Volume 21, Issue 3, June 2009, Pages 291-297, 
ISSN 0952-7915, 10.1016/j.coi.2009.05.008. 
(http://www.sciencedirect.com/science/article/pii/S0952791509000880) 
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Figure 3-17: 
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We think that enrichment of T-cell deletion signature in CD8+BTLA- TIL is likely 
related to its highly-differentiated state, since it has been shown that CD8+ TIL with highly-
differentiated phenotypes failed to persist in vivo after adoptive transfer (136).  Previously, 
we have reported expression of multiple KIRs in CD8+CD28- TIL, and that this subset of TIL 
exhibited decreased telomere length and were hypo-responsive to proliferative signals (66).  
Others have found KIR expressions on CD8+PD-1- T cells, which also co-expressed 
CD45RA, in the normal donor peripheral blood (166).  Furthermore, we have re-analyzed 
microarray data from a previous study on the human CD8+ T cell subsets in the peripheral 
blood (196) and have observed that TEMRA had the highest expression of different KIRs, when 
compared with TEM or TCM (Fig. 3-18B).  Based on all these observations, we propose that 
the expression of KIR family of receptors, together with CD45RA (127), may serve as better 
markers for terminally-differentiated and senescent CD8+ T cells in humans.  
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Figure 3-18:  Terminally-differentiated CD8+ T cells in humans express KIRs and other 
natural-killer (NK) cell’s receptors.  (A) CD8+ T cell subsets in normal human PBMC, as 
defined by CCR7 and CD45RA expressions, were sorted on a MoFlow Cytometer 
(DakoCytomation), with purity of the isolated subpopulations between 93%-98% as 
described in Willinger, T., et al. 2005. J. Immunol. 175: 5895–5903.   (B) Microarray data on 
the sorted CD8+ T cell subsets corresponding to the aforementioned publication was obtained 
from European Bioinformatics Institute ArrayExpress public database (Accession #E-
TABM-40).  We used a comprehensive software package, BRB-ArrayTools v4.2.1 (NCI, 
Bethesda, MD), to determine a list of genes that are statistically different (p < 0.01)      
between TN, TEM, and TEMRA subsets using a random variance F-test.   Two-way hierarchical 
clustering was performed using centered correlation and average linkage.  The resulting 
heatmap was generated by BRB-ArrayTools v4.2.1.   
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Figure 3-18: 
CD8+subsets in human peripheral blood:
Naïve CD8+ T cells
CD8+TEMRAcells
TEM
TCM
A. B.  Microarray 
(Re-analyzed from Willinger T et al,
J. Immunol. 175(9): 5895-63).  
TN TEMTEMRA
KIRs
and 
NK
receptors
-0.7 0.5
Genes centered
Log-intensities saturated at -4.8 to 4.9
 
 
 
 
 
                                                                                          
 
- 182 - 
 
We also observed that CD8+BTLA- TIL, though hypo-responsive to proliferative 
signals, nevertheless maintained a similar cytotoxic capability as the CD8+BTLA+ TIL.  This 
phenomenon may be due to the unique signaling of KIRs on human CD8+ T cells; other 
previous studies have found that their presence on CD8+CD28− T cells, unlike NK cells, only 
inhibits complex cellular functions, such as proliferation, while leaving certain effector 
functions, such as cytotoxicity, essentially intact, presumably due to delayed recruitment to 
the TCR synapse after activation (229).  Additionally, although there was discordance 
between enrichment of multiple KIRs’ gene transcripts in the CD8+BTLA- TIL and a few 
KIR actually being expressed at the protein level in our present study, this may be explained 
by a recent finding where it was shown that human CD8+ T cells, distinct unlike NK cells, 
generally express only one activating or inhibitory KIR (230).  This suggests that post-
transcriptional regulation may play a role in limiting the expression of a full repertoire of 
active KIR transcripts in the CD8+BTLA- TIL, although such potential mechanism will need 
to be addressed in a future study.   
We have discovered that BTLA, upon binding to its cognate receptor, HVEM, 
delivered a pro-survival signal in CD8+ TIL. The prosurvival role of BTLA was initially 
suggested in a study by Hurchla et al., who found, in a GvHD model, that the transferred 
BTLA−/− splenocytes in a new host were unable to sustain its proliferation and the GvHD 
response compared with wild-type counterparts (231).  Moreover, it was reported that BTLA 
has a third conserved tyrosine-containing motif within the cytoplasmic domain that could 
recruit Grb-2 and p85 subunit of PI3K in vitro (51).  Interestingly, a recent study 
demonstrated that ligation of BTLA in vitro results in a signaling cascade similar to but 
weaker than that seen with CD28 and ICOS signaling (232).  Based on these observations, it 
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seems likely that BTLA may exert inhibitory activity on T cells while simultaneously 
promote their survival (219) (Fig. 3-19).  We initially tested this hypothesis by co-culturing 
bulk TIL with HVEM-expressing vs. control L cells loaded with αCD3 antibody for 5 days.  
We consistently found that TIL co-cultured with HVEM+ L cells had significantly lower 
percentage of apoptotic cells compared to that of the control L cells. We further explored this 
phenomenon in sorted CD8+BTLA+ vs CD8+BTLA- TIL in a cleaner system by stimulating 
them with plate-bound HVEM-Fc fusion protein and αCD3.  We found that TCR stimulation 
together with ligation of BTLA on CD8+BTLA+ TIL with HVEM-Fc led to higher level of 
phosphorylated Akt (Ser473), when compared to that of the control-Fc fusion protein, as 
early as 2 h after stimulation. This enhanced Akt activation was abrogated with the addition 
of a BTLA blocking antibody.  Also, we did not see the enhanced Akt activation in 
CD8+BTLA- TIL after stimulation with HVEM-Fc.  We speculate that the loss of BTLA in a 
highly-differentiation state, hence a loss of pro-survival Akt activation, may contribute to the 
enrichment of T cell deletion gene signature (198), in the CD8+BTLA- TIL.   
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Figure 3-19:  BTLA, a dual signaling molecular rheostat?  Analogous to PD-1, the 
cytoplasmic domain of BTLA contains two immunotyrosine-based inhibitory motifs (ITIMs).  
Binding of PD-1 and BTLA to PDL1/2 and HVEM, respectively, generally activate 
inhibitory signaling pathways in T cells, as their two ITIM motifs in the cytoplasmic tails 
recruit SHP1/2 phosphatases and dephosphorylate TCR signaling molecules.  This leads to 
decreases in T-cell’s proliferation and cytokine secretion.  Additionally, in the case of PD-1 
signaling, it leads to both CD8+ T cell anergy (233) and deletion (234, 235).  However, 
unlike PD-1, the cytoplastmic domain of BTLA has been reported to contain a third 
conserved tyrosine-containing motif, which has been shown to recruit Grb-2 and p85 subunit 
of PI3K in vitro.  We think that BTLA plays a more complex role in T-cell than simply 
acting as an inhibitory receptor.  We propose that it acts as a molecular rheostat by regulating 
the degree of T-cell activation depending on the relative TCR signaling strengths.  When the 
TCR signaling strength is low, inhibitory signaling through BTLA predominates.  When the 
TCR signaling strength is high such that T-cell is prone to die by activation-induced cell 
death (AICD) (61, 236), BTLA promotes the survival of T-cells by attenuating TCR 
signaling and by activating the pro-survival Akt/PKB signaling pathway.   
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These findings in our study demonstrated the specificity of the interaction between 
BTLA and HVEM.   Although we found that LIGHT was up-regulated on CD8+ TIL after 
TCR activation and could potentially interact with HVEM, we did not think that the pro-
survival effect could be mediated through LIGHT since it has no obvious signaling motif 
(237), and it has been reported that signaling through HVEM upon binding to LIGHT was 
required to influence T cell’s survival in vivo (238).  Lastly, in agreement with other studies 
on BTLA’s inhibitory role (50, 52, 239), we found that TCR stimulation, together with 
ligation of BTLA on CD8+BTLA+ TIL with HVEM-Fc fusion protein, led to significant 
decreases in proliferation and productions of IFN-γ and TNF-α.    
In an attempt to determine the difference in  persistence between the CD8+BTLA+ vs. 
CD8+BTLA- TIL subsets in vivo, we, in collaboration with Adaptive Biotechnology™, had 
performed high-throughput DNA sequencing of TCR clonotypes deriving from CD8+BTLA+ 
vs. CD8+BTLA- TIL before infusion and at various time points after infusion in two 
melanoma patients.  Our preliminary study on two patients who had received infusion with 
TIL showed that there were more persisting T cell clones from CD8+BTLA+ than BTLA- TIL 
(data not shown).  We anticipate that, by having more patient samples available in the near 
future, there will be more statistical power to link the persistence of CD8+ T cell clones with 
the CD8+BTLA+ TIL subset.  At this point, our preliminary results have shown a conceptual 
agreement with other reports demonstrating that the persistence of the infused TIL clones 
was one of the most important factors associated with positive clinical response after ACT 
(102, 103).      
In summary, our study provides a molecular basis for our previously observed 
positive clinical correlation with CD8+BTLA+ TIL after adoptive transfer in metastatic 
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melanoma patients. This is due to the less differentiated state of CD8+BTLA+ TIL subset, 
their ability to receive pro-survival signal through BTLA, as well as their ability to persist 
better after adoptive transfer in vivo.  Our study provides a rationale to improve persistence 
of the T cell clones in vivo by selectively isolating the CD8+BTLA+ TIL prior to infusion into 
melanoma patients.  Based on our novel discovery of BTLA’s pro-survival effect, it will be 
of interest to further modify the domains within the cytoplasmic tail of BTLA, which can 
help dissect its inhibitory from prosurvival roles (219).  We speculate that, by transducing 
TIL with a modified form of BTLA in which only Grb2-recruitment domain exists, it may 
help to remove the inhibitory influence from the tumor microenvironment while promoting 
CD8+ TIL’s survival and normal differentiation.      
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General Discussion 
 
Taken together, the two studies described in this dissertation provided a 
comprehensive characterization of the changes in CD8+ T-cell differentiation markers in TIL 
from metastatic melanoma and the functional characterization of two unique TIL subsets, of 
which one (CD8+BTLA+) is associated with clinical tumor regression during adoptive cell 
therapy with TIL.  In the first study (Chapter 2), we initially hypothesized that CD57 
marked senescent and terminally-differentiated CD8+ TIL, similar to those found in HIV 
patients (131).  When we examined the CD8+ T cells in the peripheral blood of normal 
donors as well as melanoma patients, we found that the CD8+CD57+ T cells showed highly 
differentiated phenotype (CD27-CD28-), exhibited high level of cytotoxic (GBHi, PerfHi) and 
effector (IFN-γ production) activities, in agreement with what was known about this subset 
of CD8+ T-cells from the literature (127).  However, when we looked at the CD8+ TIL 
residing in melanoma metastases, the simplistic description of CD57 as a senescent marker 
became much more complex.   We found that the CD8+CD57+ TIL co-expressed early TEM 
markers (CD27 and CD28) and were GB+ but PerfLo, unlike the CD8+CD57+ T cells found in 
the peripheral blood of melanoma patients’ peripheral blood (202).  We have also shown that 
CD8+CD57+ TIL could be induced to divide and produce cytokines after TCR stimulation 
(202) similar to other recent studies on CD8+CD57+ T cells in humans (127, 181).  This 
CD8+CD57+ TIL subset that had high CD28 as well as CD27 expressions, were not senescent 
and retained functional characteristics of early TEM cells.  We believe this novel TIL subset 
may functionally resemble the CD8+BTLA+ TIL we described in the second study (Chapter 
3).  We found that CD8+BTLA+ TIL subset exhibited high degree of effector functions and 
also co-expressed early TEM markers (CD27, CD28) and late-differentiation markers, such as 
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CD57, CX3CR1 [ref. (167, 209)], and ITGAM [integrin, alpha M, Table 3-II and Fig. 3-14].  
We believe that this unique incompletely-differentiated phenotype may have arisen as a 
consequence of the altered differentiation program in the CD8+ TIL within the tumor 
microenvironment (202, 240) (Fig. 4-1) 
One of the incompletely answered questions from the first study was what 
immunosuppressive factors within the tumor microenvironment could promote the CD8+ TIL 
to accumulate in an incompletely differentiated state.   Although we have established TGF-β1 
as one possible factor in this process (Chapter 2), we think that inhibitory signaling through 
PD-1 or BTLA (similar structural monomeric members of the Ig family of negative 
costimulatory molecules) may also play a role.  PD-1 signaling generally leads to decreases 
in CD8+ T-cell effector function (241), and induction of anergy (233) and deletion (234, 
235).  On the other hand, BTLA signaling also regulates CD8+ T cell effector function (52), 
however in a more unique way than PD-1 because it also seems to promote cell survival via 
the Akt/PKB pathway (Chapter 3).   It has been reported that the ligands for PD-1 and 
BTLA, PD-L1 and HVEM, respectively, are expressed by melanoma tumors (43, 52).  
Therefore it is likely that, within the tumor microenvironment, both signaling pathways 
through PD-1 and BTLA are active in CD8+ TIL.  It has been shown that PD-1 and BTLA 
are recruited to the immune synapse during T-cell-APC interaction (242, 243).  These 
findings suggest an intriguing possibility that, in the context of chronic antigen stimulation 
within the tumor microenvironment, PD-1 and BTLA ligations by PD-L1-expressing or 
HVEM-expressing melanoma cancer cells may arrest the differentiation of CD8+ TIL while 
enhancing their survival, leading to their accumulation in an incomplete-differentiated state 
(202, 240) (Fig. 4-1). 
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One of the most intriguing questions raised in this dissertation is whether CD8+ TIL 
in melanoma can be adequately defined as exhausted.  T-cell exhaustion was originally 
described more than a decade ago as dysfunction and subsequent physical deletion of 
antigen-specific T cells during chronic viral infection by lymphocytic choriomeningitis 
(LCMV) clone 13 in mice (244), and has since been reported in CD8+ T cells in melanoma 
(164, 217).  However, if exhaustion is defined as a permanent state of CD8+ T-cell 
differentiation, it would not explain the feasibility of expanding the TIL with high-dose IL-2 
ex vivo, as well as some of our findings here with highly proliferative and functional BTLA+  
TIL that nevertheless express high levels of PD-1 and TIM-3.  TIL generally recover their 
proliferation and other effector functions with IL-2 culture and are capable being expanded 1 
to 2,000-fold ex vivo after the REP.  A characteristic feature often used to define exhausted 
CD8+ T cells in chronic viral infection and cancer has been the co-expression of multiple 
inhibitory receptors such as PD-1, TIM-3, BTLA, LAG3, CD160, and 2B4 (53, 217, 221, 
222).  In contrast, in our second study (Chapter 3), we found that CD8+BTLA+ TIL, which 
also co-expressed PD-1 and TIM-3, had intact effector functions and are positively correlated 
to clinical response to ACT.  We surmise that the reason why T-cell exhaustion is more 
readily observed in chronic viral infection, as opposed to cancer, may be due to the nature of 
the antigens.  Antigens from viruses such as HIV and EBV are completely foreign to the 
host, and therefore exhibit high affinity and avidity for host’s TCR.  The persistence of these 
antigens in chronic viral infection continuously induces strong TCR signaling in the 
responding CD8+ T cells. PD-1 is induced and maintained persistently due to continuous 
induction of a transcription factor downstream from TCR signaling, nuclear factor of 
activated T-cells, cytoplasmic 1 (NFATc1) (245), which is also one of the genes highly 
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expressed in exhausted T-cells in chronic viral infection (218).  In this setting, the high PD-1 
expression by CD8+ T cells truly defines exhausted T cells.  In contrast, because many of the 
melanoma-associated antigens are self-proteins, they do not bind as avidly to TCR and thus 
do not induce strong effector T-cell response from the host, as a consequence of immune 
tolerance (246).  This often allows melanoma cells to escape from immune responses.  At the 
same time, the weak TCR signaling by the tumor antigens in TIL do not trigger NFATc1 as 
strongly.  Thus, CD8+ TIL naturally express PD-1 as a reflection of their state of 
differentiation, not due to the persistence of NFATc1.  We think the lack of a true exhausted 
state in TIL may help explain why they can often be harvested for adoptive cell therapy.  
From a basic science point of view, it will be interesting to examine how the PDCD1 gene 
locus (corresponding to the PD-1 protein) is differentially regulated by transcription factors 
in chronic viral infection vs. cancer.    
However, how this model applies to TIL reactive against epitopes generated from 
mutated tumor antigens [so-called “mutatopes” (247)], where prior self-tolerance would not 
play a role and TCR affinities for these epitopes would be much higher, is not known.  Other 
immunosuppressive factors in the tumor environment, such as TGF-β, adenosine, hypoxia, 
IDO, may also regulate the state of TIL activation or “exhaustion” through the expression of 
these negatively signaling co-receptors.  Also, it is possible that many of these tumor neo-
epitoe or mutatope specific T cells are deleted through AICD or are lost as the tumor 
progresses and loses the expression of these epitopes due to immunoediting (248).  Thus, 
what we see by the time we have access to a cancer (melanoma) patient is a highly 
immunoedited situation with constant selective pressure to “reign in” these highly reactive T-
cells through these inhibitory pathways, which may be mistaken as “exhaustion.”  Thus, 
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these T-cells are highly activated cells being subjected to negative regulation, a natural 
response of the immune system to prevent runaway immune responses and autoimmunity.  
This would explain why the CD8+BTLA+ (and PD-1+ and TIM-3+) TIL were such highly 
active cells ex vivo out of the host’s tumor microenvironment.  Future studies, however, will 
be need to determine whether these infused T-cell clones arising from these ex vivo highly 
active subsets are also more active in vivo during adoptive cell therapy, and whether this 
negative regulation still exists to try to “reign them in.”  This new viewpoint can then lead us 
to a newer perspective by which we view this system and novel approaches to further 
facilitate the functioning of these cells to improve clinical response rates.   
 
Future Directions 
 Throughout this dissertation, we have used the term “tumor-infiltrating lymphocytes 
(TIL)” loosely.  A recent study has revealed distinct histologic infiltrative patterns of T-cells 
within melanocytic lesions in humans (43) (Fig. 4-2).   We think that the term, TIL, can be 
misleading in that it gives the impression that the T-cells isolated from melanoma metastases 
always infiltrate deeply into tumor mass, when in fact T-cells in a melanocytic lesions can be 
found either inside the tumor mass, at the advancing edge of an invasive tumor, or at the 
perivascular area (Fig. 4-2).  Therefore, we think that a more general terminology to describe 
these T-cells within melanoma tumor mass, tumor-associatd lymphocytes (TAL), is more 
appropriate at capturing the complexity of the T-cells-tumor interaction in the tumor 
microenvironment.     
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In the first study (Chapter 2), we have identified a unique subset of 
CD8+CD27+CD57+ T-cells in melanoma metastases by flow cytometry.  However, we are 
not certain of the location of this unique TIL subset within the tumor mass.  Therefore, one 
future direction of this project will be to utilize double or triple immunofluoresence staining 
in combination with hematoxylin/eosin staining of melanoma tumor sections in order to 
precisely determine the infiltrative pattern of the CD8+CD27+CD57+ T cells.  This will allow 
us to determine whether this subset of T-cells is actively interacting with tumor cells either 
within the tumor mass or at the advancing edge of an invasive primary melanoma (Fig. 4-2A 
and B), or they are merely “bystander” T-cells in the perivascular area (Fig. 4-2C).   
Additionally, we hypothesize that it is likely that there is a correlation between the patterns of 
T-cell infiltration in tumors and melanoma patients’ prognosis after adoptive T-cell therapy.   
We think that the infused TIL may exert the greatest efficacy at controlling tumor growth 
when they are present at the invasive edge of the tumor mass, which will limit tumor’s 
growth or metastatic potential.  However, another recent study has shown that the edges of 
melanoma tumors were often surrounded by immunosupressive tumor-associated fibroblasts 
(TAF), which could upregulate inhibitory receptor ligands, PD-L1 and PD-L2, under the 
influence of IL-1 produced by melanoma cells with BRAF V600E mutation (249).    Thus, it 
remains an open question which T-cells’ infiltrative patterns are related to the optimal control 
of tumor growth.   
Also, we do not know why CD8+CD27+ T-cells prematurely expressed CD57, a 
marker of highly-differentiated T-cells, in the tumor microenvironment.  We think that TGF-
β may play a role in inducing CD57 expression.  Furthermore, it would be helpful to know if 
there was a correlation between the presence of TGF-β and the amount of CD8+CD57+ T 
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cells in the histologic melanoma tumor specimen. Also, CD57 has been shown to have cell-
adhesion function for motor neurons in the central nervous system (Chapter 2, Discussion).  
It is possible that the CD57 expressed by T-cells may play a role in enhacing the attachment 
of infiltrating T-cells to tumor cells, in addition to its role as a differentiation marker.  
Therefore, it will be of interest to examine the transcription factors controlling the CD57 
locus in CD8+ TIL vs. CD8+ T-cells in the peripheral blood.   
The last key question raised in this dissertation was which set of markers defined 
terminally-differentiated and senescent CD8+ T cells in humans.  In our first study, we found 
that the CD8+CD27+CD57+ TIL could be induced to differentiate into CD27-CD57+ TIL, or, 
in some patients, into CD27-CD57- TIL.  Therefore, we think that CD57 does not define the 
penultimate state of human CD8+ T-cell’s differentiation.  From our current study (Chapter 
3) and an earlier study by our group (96), we observed that the loss of CD28 and BTLA on 
CD8+ TIL corresponded to their loss of proliferative and other effector functions.  This is 
associated with the re-expression of CD45RA and acquisition of NKR (Chapter 3, Fig. 3-14), 
such as the KLRG-1 (171) and KIRs (96, 166).  Among all the NKRs, We found that KIRs 
were the most highly expressed genes in the CD8+BTLA- TIL subset.  Thus we think the 
truly senescent CD8+ T cells in humans, or those that are the immediate precursors of 
terminally-differentiated /senescent CD8+ T cells, are mainly defined by CD45RA and KIRs.  
Because most of the ligands [e.g., nonclassical HLA-G (250)] for these KIRs are expressed 
on somatic cells,  it is possible that the activation of these CD8+ T cells is no longer under the 
control of pAPC, and instead under the control of the tissue microenviroment, similar to NK 
cells (195).  At the present time, we do not know whether these NKR-expressing, senescent 
CD8+, despite being CD3+ (TCR+), exhibited HLA-unrestricted cytotoxicity like NK cells, 
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(Chapter 3). It will be of interest in a future experiment to co-incubate KIR-expressing 
CD8+ TIL with NK-sensitive cell line such as the K562 (human myelogenous leukemia) (251), 
and determine whether these target cells can be killed independently of TCR triggering.  
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Figure 4-1:  Proposed differentiation pathway of the tumor-infiltrating CD8+ T cells in 
metastatic cancer.  In situations where CD8+ T cells encounter persistent, chronic antigenic 
stimulation such as metastatic cancer or uncontrolled chronic viral infections, CD8+  effector-
memory (TEM) cells fail to coordinate down-regulation of CD27 with up-regulation of an end-
stage CTL marker, CD57.  Thus TEM fail to transition from a granzyme B (GB+) perforinlo 
(Perflo) cells into Perfhi, highly cytotoxic end-stage CTL.  This resulted in accumulation of 
CD8+ T cells at a transitional stage where markers for early effector-memory T cells, CD27, 
CD28, BTLA, and PD-1, are co-expressed with CD57, even though the cells remain PerfLo.  
We think that TGF-β1 or signaling through PD-1 and BTLA may contribute to the arrested 
differentiation and accumulations of CD27+CD57- precursor T cells and CD27+CD57+ T cell.  
CD27+CD57+ T cells highly express inhibitory receptors, PD-1 and BTLA, which implies 
that they may exhibit a higher level of effector activity.  When these tumor-infiltrating 
lymphocytes (TIL) are expanded with IL-2, a minor fraction (~30%) of CD27+CD57- subset 
differentiated into CD27+CD57+  T cells.  After TCR stimulation ex vivo,  the CD27+ CD57- 
subset directly differentiated to become CD27-CD57- T cells, while the CD27+CD57+ subset 
differentiated to become CD27-CD57+, and, in some patients, CD27-CD57- , with down-
regulation of PD-1 and BTLA with progressive differentiation.  These phenotypic changes 
were accompanied by increased perforin expression and acquisition of potent cytotoxicity 
against tumor cells.  We think that CD57 is not a marker for T-cell senescence, but rather 
marks highly differentiated T cells that is in the process of transitioning into a truly end-
stage, senescent effector CTL.  We propose that the truly end-stage CTL is more NK-like, 
and could be defined by a CD45RA+, KIRs++, KLRG-1+, CD56+, and CD122+ (?) phenotype 
(conventional CD8+ T cells are CD122-).   CTL: cytotoxic T lymphocytes; Ag: antigen; 
CD122: IL-2Rβ; CD56: Neural cell adhesion molecule; KIRs: killer-cell immunoglobulin-
like receptors. KLRG-1: killer-cell lectin-like receptor G1.   
Reprinted with permission from: Wu RC, Hwu P, and Radvanyi LG.  2012. New insights 
on the role of CD8+CD57+ T cells in cancer.  Oncoimmunology.  1(6): 954-956. 
http://dx.doi.org/10.4161/onci.20307  
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Figure 4-1: 
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Figure 4-2:  Distinct geographic infiltrative patterns of T-cells within melanoma 
metastases.  (A) Rare CD3+ TILs identified by IHC in a benign nevus, indicated by arrows. 
200x original magnification (size bar 50 um).  (B) A ‘moderate’ infiltrate of CD3+ TILs at the 
advancing edge of an invasive primary melanoma, nodular histologic subtype, 40x original 
magnification (size bar 200 um).  (C) 400x original magnification (20 um size bar) of the 
boxed area shown in panel B.  (D) Only singular CD3+ TILs were observed, predominantly 
in perivascular areas and not infiltrating among tumor cells, in a melanoma metastasis. 200x 
original magnification (size bar 50 um).   
“From Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein 
AP, Pardoll DM, Topalian SL, and Chen L.  2012.  Colocalization of inflammatory response 
with B7-h1 expression in human melanocytic lesions supports an adaptive resistance 
mechanism of immune escape.  Sci. Transl. Med.  4(127): 127ra37.  Reprinted with 
permission from AAAS.”   
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